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CHAPTER 1
General introduction
Based on sections of:
De bron van specifiek IgE: B-geheugencellen en plasmacellen.
Heeringa JJ, van Zelm MC.
Ned Tijdschr Allergie & Astma 2015
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Chapter 1
Allergy
Allergy is an abnormal response of the immune system against otherwise harmless 
substances and it is therefore often related to as a hypersensitivity reaction. Allergies 
can cause considerable symptoms, and in the case of anaphylaxis even death. In the past 
decades, the prevalence of allergy has dramatically increased, and at present up to 40% of 
the Western world population is affected by one or more allergies.1 Based on the underlying 
immune response, allergic reactions can be divided into four types. The most common type 
(type I) is mediated by IgE antibodies and is associated with asthma, hay fever, food allergy 
and atopic dermatitis. Normally, immunoglobulin (Ig)E is involved in the protection against 
parasites, such as helminths. However in IgE-mediated allergies specific IgE molecules are 
directed against common allergens of house dust mite, pollen or peanut, and exposure can 
result in allergic symptoms. In this General Introduction, the function of a healthy immune 
system and the abnormal response in IgE-mediated allergic diseases will be described. In 
particular the mechanisms which lead to the production of IgE will be highlighted.
The human immune system
All humans are continuously exposed to micro-organisms such as bacteria, viruses, fungi 
and parasites. To protect itself against the harmful effects of these microorganisms, the 
human body has developed a physical and chemical barrier (skin, mucosa) and the innate 
and the adaptive responses of the immune system. The cells lining the skin and the mucosal 
surfaces of the lung and gut are the first to come into contact with micro-organisms. These 
epithelial cells are tightly connected together to form a physical barrier making it difficult for 
micro-organisms and substances to penetrate.2 An additional mechanical barrier is provided 
by coughing and sneezing and by peristaltic movement of the bowel, which expels micro-
organisms and irritants.3 Next to that, epithelial cells produce peptides with antimicrobial 
properties to provide a chemical barrier which prevents the attachment and proliferation of 
micro-organisms.4 Furthermore, the skin and the mucosal surfaces of the gut and lung are 
populated with commensal bacteria, as a whole called the microbiota, which are typically 
harmless for the human body and prevent colonization of pathogenic micro-organisms.5 
Still, sometimes pathogens pass these barriers, and come into contact with cells of the 
immune system.
Innate immune responses
After the penetration of a pathogen, the nonspecific innate arm of the immune system will 
get activated, which induces a fast response, but which has a limited capacity. Still innate 
immune cells are able to act against a variety of microorganisms. Typical for cells of the 
innate immune system is their direct activation and immediate effector functions. These 
cells are mostly located in tissues with contact to the outside world.6 There are several 
cells of the innate immune system, i.e. natural killer (NK) cells, granulocytes (neutrophils, 
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eosinophils, and basophils), mast cells and monocytes, and each responds differently against 
micro-organisms. A cellular response is elicited by viruses and intracellular bacteria. If cells 
get infected, peptides of these microorganisms can be degraded internally in the cells and 
get displayed externally by the major histocompatibility complex class I (MHC-I) molecule, 
thereby forming a complex which can be recognized by immunocompetent T-lymphocytes. 
NK cells continuously scan cells for the presence of MHC-I and if expression lacks, induce cell 
death. Extracellular bacteria elicit a humoral immune response, in which soluble factors of 
the immune system, such as complement and antibodies, attach to bacteria. This facilitates 
recognition of bacteria by phagocytes (mainly monocytes and neutrophils). Subsequently 
these cells can locally release chemokines and pro-inflammatory cytokines, which induce 
the dilatation of blood vessels and thereby facilitate the recruitment of other cells of the 
immune system.9 Mediators released by these cells cause the features of inflammation, 
including redness, swelling and pain or itch. Monocytes migrate into tissue, and differentiate 
into macrophages which together with neutrophils can take up pathogens or cell debris by 
phagocytosis and subsequently degrade these fragments internally in endosomal structures, 
leading to the clearance of unwanted intruding microbes.10 Since parasites are often too big 
for phagocytosis a specific IgE-mediated immune response is triggered, in which the IgE 
antibody recognizes epitopes of the parasite and thereby activates eosinophils and mast 
cells. Upon activation, these cells release mediators which induce mucus production and 
itch, thereby facilitating parasite clearance. Some of these effects are also a feature of an 
allergic reaction. This can be explained by the fact that these responses share a common 
immunological response.
The innate immune system is not capable to develop any memory function for 
pathogens, but the adaptive immune system can. To activate the adaptive immune system, 
antigen presenting cells (APCs) phagocytose micro-organisms, process these internally and 
display small peptides on their cell surface via a specific receptor (MHC- II).6 Dendritic cells 
are the predominant APCs and are therefore regarded as the bridging cells between innate 
and adaptive immunity. Another important cell type in the activation of the adaptive arm 
of the immune system are innate lymphoid cells. These cells lack antigen specific receptors, 
but can influence the type of adaptive immune response through the production of specific 
cytokines.7
Adaptive immune responses
Adaptive immune responses are generated by B and T-lymphocytes, which have the unique 
property of memory formation against previously encountered pathogens. Both cell types 
originate from hematopoietic stem cells in the bone marrow (BM). While subsequent 
B-lymphopoiesis occurs in parallel with innate cell development in BM, early lymphoid 
progenitors also seed the thymus, where these commit to the T-cell lineage and develop 
into mature CD4+ or CD8+ T cells. Throughout differentiation in the bone marrow or thymus, 
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B- and T-cells each undergo multiple steps, leading to the formation of a large pool of cells 
with a unique B-cell or T-cell receptor.8 When fully matured, these cells migrate to secondary 
peripheral organs where upon recognition of a micro-organism (or parts of a micro-
organism presented by APCs) they can differentiate into effector cells or into memory cells. 
T-cells include cytotoxic T-cells (CD8+), which are involved in the direct killing of infected 
cells, and T-helper (Th) cells (CD4+), which aid other immune cells in the immune response. 
Cytotoxic T-cells are activated through MHC-I-mediated peptide presentation and thus any 
infected cell can induce a cytotoxic T-cell response. T-helper cells only recognize peptides 
presented through MHC-II. In contrast to MHC-I, MHC-II is only expressed by immune cells, 
and in particular APCs.
Figure 1 Memory function adaptive immunity. After a primary infection with antigen A, the 
immune system (i.e B-cells) produces antibodies against the encountered antigen (in the figure 
depicted as a small peak termed primary anti-A response). When the antigen is cleared from 
the body, serum antibodies against antigen A (red line) remain present. When the body then 
encounters the same antigen again, the immune system induces a faster and stronger response 
against the antigen, which can be seen as a higher serum antibody titer. This principle is called 
the memory function of the adaptive immune system.
Effector B-cells, also called plasma cells, produce antibodies which are the soluble 
counterparts of the B-cell receptor.9 The main actions of antibodies are: 1) neutralization 
of microorganisms by blocking parts of the surface of a bacteria or virus; 2) agglutination, 
in which antibodies form complexes between microbes which are then attractive 
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for phagocytosis and immune cell activation and 3) complement activation in which 
complement can bind to antibodies and thereby lead to cell lysis.8 Antibodies exist in five 
different classes: IgM, IgD, IgG, IgA and IgE. Initially, early in the immune response, plasma 
cells produce IgM, which is important for the primary immunity. However, during an immune 
response, B-cells can switch to the production of one of the other antibody classes. Each of 
the five Ig classes has unique effector functions and can lead to a different immune response. 
This often results in the most appropriate response against the encountered microorganism. 
Memory B- and T-cells do not have direct effector functions but, upon a secondary encounter 
with the same antigen, can differentiate faster into effector cells resulting in a quicker and 
stronger immune response, which is the hallmark of immunological memory (Figure 1).10, 11
GENERATION OF ANTIGEN RECEPTOR DIVERSITY IN 
LYMPHOCYTE DEVELOPMENT
Antigen-independent B-cell differentiation
B-cell development starts in the bone marrow where B-cell precursors are continuously 
produced from hematopoietic stem cells via stepwise differentiation. During these 
differentiation steps, B-cells generate a functional B-cell receptor (BCR) which is composed 
of two identical heavy chains (IgH) and two identical light chains (either Igκ or Igλ) which 
together form a functional membrane Immunoglobulin (Ig) molecule (Figure 2).12, 13 Both 
the heavy chains and the light chains are composed of variable domains and constant 
domains. An Ig molecule has two antigen-binding domains, each composed of one variable 
region from the heavy- and one from the light chain. The variable domains are the domains 
which directly interact with the future antigen. The constant domains from the heavy 
chains determine the effector function of the soluble Ig.14 Whereas the constant domains 
are germline encoded, rearrangements in the genomic DNA encoding heavy- and light 
chains are needed to form functional variable domains. Separate Variable (V), Diversity (D) 
and Joining (J) genes in the IGH, IGK and IGL loci rearrange to encode a functional protein 
in a process termed V(D)J recombination (Figure 2).15-17 The process of V(D)J recombination 
starts in the heavy chain locus, where first DH to JH rearrangement is initiated, followed by 
rearrangement of a VH gene to the previously formed DJH element. This VDJ exon will be 
transcribed and spliced to the exons encoding the constant region, and if this is in-frame, it 
will encode the BCR receptor (Figure 2). When a functional heavy chain protein is generated, 
rearrangements in the IGK or IGL loci are initiated between V and J genes.18 Once an Ig light 
chain protein is formed that can pair with the IgH protein, the cell will undergo positive and 
negative selection processes to ensure the generation of a functional BCR which does not 
recognize self-antigen. Thereby it finally develops into a functional immature B-cell.19 The 
human Ig loci contain many different V, D and J genes and as a result of the random nature 
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of V(D)J recombination, this yields a large pool of B-cells with a unique receptor for each 
cell. Together, this forms a broad repertoire of antigen receptors which have the potential 
to specifically recognize a wide range of pathogens.20
Figure 2. V(D)J recombination. V(D)J recombination commences in the IGH locus, where 
first a DH to JH rearrangement occurs, followed by complete VH to DJH rearrangement to form a 
functional exon. The VDJ exon is transcribed and spliced to the IGHM exons. After a functional IgH 
protein is generated, similar rearrangements are initiated in the IGK or IGL loci between one V and 
one J gene segment. Together these can result in the formation of a functional B-cell receptor.
Antigen-dependent B-cell maturation
Upon generation of a functional BCR, precursor B cells migrate from the bone marrow to 
the periphery as transitional B cells. Here they mature into naive mature B cells, which can 
respond to antigen. The B-cell response to antigen depends on the binding strength with 
the encountered antigen and on costimulatory signals, mostly provided by T-helper cells.21 
Typically this response takes place in a germinal center, a highly organized structure within 
lymph nodes. During this response B cells undergo extensive proliferation accompanied 
by affinity maturation (Figure 3).22 In this process, the rearranged exons encoding the 
variable domains of Ig genes are intensely targeted by random mutations, a process called 
somatic hypermutation (SHM). The enzyme ‘activation induced cytidine deaminase’ (AID) 
induces these mutations which lead to antibody diversity.23 Whereas mutations in the 
framework regions (FR) that encode the structural element are unfavourable, mutations in 
the complementarity determining regions (CDRs: the sites involved in antigen recognition) 
can result in increased affinity for the encountered antigen. Such mutations provide the B 
cell with a selective advantage for presenting antigen to T-helper cells and receiving co-
stimulation, and are thus positively selected to undergo clonal proliferation.23, 24 As a result, 
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the infection with a micro-organism leads to production of antibodies specifically aimed 
against the microbe.
Figure 3. Germinal center reaction. Naive B-cells (expressing IgM) circulate through the 
bloodstream and lymph vessels. In lymph nodes naive B-cells have an increased chance to 
encounter antigen, after which they can get activated. The cells then proliferate and somatic 
hypermutation (SHM) occurs in the genes encoding the B-cell receptor. Since SHM is a random 
process, it can either lead to reduced affinity of the B-cell for the encountered antigen, resulting 
in lack off co-stimulation and apoptosis. Alternatively, it can also result in increased affinity, after 
which the cells have improved ability to present the antigen to follicular helper (Tfh) T-cells. Tfh 
cells can then stimulate naïve B-cells to differentiate and to undergo class switch recombination 
(CSR). In this process, B-cells undergo an isotype switch, for example from IgM to IgG. Moreover, 
B-cells can either differentiate into memory B-cells, which recirculate throughout the body, or 
differentiate into plasma cells, which produce soluble immunoglobulins.
B-cell effector response
After V(D)J-recombination in the bone marrow, the antigen-binding variable domain is by 
default spliced to the constant μ or δ regions (Cμ or Cδ), resulting in the expression of IgM 
or IgD respectively. To increase the efficiency of the immune response to specific antigens, 
the constant domain of the heavy chain of the BCR has different isotypes, namely IgG (with 
the 4 different subclasses IgG1, IgG2, IgG3 and IgG4), IgA (with subclasses IgA1 and IgA2) 
and IgE. All isotypes have different properties resulting in different effector functions. In 
the periphery, during an immune response, B-cells can undergo an isotype switch to one 
of these other isotypes, called class switch recombination (CSR), which is induced by AID 
(Figure 3).25 CSR does not change the antigen specificity but influences its effector functions, 
since different isotypes have different effects on the immune response 8. This recombination 
can either occur in a direct process, for example from IgM to IgE, or in an indirect process, 
for example from IgM to IgG1 and in a subsequent response from IgG1 to IgE.26 Finally after 
CSR, B-cells can either differentiate into plasma cells, which produce soluble Ig’s, or into 
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memory B-cells, which upon secondary encounters with the same antigen can initiate a 
faster and stronger immune response.10, 27
Figure 4 Memory B-cell formation. Naïve B-cells can differentiate into memory B-cells through 
several differentiation pathways resulting in distinct memory B-cell subsets. CD27+IgM+, CD27-
IgG+, CD27+IgG+ and CD27+IgA+ memory B-cells develop through a classical germinal center 
reaction and display signs of high proliferation and BCR maturation status. CD27+IgM+IgD+ 
(natural effector) B-cells develop in the marginal zone of the spleen, whereas CD27-IgA+ B-cells 
differentiate from T-cell independent responses in the gut. These subsets display characteristics 
of less proliferation and BCR maturation.
Memory B-cell differentiation
Molecular characteristics of purified memory B-cell subsets show evidence that memory 
B-cells can originate via three differentiation pathways (Figure 4).28 This can occur via 
germinal center reactions in a T-cell dependent maturation pathway, yielding memory 
B-cells with high SHM levels and a high replication. This accounts for IgM only, IgG+CD27-, 
IgG+CD27+ and IgA+CD27+ memory B-cell subsets, in which IgA+CD27+ and IgG+CD27+ 
memory B-cells display the highest replication and SHM levels, suggestive of consecutive 
germinal center reactions. Alternatively, T-cell independent responses in the marginal 
zone of the spleen lead to the differentiation of natural effector B-cells (IgM+IgD+CD27+), 
whereas IgA+CD27- memory B-cells originate from T-cell independent responses in the 
lamina propria of the gut. The latter two subsets display less proliferation history and BCR 
maturation (Figure 4). Knowledge on IgE+ memory B-cell biology is limited and it is even 
being discussed if IgE+ memory B-cells in human exist. Moreover, if differentiation of IgE+ 
memory B-cells is affected in allergic disease is not well known.29, 30
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IgE-mediated allergic disease
Based on the immunologic mechanism, allergies can be divided into four categories, namely 
type I) the IgE mediated immediate allergic response; type II) the cytotoxic allergic reaction; 
type III) an immune complex mediated allergy; and type IV) delayed type hypersensitivity 
reaction.8 IgE-mediated allergies underlie the most common phenotypes of allergic disease: 
atopic dermatitis, food allergies, hay-fever and allergic asthma (Table 1).31, 32 These cause a 
high disease burden and it is estimated that up to 40% of the Western world is affected by 
one or more allergies, with the highest prevalence in children and adolescents.1, 33, 34 Atopic 
dermatitis is often one of the earliest allergies to develop in young children. Of all allergic 
children, 45% has onset of atopic dermatitis in the first 6 months of life, increasing to 85% 
before the age of 5 years.35, 36 The incidence of food allergy seems to be highest in children 
aged 1-3 years (5-8%), although exact numbers vary greatly due to the difference in self-
reported food allergy and food allergy confirmed with a double-blind provocation test.37, 
38 The peak of allergic asthma is at a slightly older age, with a documented prevalence of 
13.5% at the age of 13-14 years.39 IgE-mediated allergic diseases may develop subsequently. 
This phenomenon is often related to as the atopic march, where infants first develop 
atopic dermatitis, progressing to allergic asthma in later childhood and allergic rhinitis at 
adolescence (Figure 5).40 In general, this complete sequence appears to be quite rare, but 
it has been shown that about 50% of children with severe atopic dermatitis will develop 
asthma and about 75% develops allergic rhinitis later in life.41-44
Table I. Characteristics of IgE mediated allergic diseases
Typical age 
of onset
Route of entry
Common 
allergens
Symptoms
Atopic dermatitis 1< yrs Skin/oral Various (e.g. 
egg, milk)
Dry skin, itch, redness
Food Allergy 1-3 yrs Oral Nuts, shell fish, 
egg, milk
Vomiting, diarrhea, 
urticaria
Asthma 6-10 yrs Inhalation Dander, pollen Shortness of breath, 
airway constriction, 
mucus production
Atopic Rhinitis 13-14 yrs Inhalation House dust 
mite, pollen
Sneezing, irritation of 
eyes, itch
Anaphylaxis Variable Intravenous 
(sometimes as 
result of oral 
absorption)
Insect venom, 
peanut
Angio edema, vas-
cular permeability 
(low blood pressure), 
death
1
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Figure 5 Atopic march IgE mediated allergic diseases tend to develop in a subsequent manner. 
Children aged 1-2 years often first develop atopic dermatitis and food allergy, later at ages 6-10 
years develop asthma and at ages 13-14 develop atopic rhinitis.
Pathogenesis of IgE mediated allergies
The underlying pathogenesis of IgE-mediated allergic disease is multifactorial, with 
genetic, environmental and immunological factors contributing to the onset of disease.45-47 
Genome wide association studies (GWAS) have contributed to the identification of various 
susceptibility factors, such as an adequate function of the epithelial and epidermal 
barrier.48-50 Mutations in the human filaggrin gene (FLG), a structural protein in the stratum 
corneum of the epidermis, have been identified as the single most significant risk factor for 
the development of atopic dermatitis and related allergic diseases, such as food allergy and 
asthma.51-54 The importance of an intact epidermal barrier is underlined by the described 
atopic diathesis and elevated IgE serum levels in Netherton syndrome55, a disease caused 
by mutations in the ‘serine protease inhibitor of kazal type 5’ (SPINK5) gene, which leads to 
increased desmosome cleavage and reduced filaggrin proteolytic processing.56
Fundamental in the abnormal immune response in allergic disease is the generation 
of IgE antibodies to allergens such as pollen, peanut or house dust mite (HDM).57 Hence 
the central role of total- and specific serum IgE levels in the diagnosis of allergic disease. 
IgE antibodies bind to high-affinity receptors (FcεRI) on mast cells and basophils, where 
they can act as a receptor complex which, upon allergen binding, can crosslink and induce 
degranulation of these cells. The release of mediators and cytokines from granules in the 
tissue causes allergic symptoms such as itching, sneezing or wheezing.58
21
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Figure 6 Mechanism of allergic sensitization Allergen comes into contact with the immune 
system through the epithelial cells of the skin or mucosal tissue of the respiratory tract and the 
gut. Epithelial damage increases allergen penetration and results in cytokine secretion such as 
IL-25, IL-33 and TSLP which activates cells of the immune system lining the mucosa i.e. dendritic 
cells, innate lymphoid cells, basophils). Subsequently, dendritic cells can take up allergen and 
migrate to lymph nodes, where they present allergen epitopes to Th2 cells. Th2 cells produce 
the cytokines IL-4 and IL-13 and thereby induce class switch recombination of allergen specific 
naïve B-cells to IgE+ B-cells. Allergen specific soluble IgE produced by plasma cells can bind to 
mast cells, after which the immune system is sensitized for the encountered allergen.
The generation of allergen-specific IgE and the resulting sensitization is thought to be 
triggered by enhanced allergen exposure in the affected tissue, mainly due to epithelial 
damage or inflammation (Figure 6).59-61 In addition, many allergens have protease activity, 
which leads to the cleavage of tight junction proteins and thereby can act on epithelial cells 
by decreasing their barrier function.62 The resulting increase in allergen exposure promotes 
the epithelial secretion of cytokines such as interleukin (IL)-33, IL-25 and thymic stromal 
lymphopoietin (TSLP), which activate dendritic cells, innate lymphoid type 2 cells (ILC2) 
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and basophils (Figure 6).63 Some allergens can also directly activate Toll-like receptor (TLR) 
4 on epithelial cells and thereby induce the production of specific cytokines.64, 65 IL-25 and 
IL-33 are especially potent in stimulating innate lymphocytes to produce the Th2 related 
cytokines IL4, IL5 and IL13.63, 66-69 TSLP drives the expansion and differentiation of DCs70, 
resulting in their migration and the upregulation of costimulatory molecules.71 GWAS studies 
in patients with allergic disease have identified single-nucleotide polymorphisms (SNPs) in 
genes encoding TSLP and IL1RL1, ST2 the IL-33 receptor, confirming the importance of these 
epithelial-derived cytokines in the involvement of allergic diseases.72, 73 Once DCs lining the 
epithelial membranes get stimulated, they can migrate to draining lymph nodes where 
they can present processed allergen peptides via MHC-II to naive T cells. The naive T cells 
that specifically recognize the MHC-II – peptide complex with their cognate T-cell receptor 
differentiate into Th2 cells under influence of costimulatory signals and through the cytokine 
IL4.74, 75 Simultaneously, naive B-cells in the lymph node can recognize soluble allergens 
directly with their BCR, without help of APCs. Similar to DCs, B cells can process internalized 
allergen and display allergen peptides via the MHC-II to the activated Th2 cells. Activated 
Th2 cells will then produce cytokines (mainly IL-4, IL-13 and IL-21) and can thereby induce 
the differentiation of naive B-cells into allergen-specific IgE producing plasma cells.76, 77
In principal CSR of B-cells is thought to take place in germinal centers in lymph nodes. 
CSR to IgE is regulated by IL4, IL13 and the tumor necrosis factor receptor (TNFR) superfamily 
member CD40.77 CD40 ligation activates NF-κB78, which together with signal transducer and 
activator of transcription 6 (STAT6) activated by IL4, induces AID gene expression, essential 
for CSR.79, 80 Next to that STAT6 can activate the transcription of the Iε promotor, which is 
indispensable for Cε germline transcription preceding CSR to IgE. In addition to IL4, also 
IL13 can induce the activation of STAT6 and thereby initiate CSR to IgE.
Once B-cells are differentiated in IgE producing plasma cells, the secreted allergen-
specific IgE will bind to FcεRI on mast cells and basophils, by which the immune system 
is sensitized for a certain allergen. Upon subsequent exposure to the same allergen, the 
allergen-specific IgE bound to the surface of mast cells and basophils can cross link and 
thereby activate these effector cells resulting in the immediate allergic response (Figure 7).81 
In addition, a delayed response is induced involving eosinophils, with chronic inflammation 
resulting in tissue remodeling e.g. in asthmatic airways (Figure 7).82 In the latter process, 
chronic immune activation leads to subepithelial fibrosis, increased smooth muscle 
mass, epithelial shedding and excessive mucus production, which can prompt asthmatic 
symptoms irrespective of allergen exposure.83, 84 Why some individuals generate Th2-
mediated IgE responses to harmless allergens and others do not, is not entirely clear. In 
addition to genetic predisposition, environmental risk factors affecting epithelial cell-DC 
interaction such as allergen- or cigarette smoke exposure, viral infections and air pollution 
are important contributors.59 Central in this process is a disturbed balance between Th1 and 
Th2-type immunity resulting in the development of IgE-producing B-cells. Investigating IgE+ 
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B-cells and studying IgE+ B-cell differentiation in healthy individuals and in individuals with 
allergic disease, may enable the identification of processes important in this development
Figure 7 Mechanism of allergic reaction Allergen can be internalized by dendritic cells, 
processed in epitopes and presented to naïve T-cells via MHC class II. Naïve T-cells can recognize 
the MHC-epitope complex with their T-cell receptor, which, under the right stimuli, leads to their 
differentiation into Th2 cells. Simultaneously naïve B-cells can recognize allergen with their 
B-cell receptor, process the allergen and present it to Th2 cells. Activated Th2 cells then produce 
cytokines such IL-4 and IL-13, which stimulates naïve B-cells to differentiate into IgE producing 
plasma cells through the regulation of signal transducer and activator of transcription 6 (STAT6) 
. IgE+ plasma cells produce allergen specific IgE, which can bind to high affinity IgE receptors 
on mast cells and basophils (FcεRI). This results into the sensitization of the immune system for 
the specific allergen. Upon a re-exposure, allergen will bind FcεRI-bound IgE, which will lead to 
cross-linking of IgE and degranulation of the effector cells, resulting in allergic complaints. Next 
to that a late phase reaction can be induced by tissue infiltrating eosinophils.
IgE+ memory B-cell biology
It has long been under debate if IgE+ memory B-cells are generated in humans or that 
memory is maintained by long-lived IgE-producing plasma cells in bone marrow and 
allergen specific IgG+ memory B-cells that switch to IgE production upon secondary 
encounters.29, 85 IgE+ memory B-cells are difficult to detect. Three apparent reasons for this 
are the low numbers of IgE+ B-cells81; the low expression of surface IgE on IgE+ B-cells 
which is due to suboptimal polyadenylation signals downstream of the exons encoding the 
cytoplasmic tail of IgE leading to instable mRNA and therefore low membrane expression 
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of IgE86; and finally the false positive detection of IgE+ B-cells, as many cells express the low 
affinity IgE receptor, Fc?RII (CD23), making them IgE+ without expressing IgE themselves.87 
To overcome these technical difficulties, several mouse models have been designed to 
enable reliable detection of IgE+ B-cells. Alternative methods are aimed at intracellular IgE 
detection or at dissociation of the IgE-Fc?RII complexes through a short incubation with cold 
acid.88 Based on these approaches, it has been shown that in mice IgE+ B-cells can either 
develop directly from naive IgM+ B-cells or differentiate from antigen experienced IgG+ 
B-cells through a secondary immune response.89-94 How much either differentiation pathway 
contributes to IgE+ memory B-cell development is unknown. Still, direct CSR to IgE seems 
predominantly responsible for the production of short lived plasma cells with low affinity, 
whereas indirect CSR via IgG1 results in the production of IgE with high affinity. In the latter 
differentiation pathway, IgG1 B-cell differentiation is important for the affinity maturation of 
the B-cell receptor.93 In both pathways there is a strong predisposition for the development 
of IgE-producing plasma cells, with little or no IgE+ memory B-cell development.94 Possibly 
this is the result of impaired BCR expression and function with the consequence that IgE+ 
B-cells are unsuitable to undergo a conventional germinal center reaction.90 Based on these 
results it has been postulated that IgE memory function might primarily be the result of 
IgG1+ B-cells, which are prone to develop into IgE producing plasma cells during a secondary 
response.93 In contrast to this, other studies have shown that B-cells can directly develop 
into IgE+ memory B-cells and IgE+ plasma cells in a germinal center reaction95, and that 
IgE+ memory B cells can develop into IgE+ plasma cells independent of a germinal center 
reaction.92 Still, all these studies were performed using mouse models, some of which 
contained modified membrane IgE-expression levels, and that were all exposed to artificially 
high doses of allergens and sensitization schedules to induce allergic disease. Thus, it still 
has to be determined how much of these new insights can be translated to human disease. 
Only few studies have aimed to directly identify IgE+ B-cells in humans, with little data on 
their immunophenotype and their role in allergic disease.30, 96 Still, IgE transcripts have been 
detected in various tissues and in blood of healthy controls and allergic subjects, indicative 
of the presence of IgE-expressing B cells.97-100 Furthermore, several studies have shown signs 
of active Ig-class switch recombination to IgE in bronchial and nasal mucosa.101-105 Tissue 
samples showed expression of AID, the enzyme important for IgE class switch recombination 
and SHM.102 Furthermore, transcripts from DNA excision circles containing S?-Sμ and S?-Sγ 
switch regions were detected, demonstrating signs of direct IgM to IgE and indirect IgG to 
IgE class switch recombination.101 However, data on cellular characteristics and their relation 
to other subsets of the immune system are lacking, but are critical to explore the possibilities 
in diagnostic purposes or more important, as target for treatment.
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Treatment of allergic disease
It is not known whether circulating IgE+ memory B-cells sustain the underlying allergy, but 
in view of the function of memory B-cells in general it is probable that increased circulating 
IgE+ memory B-cells actively contribute to allergic disease.106 To achieve desensitization and 
possibly even cure allergic disease it is therefore important to develop therapies aimed to 
reduce IgE+ memory B-cells. Omalizumab has shown to decrease the production of IgE in 
patients with IgE-mediated asthma.107 However, it mainly targets soluble IgE. Quilizimab is an 
antibody directed against the M1 prime epitope of membrane IgE, and therefore only targets 
surface IgE on IgE-expressing memory B cells.108 Importantly, because Quilizimab does not 
bind soluble IgE, it could be more efficient in binding to IgE on B cells than Omalizumab. In 
mouse studies it not only decreased serum IgE, but also depleted IgE producing B-cells.109 
In human trials, Quilizimab also led to a reduction of IgE serum levels, lasting 6 months after 
treatment cessation. Yet the effect on clinical parameters, such as asthma exacerbations, 
lung function or quality of life, was variable.110, 111 The biomarkers that were studied could not 
identify patient groups with a beneficial treatment effect. However, if IgE+ memory B-cells 
can be reliably identified, patients that would possibly benefit from anti-IgE treatment could 
be easily selected.
A different approach to desensitize patients with allergic disease is Specific Immune 
Therapy (SIT), in which patients are treated with small, but increasing dosages of allergen.112 
This can be either admitted subcutaneous (SCIT) or sublingual (SLIT) and results in the 
deviation of local and systemic immune responses with an effect on the number and 
function of effector cells, APCs, T cells and B cells.113, 114 SIT has been proven to have a 
therapeutic effect that remains after stopping treatment.115-117 In addition, SIT can prevent 
the onset of new sensitizations118, and has the ability to reduce the development of asthma in 
patients with allergic rhinitis.119 Effective immunotherapy has been shown to reverse the Th2 
dominance, and to result in anergy of allergen-specific T cells,120, 121 induction of regulatory 
T cells122-124 and production of blocking antibodies of the IgG isotype.125, 126 Specifically, IL-10 
produced by Tregs is pivotal for the successful immune deviation in immunotherapy.127, 128 
The tolerogenic functions of IL-10 are extensive, but IL-10 in combination with IL-4 and IL-13 
directs Ig CSR of B cells to IgG4 instead of IgE.129 Indeed, one of the known effects of SIT is an 
increase in allergen-specific serum IgG4 and an increase in the serum IgG4/IgE antibody ratio 
which is associated with successful outcome.130 Since immunotherapy has been attributed 
to have long lasting beneficial effects, it is of specific interest to understand if this is the 
result of changes in immunological memory, i.e. memory B and T cells. Such studies would 
require reliable detection of IgE and IgG4+ memory B-cells and a deeper understanding 
of the biology of these cells.
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Is IgG4 always beneficial?
IgG4 is presumed to have an immune dampening effect.131, 132 The IgG4 molecule displays 
weak or negligible binding to both C1q and Fcγ receptors.133, 134 In addition, IgG4 molecules 
have the exclusive ability to exchange Fab-arms, thus creating monovalent bispecific 
antibodies that can prevent the formation of immune complexes.135 Therefore, IgG4 only 
has a limited ability to stimulate the immune system for the induction of an immune 
response. However, several diseases have been associated with a possible pathologic role 
for IgG4 and in 2012 a novel disease entity has been defined, termed IgG4-related disease 
(IgG4-RD).136 IgG4-RD patients suffer from tissue fibrosis with atypical infiltration of IgG4+ 
plasma cells in various organs, but most predominantly in the retroperitoneal space, thyroid, 
pancreas, salivary glands and orbital tissue.136 Furthermore, IgG4 serum levels are increased 
in 50-70% of patients with IgG4-RD.137, 138 These observations lead to the discussion whether 
IgG4 is involved in the pathogenesis of the disease. Still it could also be a reflection of 
chronic inflammation. Since the current limitations in our understanding of IgG4+ B-cells, 
it is yet unclear how these cells function in alleviation of allergic symptoms following 
immunotherapy, or in pathogenesis of IgG4-RD.
AIMS OF THIS THESIS
Allergen-specific IgE plays a central role in the pathophysiology of IgE-mediated allergy. Still, 
little is known about the cells producing IgE or about memory B-cells which might sustain 
increased IgE production. Notably, this is the result of the inability to reliably identify IgE+ 
B-cells, while knowledge on IgE+ B-cell differentiation and their role in allergic disease is 
crucial to understand the development of IgE mediated allergies. Moreover, treatment of 
allergic disease is typically aimed at symptom relief and none of the current therapies is able 
to cure allergic disease. Therefore, more insights into IgE-expressing B cells and their relation 
to other immune cells are needed to understand disease pathogenesis. This knowledge 
might be readily translated into diagnostic purposes or uncover targets for treatment. In 
Chapter II we aimed to reliably identify and immunophenotype IgE-producing plasma 
cells and IgE+ memory B-cells. Based on our knowledge on mature B-cell development, 
we identified distinct IgE+ B-cell subsets, studied their differentiation pathways based 
on molecular characteristics, and investigated their abnormalities in atopic dermatitis. In 
Chapter III we aimed to increase our knowledge of IgE+ B-cell involvement in three major 
types of IgE-mediated allergic diseases. We studied the immune compartment of children 
with atopic dermatitis, food allergy and asthma, focusing on IgE+ B-cells and their relation 
to T-cell and innate cell subsets involved in the allergic response. Since a disturbed epithelial 
barrier results in increased allergen exposure, we sought to study the effect of barrier 
dysfunction on IgE+ B-cell development in Chapter IV. Here, we studied the peripheral 
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immune compartment of patients with Netherton disease, a disease caused by mutations 
in the SPINK5 gene which results in a disrupted epidermal barrier.
Subsequently, we investigated the effect of different treatment strategies on the immune 
compartment of children with allergic disease. Chapter V describes the observed effects of 
multidisciplinary outpatient treatment at sea level and inpatient treatment at high altitude 
in children with moderate to severe atopic dermatitis. To further investigate the effect of 
desensitization on IgE+ and IgG4+ memory B-cells, we performed a longitudinal study in 
patients with hay-fever receiving SLIT. In Chapter VI we discuss the results of this therapy 
on various B- and T-cell subsets.
In Chapter VII and Chapter VIII we studied pathological aspects of IgG4+ B-cells in 
chronic inflammatory diseases. We performed detailed cellular and molecular studies in 
patients with IgG4-RD. The implications of these studies are discussed in the General 
Discussion, which also speculates on future directions.
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ABSTRACT
Background The prevalence of IgE-mediated diseases increases worldwide. Still, the IgE-
expressing B cells are poorly characterized, mainly due to their scarcity and low membrane 
IgE levels.
Objective To study the immunobiology of human IgE-expressing B cells in health and allergic 
disease.
Methods Stepwise approach for flow cytometric detection and purification of human IgE-
expressing B cells in controls, CD40L-deficient patients and patients with atopic dermatitis. 
Molecular analysis of replication histories, somatic hypermutations (SHM) and Ig class 
switching.
Results Using multi-color flow cytometry, we reliably detected IgE-expressing plasma cells 
and two IgE-expressing memory B-cell subsets. These IgE-expressing cells showed molecular 
and phenotypic signs of antigen responses. The replication history and SHM levels of IgE+ 
plasma cells and CD27+IgE+ memory B cells fitted with a germinal center (GC-)dependent 
pathway, often via an IgG intermediate, as evidenced from Sγ remnants in Sμ-Sε switch 
regions. CD27−IgE+ cells showed limited proliferation and SHM, and were present in CD40L-
deficient patients, indicating a GC-independent origin. Patients with atopic dermatitis had 
normal numbers of blood IgE+ plasma cells and CD27+IgE+ memory B cell, but increased 
CD27−IgE+ memory B cells with high SHM loads as compared to healthy controls and patients 
with psoriasis.
Conclusions We delineated GC-dependent and GC-independent IgE+ B-cell responses in 
health, and indicated involvement of the GC-independent pathway in a human IgE-mediated 
disease. These findings provide new insights into the pathogenesis of IgE-mediated diseases, 
and may contribute to accurate monitoring of IgE+ cells in patients with severe disease 
undergoing anti-IgE treatment.
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INTRODUCTION
Allergic disease incidence has increased over the past decades in most Western countries.1 
It has been estimated that currently ~8% of adults in the United States suffer from asthma,2 
and 30-40% of the world population is affected by one or more allergies.3 Allergic responses 
are mediated by an expansion of T helper type 2 (TH2) cells and isotype switching of B cells 
to generate allergen-specific immunoglobulin (Ig)E.
Allergic patients have IgE with specificities towards harmless food- or airborne particles 
(allergens) that underlie the disease.4 Despite the crucial role of IgE, little is known about 
the cellular aspects of IgE+ B-cell responses.5 The three main reasons for this are: 1) the 
presumed scarcity of the IgE-expressing B cells,6 2) the poor expression of membrane 
IgE due to suboptimal polyadenylation signals downstream of the exons encoding the 
cytoplasmic tail of IgE,7 and 3) the presence of the low-affinity receptor FcεRII (CD23) on B 
cells that binds IgE and results in detection of IgE on non-IgE-producing B cells.8
Class-switching towards IgE is primarily thought to take place in lymphoid germinal 
centers (GC), where it is mediated by IL-4, IL-13, IL-21 and CD40L on activated TH2 cells.9-12 In 
addition, co-stimulatory signals can be provided by the interaction between CD23 and CD21 
on B cells, as well as signaling via CD86.13,14 Still, respiratory mucosa and the gastrointestinal 
tract also show molecular signs of IgE class-switching.15 This is reminiscent of mucosal IgA 
responses that can take place independently of cognate T-cell help, possibly against non-
peptide antigens.16,17
In recent studies with mouse models, IgE-producing plasma cells in lymph nodes 
were found to be derived from GC reactions. These cells were mostly short-lived and their 
participation in GCs seemed transient. Long-term memory was generated in the form of 
post-GC IgG1+ cells that switched to IgE upon subsequent antigen encounter.18,19 Direct 
IgMàIgE class-switching was found as well,20,21 but the generation of high-affinity IgE 
antibodies depended on indirect IgMàIgG1àIgE switching.22 IgE+ memory B cells have only 
been observed by Talay et al.,23 which is potentially due to the manipulated IgE allele.24
Due to continuous antigenic pressure, human lymph nodes have persistent GCs, 
and large numbers of memory B cells can be found in blood. These features limit direct 
extrapolation from (manipulated) mouse models to human disease. We have recently 
delineated the human memory B-cell compartment by direct ex vivo analysis of Ig genes in 
sorted B-cell subsets.25 The Ig genes are targets of unique processes that leave permanent 
marks in the genomic DNA: V(D)J recombination for Ig repertoire development, somatic 
hypermutation (SHM) for affinity maturation, and Ig class-switch recombination (CSR) for 
effector function. CD27−IgA+ B cells and CD27+IgM+IgD+ ‘natural effector’ B cells (at least 
in part) were derived from local and systemic GC-independent responses, respectively; 
CD27−IgG+ and CD27+IgM+IgD− ‘IgM-only’ B cells were derived from primary GC responses 
and CD27+IgG+ and CD27+IgA+ B cells (at least in part) from consecutive GC responses.
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We now developed an 8-color flowcytometry-based strategy to reliably detect IgE+ 
plasma cells and CD27−IgE+ and CD27+IgE+ memory B-cell subsets following stepwise 
exclusion of IgM+, IgD+, IgG+ and IgA+ B cells. These IgE+ B cells lacked CD23 expression and 
carried IgE transcripts. We employed molecular analysis of their replication history, SHM, 
and CSR profiles and studies in CD40L-deficient and in atopic dermatitis patients to reveal 
new insights into their maturation pathways and involvement in allergic disease.
METHODS
Patients
Peripheral blood samples from patients and healthy donors, and childhood tonsils were 
obtained with informed consent and according to the guidelines of the Medical Ethics 
Committee of Erasmus MC.
All CD40L-deficient patients lacked CD40L protein expression on activated T cells as 
measured after 5-hour stimulation with phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 
calcium ionophore (Sigma-Aldrich), and carried hemizygous mutations in their CD40L gene.
Patients with atopic dermatitis and psoriasis vulgaris were selected from the outpatient 
clinic of Dermatology and Venereology at Erasmus MC in Rotterdam. The diagnosis of 
psoriasis vulgaris was made by certified dermatologists by clinical examination only. 
Patients with atopic dermatitis fulfilled the criteria by Hanifin and Rajka.26 Disease severity 
was scored for both groups by the attending physician. Total serum IgE and IgE against 
common inhalant allergens (Phadiatop) were measured with ImmunoCAP 250 (Phadia, AD 
Sweden) according to the manufacturer’s manual.
Flow cytometric immunophenotyping and cell sorting
Absolute counts of blood CD3+ T cells, CD16+/56+ NK cells and CD19+ B cells were obtained 
with a diagnostic lyse-no-wash protocol. Eight-color flow cytometry of memory B cells from 
peripheral blood and plasma cells from tonsils was performed using monoclonal antibodies. 
Intracellular staining was performed upon fixation and permeabilization with the FIX&PERM® 
Kit (An der Grub).
CD19+CD38dimCD27+IgD−IgM−IgE+ and CD19+CD38dimCD27−IgD−IgM−IgE+ were purified 
(>95% purity) on a FACSAria cell sorter (BD Biosciences) following AutoMACS (Miltenyi 
Biotec) enrichment of CD19+ B cells from post-ficoll mononuclear cells of healthy donors.25, 27
Molecular analysis of replication history and Ig gene rearrangements
DNA was isolated from each sorted B-cell subset with a mammalian DNA Miniprep Kit (Sigma-
Aldrich) to assess the replication history with the Kappa-deleting Recombination Excision 
Circles (KREC) assay, and the frequency of mutated IGK alleles was determined with the Igκ 
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restriction enzyme hot-spot mutation assay (IgκREHMA).27 RNA from CD19+CD38dimCD27+IgD−
IgM− and CD19+CD38dimCD27−IgD−IgM− B cells and total plasma cells was isolated using 
a mammalian RNA Miniprep kit (Sigma-Aldrich) and reversely transcribed with random 
hexamers. Complete IGH gene rearrangements were amplified in a semi-nested approach 
with previously described L-VH forward primers,28 and two different IGHE primers in the 
first (5’-CATCACCGGCTCCGGGAAGTAG-3’) and second (5’-GTTTTTGCAGCAGCGGGTCAAG-3’) 
reactions, or in a one-step PCR with either IGHM, IGHA or IGHG consensus reverse primers.25 
PCR products were cloned into the pGEM T-easy vector (Promega) and sequenced on an 
ABI Prism 3130XL (Applied Biosystems). Obtained sequences were analyzed with the IMGT 
database (www.imgt.org),29 and the JoinSolver program.30
Ig switch region analysis
Hybrid Sμ-Sε regions were amplified from genomic DNA in a nested long range PCR (LR-
PCR) using two Sμ-Sε primer sets for the first and second reactions.31, 32 PCR products were 
sequenced on the ABI Prism 3130XL and the results were aligned with the IGH reference 
sequence (NG_001019)
In vitro plasma cell differentiation
Naive mature, IgG+ and IgE+ B-cell subsets were purified, and 10,000-25,000 cells of each 
subset were cultured in 100μl IMDM supplemented with 10% fetal calf serum, 10 μg/ml anti-
CD40 (Bioceros B.V.) and 50 ng/ml IL-21 (PeproTech).33 Plasma cell maturation was assessed 
with flow cytometry after 6 days.
Statistical analyses
Statistical analyses were performed with the Mann-Whitney U test, paired t test or χ2 test as 
indicated in detail in Table and Figure legends. p values <0.05 were considered statistically 
significant.
RESULTS
IgE+ plasma cells in childhood tonsils
The identification of IgE+ B cells by flow cytometry has been controversial because of the 
scarcity of these cells, the low IgE expression levels and the presence of cells that have 
captured IgE with their Fcε receptors.6,7 We acknowledged these difficulties by the design of 
a novel 8-color flow cytometric approach to detect IgE+ plasma cells in childhood tonsil and 
IgE+ memory B-cell subsets in blood (Fig 1 and Fig 2). We identified plasma cells based on the 
CD19+CD38high phenotype. Subsequently, we selected IgM−IgD− cells within the plasma-cell 
gate, and analyzed IgE, IgA and IgG expression on these cells (Fig 1A and Fig E1). In childhood 
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tonsil, CD19+CD38high plasma cells constituted ~4% of total CD19+ cells. These plasma cells 
were mostly CD138−, of which 66% co-expressed IgM and IgD. About 30% of the total plasma 
cells was surface Ig negative, but expressed cytoplasmic IgG (not shown). The remaining 
plasma cells either expressed IgG (2.6%), IgA (1.2%) or IgE (1.6%) on their membrane.
Sequencing of IGHE transcripts from plasma cells yielded diverse clones that nearly 
all contained SHM in their IGHV regions (Fig 1B and C). In both childhood tonsil and adult 
blood, the SHM levels were similar to IgM+ plasma cells, and significantly lower than in IgA+ 
and IgG+ plasma cells. Still, targeting of SHM to hypermutable motifs and selection against 
replacement mutations in CDR regions were similar in all plasma-cell subsets (not shown).
Figure 1. Detection of IgE+ plasma cells in tonsil and peripheral blood. (A) Representative images 
from flow cytometric analysis of plasma-cell subsets in childhood tonsil. IgM−IgD− cells were 
gated within the total CD19+CD38high plasma cell fraction and analyzed for surface IgG, IgA and 
IgE expression. (B and C) SHM frequencies in rearranged IGHV genes in IGHM, IGHG, IGHA and 
IGHE transcripts from childhood tonsil (B) and adult blood (C). Each dot represents an individual 
sequence, red lines represent median values and the dashed line indicates the median SHM 
frequency in centrocytes. Data were statistically analyzed with the Mann-Whitney test. *, p<.05, 
**, p<.01, ***, p<.001.
Two IgE+ memory B-cell subsets in blood
Subsequently, we analyzed blood of healthy adult donors, who carry large numbers of 
circulating memory B cells.25 Within the CD19+CD38dimIgM−IgD− class-switched memory B 
cells we detected two subsets of IgE+ B cells with differential expression of CD27: CD27+IgE+ 
and CD27−IgE+ B cells (Fig 2A).
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In young children (<6 years), CD27+IgE+ cells were scarce with a median frequency of 
0.03% of total CD19+ B cells (Fig 2B). This frequency increased with age and reached 0.1% 
of total B cells in adults of 31-40 years. In contrast, CD27−IgE+ cells were more abundant in 
children than in adults, with the highest frequency of 0.12% of total B cells in children of 
6-15 year. Thus, two subsets of IgE+ B cells can be reproducibly detected in blood of healthy 
individuals and show distinct kinetics with age.
Figure 2. Two IgE+ memory B-cell subsets in blood. (A) Stepwise gating strategy for idenfification 
of CD27+IgE+ and CD27−IgE+ subsets. (B) CD27+IgE+ and CD27−IgE+ B-cell frequencies in healthy 
children and adults. Bars represent mean values with SEM. (C) Expression levels of CD79b on 
IgM+, IgG+, IgA+ and two IgE+ memory B-cell subsets. Each histogram is composed of merged 
data from 6 healthy donors, and contains a light grey filled histogram representing CD3+ T cells, 
and a dark grey histogram representing naive mature B cells. (D) Median fluorescence intensity 
of CD79b on B-cell subsets and T cells from 6 individual donors. Data were statistically analyzed 
with the Mann-Whitney test. *, p<.05; **, p<.01. (E) Expression levels of selected markers on IgM+, 
IgG+, IgA+ and IgE+ memory B-cell subsets. Light grey filled histograms represent isotype controls; 
dark grey histograms represent naive mature B cells.
IgE expression seemed dim on memory B cells, which could be due to suboptimal 
polyadenylation signals in transcripts encoding membrane IgE.7 To study whether B-cell 
receptor levels were indeed low, we determined the expression levels of the B-cell antigen 
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receptor complex member, CD79b, on all memory B-cell subsets. CD79b expression was 
high on IgG+ and natural effector B cells, intermediate on naive mature B cells, reduced on 
IgA+ cells and clearly the lowest on IgE+ memory B cells (Fig 2C and D). The differences in 
CD79b expression were not due to steric hindrance of the anti-IgA and anti-IgE isotypes 
(Supplemental Fig 1D). The low IgE membrane levels might have prevented prior detection 
of IgE+ memory B cells.
Subsequently, we studied the immunophenotype of the IgE+ memory B cells, and 
compared this with naive mature B cells and the 6 previously defined memory subsets.25 All 
analyzed B-cell subsets had high expression of CD21 (Fig 2E). A minor fraction of CD27−IgA+ 
and CD27−IgG+ cells lacked CD21 expression, confirming previous observations that part of 
the CD21low B-cell subset is negative for IgM and IgD.34 CD23 was highly expressed on naive 
B cells, but not on memory B cells.35,36 The detection of IgE on CD27+ and CD27− memory 
B-cells subsets is therefore not the result of FcεR-bound molecules. Furthermore, CD27+IgE+ 
and CD27−IgE+ B cells showed an immunophenotype that was characteristic for activated 
cells; with increased expression of the B7 family members CD80 and CD86, and TNF receptor 
superfamily member TACI as compared to naive mature B cells. In contrast to other memory 
B cells, IgE+ B cells did not show upregulation of TLR-related CD180. Still, CD27+IgE+ and 
CD27−IgE+ B cells carry a typical memory B-cell immunophenotype with absence of CD23, 
presence of CD21 and upregulation of activation markers.25,37
Replication history, SHM and class switching patterns in IgE+ memory B cells
CD27+IgE+ and CD27−IgE+ memory B cells were purified from healthy individuals for molecular 
analysis of their in vivo replication history and Ig gene maturation. CD27+IgE+ memory B cells 
showed a replication history of ~9 cell divisions (Fig 3A). This was similar to CD27+IgM-only 
and CD27−IgG+ B cells and higher than centrocytes. In contrast, CD27−IgE+ B cells had a 
limited replication history of only ~4 cell divisions, which was similar to CD27−IgA+ memory 
B cells. In agreement with the replication history, the frequency of mutated IGKV3-20 alleles 
and SHM levels in rearranged IGHV genes of CD27+IgE+ were similar to memory B cells from 
primary immune responses (Fig 3B and C). In contrast, CD27−IgE+ B cells showed few mutated 
IGKV3-20 alleles and low SHM levels in IGHV, reminiscent of GC-independent responses. Thus, 
both the replication history and SHM levels of CD27+IgE+ memory B cells suggest that these 
are post-GC cells, whereas CD27−IgE+ and CD27−IgA+ B cells share an origin from local T-cell 
independent (non-GC) responses.
Further analysis of SHM revealed high ratios of replacement versus silent mutations (R/S) 
in IGHV-CDRs of CD27+IgE+ (2.5) and CD27−IgE+ (4.7) memory B cells, and were indicative 
of antigenic selection.25 Interestingly, detailed analysis of the SHM targeting showed less 
abundant targeting of RGYW motifs in IgE+ memory B cells than in most of the other memory 
B-cell subsets, suggesting lower activity of AID in the formation of these cells.
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IgM+, IgG+ and IgA+ memory B-cell subsets in man have undergone selection against long 
IgH-CDR3 regions.25 The median IgH-CDR3 sizes of both CD27+IgE+ and CD27−IgE+ memory B 
cells were 16 amino acids, which was similar to centrocytes, but larger than the 14-15 amino 
acids found in other memory B-cell subsets (Fig 3D). Thus, selection mechanisms for IgE+ 
memory B cells seem different than for other memory B-cell subsets.
Class switching to IgE can occur indirectly via an upstream IGHG or IGHA constant region 
(Fig 3E). Theoretically, this would leave a Sα or Sg remnant in about half of the Sμ-Sμ switch 
regions. Therefore, we studied these molecular signs of indirect switching in hybrid Sμ-Sμ 
switch regions in genomic DNA of purified IgE+ memory B cells. CD27−IgE+ memory B cells 
hardly contained molecular signs of indirect switching (5%; Fig 3E). However, a substantial 
fraction of Sμ-Sε switch regions in CD27+IgE+ memory B cells (32%) contained remnants of 
an Sγ (mainly Sγ1) region. Thus, CD27−IgE+ cells seem to be almost exclusively generated 
directly from IgM+ cells, whereas IgE class-switching via an IgG intermediate is a frequent 
event in CD27+IgE+ memory B cells.
Figure 3. Distinct levels of molecular maturation in CD27+IgE+ and CD27−IgE+ memory B cells. 
(A) Replication histories of memory B-cell subsets as measured with the KREC assay.25,27 Bars 
represent mean values with SEM. Dashed lines represent values for centrocytes (n=55).27 (B) 
Frequencies of mutated nucleotides in rearranged IGHV genes. Each grey dot represents a 
unique rearrangement, and red lines indicate median values. (C) Frequencies of mutated IGKV3-
20 genes as measured with the IgκREHMA assay.27 (D) IgH-CDR3 size distributions in memory 
B-cell subsets. Differences between CD27+IgE+ and CD27−IgE+ cells were statistically analyzed 
with the Mann-Whitney test. **, p<.01 (E) Schematic representation of direct (solid lines) and 
indirect (dashed lines; via IgG1) class-switching to IGHE. Examples of hybrid Sμ-Sε switch regions 
generated from direct (upper sequence) and sequential (lower sequence) class switching to IGHE. 
Frequencies of direct and indirect class-switching in CD27+IgE+ and CD27−IgE+ memory B cells. 
The numbers of analyzed sequences are indicated in the inner circles. Data were statistically 
analyzed with the χ2 test.
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T-cell independent generation of CD27-IgE+ memory B cells
To study whether CD27−IgE+ memory B cells can indeed be formed independently of 
cognate T-cell help, we studied these in blood of 5 CD40L-deficient patients (Fig 4A). These 
patients lack IgG+ memory B cells and carry strongly reduced IgM+ and IgA+ memory B-cell 
numbers.25 While the CD27+IgE+ events were on the borderline of detection, CD27−IgE+ B 
cells were reliably detected with ~30% reduced frequencies as compared to healthy age-
matched controls (Fig 4B). From this, we concluded that IgE+ B cells can be formed in the 
absence of cognate T-cell help and these cells are nearly all CD27 negative.
Figure 4. Germinal center-dependent and -independent origin of IgE+ memory B-cell subsets in 
blood. (A) Representative images of flowcytometric analysis of circulating memory B-cell subsets 
in CD40L-deficient patients. (B) CD27+IgE+ and CD27−IgE+ B cell frequencies in CD40L-deficient 
patients and healthy age-matched donors (0-3y). Bars represent mean values with SEM.
Efficient plasma cell differentiation of IgE+ memory B cells
Plasma cell differentiation and Ig class switching can be mediated by the cytokines IL4, IL13 
and IL21.10,13,38 The receptor for IL13 was not expressed on naive and memory B-cell subsets, 
IL4R was weakly expressed and IL21R was clearly detectable (Fig 5A). To study whether the 
IgE memory B cells could differentiate into plasma cells, we cultured FACS-purified cells for 
6 days in the presence of anti-CD40 and IL21. Both IgG and IgE memory B cells generated 
CD38hiCD27+ plasma cells (Fig 5B), although the CD27+ subsets seemed more efficient than 
the CD27- cells.
Increased circulating CD27−IgE+ memory B cells in patients with atopic 
dermatitis
We exploited the reliable detection of IgE+ memory B-cell subsets in blood to study 23 
patients with atopic dermatitis, an allergic response often accompanied by increased IgE 
serum levels.39 IgE+ B-cell frequencies were compared with 16 age-matched healthy controls, 
and with 14 patients with TH1/TH17-mediated psoriasis. Frequencies of total IgE+ memory 
B cells and CD27+IgE+ B cells were not significantly different between the groups (Fig 6A). 
However, the median frequency of CD27−IgE+ cells in atopic patients (0.12%) was significantly 
higher than in healthy donors (0.8%; p<0.05) and psoriasis patients (0.5%; p<0.05).
Patients with a ‘high’ disease severity according to the criteria by Hanifin and Rajka had 
more CD27+IgE+ and CD27−IgE+ cells than patients with the ‘mild’ or ‘moderate’ manifestation 
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of the disease (data not shown).26 Due to low numbers of patients per group, these 
differences did not reach statistical significance. The frequencies of IgE+ memory B cells 
did not correlate with total or allergen-specific IgE serum levels (Fig 6B).
Figure 5. (A) Expression levels of IL4R, IL13Ra, and IL21R on naive mature, and IgG+ and IgE+ 
memory B cells. (B) The generation of plasma cells defined as CD38hiCD27+ after 6-day cultures. 
The average values for independent experiments with SEM are shown, as well as paired analysis 
of CD27+IgE+ and CD27-IgE+ memory B-cell subset (paired t test).
To study the effects of chronic disease on the IgE responses, we analyzed SHM in variable 
regions of IGHE transcripts amplified from 5 atopic dermatitis patients with a selective 
increase in CD27−IgE+ memory B cells (at least 6-fold more CD27−IgE+ than CD27+IgE+ 
B cells). The frequency of SHM in IGHV genes of CD27−IgE+ in atopic dermatitis patients 
was significantly higher than in control CD27−IgE+ memory B cells, and similar to control 
CD27+IgE+ B cells (Fig 6C). Patients’ transcripts showed molecular signs of affinity maturation 
with a high IGHV-CDR R/S ratio (3.0). Thus, patients with atopic dermatitis show increased 
levels of circulating CD27−IgE+ memory B cells that show molecular signs of extensive 
antibody maturation.
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Figure 6. Increased frequencies of CD27−IgE+ memory B cells in atopic dermatitis patients. (A) 
Frequencies of CD27+IgE+ and CD27−IgE+ memory B cells and IgE+ plasma cells in atopic dermatitis 
(AD) patients, psoriasis (psor) patients and healthy age-matched donors (ctrl). Individual data 
points are shown as grey dots with red lines indicating median values. (B) Correlation between 
CD27+IgE+ and CD27−IgE+ memory B-cell numbers, and IgE serum levels in 23 patients with 
atopic dermatitis. (C) Frequencies of mutated nucleotides in rearranged IGHV genes. Data were 
statistically analyzed with the Mann-Whitney test; *, p<.05.
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Model of IgE+ plasma cell and memory B-cell formation in human
To recapitulate our findings, we propose a model of IgE+ plasma cell and IgE+ memory 
B-cell formation in human (Fig 7). Based on the distinct molecular features and similarity to 
previously characterized memory B-cell subsets, we distinguish CD27+IgE+ memory B cells 
derived from a primary GC-dependent pathway and CD27−IgE+ memory B cells from local 
(mucosal) tissue. IgE+ plasma cells are likely to be derived from both the GC and non-GC 
maturation pathways.
Figure 7. Model for GC-dependent and GC-independent maturation of IgE+ B cells. Naive mature 
B cells scavenge the peripheral lymphoid system for antigens. Responses to peptide allergens 
with T-cell help result in extensive proliferation and affinity maturation in GCs, generating IgE+ 
plasma cells and CD27+IgE+ memory B cells, potentially via an IgG intermediate. Antigen responses 
independently from T-cell help in local tissue (e.g. mucosa, skin) induce limited proliferation, SHM 
and direct IgE switching, generating plasma cells or CD27−IgE+ memory B cells.
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DISCUSSION
Using a novel 8-color flow cytometry strategy, we reliably detected IgE+ plasma cells and two 
IgE+ memory B-cell subsets. Purification and molecular analysis of these subsets allowed us 
to dissect their origins from GC responses (IgE+ plasma cells and CD27+IgE+ memory B cells) 
and GC-independent responses (CD27−IgE+). The GC-dependent responses generated more 
SHM and frequently involved Ig CSR via IgG1, contrasting non-GC responses generating 
CD27−IgE+ memory B cells. These CD27−IgE+ cells were increased and showed extensive SHM 
in patients with atopic dermatitis.
Prior to flow cytometric selection of IgE+ B cells, we performed a stepwise exclusion 
of IgM+, IgD+, IgG+ and IgA+ cells to increase the specificity of detection of rare IgE+ B cells. 
IgE+ B cells carried low surface Ig levels as compared with other B cells, possibly due to 
the suboptimal polyadenylation signals in membrane IgE transcripts.7 Moreover, with 
this strategy, we excluded CD23+ naive B cells that stained positively for IgE due to CD23-
mediated capture from serum.35 Thus far, the detection of IgE+ B cells has been problematic, 
and often depended on cold acid wash to disrupt CD23-IgE binding,40 which can be very 
damaging to the cells. Our direct flow cytometric approach on otherwise untreated cells 
allowed detailed immunophenotyping and molecular studies.
The majority of plasma cells in childhood tonsils had an immature phenotype with 
surface Ig and low/absent CD138 expression, which is commonly seen in plasma cells in 
lymph nodes, but not in blood and bone marrow,41,42 and likely reflects recent generation. 
The IgE transcripts showed low mutation frequencies similar to IgM. Furthermore, blood 
IgE+ plasma cells had intermediate SHM levels as compared to the two IgE+ memory B-cell 
subsets. Therefore, IgE+ plasma cells are likely a mixture of cells from primary GC-dependent 
and –independent responses.25,27
In blood, we identified circulating IgE+ B cells that could be separated into CD27+ and 
CD27− subsets. Both subsets showed immunophenotypic and molecular signs of B-cell 
memory: (1) high expression of activation and costimulatory molecules; (2) antigen-driven 
proliferation; and (3) SHM levels with high R/S ratios in IGHV-CDRs. The existence of IgE+ 
B-cell memory has been disputed, although some indirect evidence exists from the kinetics 
of allergic responses.43,44 Moreover, several studies report the detection of low numbers 
of circulating IgE+ B cells displaying a plasma cell-like phenotype.45,46 The IgE+ B cells we 
identified showed a memory B-cell phenotype with low CD38 expression and upregulation 
of CD80, CD86 and TACI. In addition, FACS-purified cells expressed IgE-switched transcripts 
with SHM. Thus, IgE+ memory B cells can be formed in healthy individuals and circulate in 
peripheral blood.
The two circulating IgE+ memory B-cell subsets did not merely differ in their CD27 
expression: the replication history, SHM levels, and frequency of indirect class-switching 
were significantly higher in CD27+IgE+ than in CD27−IgE+ memory B cells. In CD27+IgE+ 
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memory B cells, these levels were slightly higher than in centrocytes, but lower than in 
CD27+IgG+ and CD27+IgA+ memory B cells, indicating that the majority of these cells in 
healthy adults are potentially derived from primary GC responses. This GC-dependent IgE 
response is most likely the source of high-affinity IgE in man. In mouse, switching to IgE takes 
place in post-GC IgG+ B cells.22 Because CD27+IgE+ memory B cells show high frequencies 
of indirect switching via an IgG intermediate, it is possible that IgE switching does not take 
place in the GC, but is a post-GC process.
CD27−IgE+ memory B cells had a limited replication history (3-4 cell divisions) and low 
SHM levels, and were present in CD40L-deficient patients, supporting their origin from 
a T-cell independent pathway. Until recently, CD27 was considered a pan-memory B-cell 
marker,47 but there is growing evidence that also CD27− Ig class-switched cells display 
memory B-cell characteristics.25,48 Importantly, the replication history and SHM levels of 
CD27−IgE+ memory B cells were similar to CD27−IgA+ memory B cells. Furthermore, both 
subsets showed predominantly direct Ig class-switching, and the frequently used IGHA2 
region in CD27−IgA+ memory B cells is genomically close to IGHE.25 These comparable 
features support a similar origin of CD27−IgA+ and CD27−IgE+ memory B cells from local 
mucosal responses.25 This contrasts with CD27-IgG+ cells that are fully dependent on T-cell 
help and share clonal relationships with CD27+IgG+ B cells.25,49 Still, it cannot be excluded 
that such clonal relationships are also present between CD27+IgE+ and CD27-IgE+ subsets. 
Multiple studies demonstrated local IgE production in the respiratory tract of patients with 
atopic rhinitis and asthma,50,51 and in the gastrointestinal tract of patients with food allergy, 
and showed increased local IL-4 and IL-13 production in these pathological conditions.52,53 
Of these, IL-4 is crucial for CD40-independent class-switching and BAFF- or APRIL-induced 
switching to IgE.54,55 CD27−IgE+ memory B cells were the predominant IgE+ subset in children. 
Since GC-dependent responses remain underdeveloped in young children, involvement 
of CD27−IgE+ cells in local responses could possibly explain early onset of some allergic 
diseases.
Atopic dermatitis patients showed increased frequencies of CD27−IgE+ memory B cells 
with high levels of SHM. While this increase was not found in psoriasis, the nature of these 
cells in atopic dermatitis remains unclear. The CD27−IgE+ phenotype could reflect the mainly 
local manifestation of this allergic disease. These cells would then be abnormally expanded 
and gained increased SHM levels. Alternatively, the CD27−IgE+ memory B cells in these 
patients are derived from a GC response with normal SHM levels, but display an abnormal 
phenotype. Still, these findings imply that analysis of CD27−IgE+ memory B-cell numbers can 
contribute to diagnosis and therapy monitoring of these patients, especially in cases with 
low IgE serum levels. Furthermore, IgE+ memory B-cell measurements could prove valuable 
in monitoring of patients undergoing immunotherapy or anti-IgE antibody therapy (e.g. 
with omalizumab). A recent study indicated that the beneficial effect of omalizumab is the 
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result of reduced IgE production.56 Therefore, the kinetics of reduction of IgE+ memory B-cell 
levels could be an early marker to predict therapy outcome for patients with severe allergies.
Thus, by implementing a new strategy to reliably detect IgE-expressing B cells, we 
provided new insights into the biology of human IgE+ plasma cells and dissected the 
molecular differences of the two memory B-cell subsets potentially derived from T-cell 
dependent and T-cell independent pathways. These insights open new possibilities to 
study the pathophysiological mechanisms underlying IgE-mediated diseases, which can 
be directly translated into patient care.
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SUPPLEMENTAL DATA
Supplemental Figure 1. Immunophenotyping details of IgE+ memory B cells and plasma 
cells. Backgating of IgE+ plasma cells from tonsil (A), memory B cells from blood of a healthy 
control (B) and a CD40L-deficient patient (C) within the IgM-IgD- gate. (D) Evaluation of steric 
hindrance of CD79b (left) and TCRαβ expression. Cells from 2 healthy donors were incubated 
simultaneously with anti-CD79b and anti-Ig isotypes or 3 min with CD79b prior to addition 
of anti-Ig isotypes. Pre-incubation with anti-CD79b prior to addition of the anti-Ig isotype 
antibodies did not lead to higher expression levels. In contrast, pre-incubation of T cells with 
anti-TCRαβ clone IP26 prior to addition of anti-CD3 clone OKT3 did lead to increased TCRαβ 
expression levels.
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ABSTRACT
Despite the critical role of soluble IgE in the pathology of IgE-mediated allergic disease, 
little is known about abnormalities in the memory B-cells and plasma cells that produce IgE 
in allergic patients. We here applied a flowcytometric approach to cross-sectionally study 
blood IgE+ memory B-cells and plasmablasts in 149 children with atopic dermatitis, food 
allergy and/or asthma, and correlated these to helper-T(h)2 cells and eosinophils. Children 
with allergic disease had increased numbers of IgE+CD27- and IgE+CD27+ memory B-cells 
and IgE+ plasmablasts, as well as increased numbers of eosinophils and Th2 cells. IgE+ 
plasmablast numbers correlated positively with Th2 cell numbers. These findings open new 
possibilities for diagnosis and monitoring of treatment in patients with allergic diseases.
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INTRODUCTION
IgE is commonly used in the diagnostic work-up of patients with allergic disease, but little is 
known about the cells producing it.1, 2 All antibodies, including IgE, are produced by plasma 
cells.3 IgM, IgG and IgA expressing memory B cells and plasma cells can be readily detected 
in tissue or blood of healthy children and adults. In contrast, IgE-expressing B cells have 
been enigmatic.4 Still, based on the presence of IgE transcripts isolated from various tissues 
and blood of healthy controls and allergic subjects5-7, the presence of IgE-expressing B cells 
has been anticipated.8 We developed a flowcytometric strategy that enabled the detection 
of IgE-expressing CD27+CD38hi plasmablasts, CD27+ and CD27- memory B cells.9 Although 
T-cell help is required to generate the former subsets, CD27-IgE+ B cells can be formed 
independent of cognate T-cell help.9, 10
More insights into IgE-expressing B cells and their interactions with other immune cells 
are needed to better understand the pathogenesis of allergic disease, which could be useful 
for diagnostic purposes or to uncover targets for treatment. Similar to immunotherapy, 
anti-IgE antibody treatment can potentially target IgE+ memory B-cells and thereby might 
resolve the underlying allergy.11
We performed a cross-sectional study into IgE-expressing B cells in allergic children 
and healthy controls. Patients were separated into three groups based on distinct allergic 
phenotypes of asthma, food allergy and/or atopic dermatitis. We studied IgE+ memory B-cell 
and IgE+ plasmablast numbers with flow cytometry, their maturation status with molecular 
studies, and related these to clinical phenotype and other clinical and immunological 
parameters.
METHODS
Peripheral blood samples were obtained from children aged 6-18 years who were recruited 
from the allergy outpatient clinics (KinderHaven and allergy department) of the Erasmus 
University Medical Center Rotterdam. All children were recruited from a tertiary referral 
center for children with allergic disease and were doctor’s diagnosed as moderate to severe 
allergic disease. All children had allergic disease based on clinical examination and confirmed 
either by atopy skin test (HEP >0.21), specific IgE serum levels (>0.35 IU/L), immune solid-
phase allergy chip (ISAC) or, in the case of food-allergy, double blind food provocation 
test. Based on symptoms, clinical findings and IgE-specificity, children with allergic disease 
were divided into three groups: 1) children with asthma in absence of food allergy (FA) and 
atopic dermatitis (AD): ‘Asthma’, n=68; 2) children with asthma in combination with FA and/
or AD: ‘Asthma + FA/AD’, n=48; and 3) children with FA and/or AD in absence of asthma; ‘FA/
AD’, n=33. Age-matched non-allergic controls were recruited among children undergoing 
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surgery in the Sophia Children’s Hospital in Rotterdam. Exclusion criteria for the study were: 
age <6 years, systemic immunosuppressive therapy and immunological diseases, such as 
immunodeficiencies and auto-immune diseases.
All peripheral blood samples were collected after written informed consent was obtained 
and with approval of the Medical Ethical Committee of the Erasmus Medical Center, which 
complies with the Helsinki declaration.
Detailed methods on flow cytometry, molecular analysis of IgE transcripts and statistics 
can be found in the supplemental data.
RESULTS
Patient characteristics
A total of 149 allergic and 15 non-allergic children were included. All allergic children were 
sensitized for either aero- or food-allergens, as detailed per group in Table S1.
Increased numbers of eosinophils, T-cells and B-cells in children with allergic 
disease
Total leukocyte counts were higher in patients with allergic disease than in non-allergic 
controls (Figure 1A). Similarly, total T- and B-cell numbers were significantly higher in each 
of the 3 groups with allergic disease than in non-allergic controls (Figure 1B). Total numbers 
and frequencies of eosinophils were significantly increased in allergic children as compared 
to non-allergic children (Figure 1C and Figure S2). Leukocyte subsets and total T- and B-cell 
numbers did not differ between the three allergic groups.
Absolute CD4+ T-cell numbers and subsets within CD4+ T-cells were significantly higher 
in children with allergic disease than in non-allergic children (Figure 1D). Still, frequencies 
of CD4 T-cells within CD3+ T-cell were not different from healthy children (Figure 1E). In 
addition, frequencies of Th1 and Th2 subsets within CD4+ T cells were not different between 
healthy children and children with allergic disease (Figure 1F). As a result, we did not observe 
a difference in Th2/Th1 cell ratios (Figure 1G) between patients and controls.
Increased numbers of circulating IgE+ memory B-cells and IgE producing 
plasmablasts
IgE+ memory B-cells were defined within the CD19+CD38dim fraction and IgE+ plasmablasts 
within the CD19+CD38+CD27hi fraction following exclusion of CD19+ B-cells expressing IgM, 
IgD, IgA or IgG (Figure 2A).9
Median cell numbers of both CD27+IgE+ and CD27-IgE+ memory B-cells were 
significantly higher in all three groups of allergic children than in non-allergic controls 
(Figure 2B). In addition, IgE+ plasmablast numbers were significantly increased in allergic 
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children (Figure 2C). IgE+ memory B-cell and IgE+ plasmablast numbers did not significantly 
differ between patient groups. The increases in IgE+ B-cell numbers in allergic children were 
not only the result of higher total B-cell counts, because their relative numbers within CD19+ 
B cells were also significantly higher in all patient groups (Figure 2D,E).
Figure 1. Absolute numbers and frequencies of leukocyte subsets and CD4+ helper-T(h) 
subsets. A. White blood cell count. B. Absolute numbers of T cells and B cells. C. Percentages of 
granulocyte subsets and monocytes within total CD45+ cells. D. Absolute cell numbers of CD4+ 
T-cells, Th1 and Th2 cells E. Percentage of CD4+ T-cells within total CD3+ T-cells. F. Percentage 
of Th1 and Th2 cells within total CD3+ T-cells. G. ratio of Th2/Th1 cells. Each dot represents 
one individual and red lines indicate median values. Grey surface represent reference values. 
Statistical analysis was performed with Mann Whitney U test. *P<0.05, **P<0.01, ***P<0.001
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Figure 2. IgE+ B-cell subsets. A. Representative flowcytometry image and gating strategy of 
IgE+ memory B-cells. B. Absolute numbers and percentages of IgE+ memory B-cells. C. Absolute 
numbers and percentages of IgE+ plasmablasts. D. Somatic hypermutation (SHM) levels in the 
IGHV gene of IgE+ plasmablasts from healthy children and children with allergic disease (n=5 
children each). E. Selection for replacement mutations in the CDR (red) and FR (blue) regions. F. 
Correlation of Th2 cell numbers with IgE+CD27-, IgE+CD27+ and IgE+ plasmablasts in children 
with allergic disease. In panels B, C and F each dot represents one individual; red lines indicate 
median values; and black lines in panel F indicate linear correlations. Statistical analysis was 
performed with Mann Whitney U test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Correlation 
was calculated with Spearman R.
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To investigate whether the increased numbers constituted normal plasmablasts, we 
studied the levels of somatic hypermutation (SHM) in IgE transcripts of sorted cells from 
allergic children (n=43 unique transcripts) and from non-allergic controls (n=34 unique 
transcripts). Transcripts from patients carried fewer mutations in their IGHV genes than 
controls (Figure 2F). As a measure for antigen-driven selection of the mutations in the 
IGHV genes, we analyzed the selection for replacement mutations in the complementarity 
determining regions (CDR) with the BASELINe program. Transcripts from healthy controls 
(PCDR/FWR -0.48) nor from children with allergic disease (PCDR/FWR 0.06) showed more replacement 
mutations than expected by random chance in the CDR regions, i.e. absence of positive 
selection (Figure 2G). Thus, the higher numbers of circulating IgE-expressing B-cells in 
children with allergic disease did not show molecular signs of enhanced antigen receptor 
maturation.
Since type 2 cytokines produced by helper-T(h) cells are important for IgE class switch 
recombination (CSR) and children with allergic disease had increased numbers of IgE+ 
B-cells, we investigated the correlation between Th cells and IgE+ B-cells. We observed 
a correlation between IgE+ plasmablast numbers and Th2 cells (r 0.271; P <0.01), whereas 
there was no correlation between IgE+ memory B-cell subsets and Th2 cells (Figure 2H).
DISCUSSION
In the present study we extended the immunological phenotype of allergic children. In 
addition to Th2 cells, eosinophils, basophils and serum IgE, we found increased numbers 
of circulating IgE+ memory cells and IgE+ plasmablasts, and a positive correlation between 
IgE+ plasmablasts and Th2 cell numbers.
In our patient group, type 2 sensitization was confirmed by high IgE serum levels, 
sensitization to various aero- and food allergens, high numbers of eosinophils in blood 
and increased Th2 cell numbers.
Our findings of increased numbers of circulating IgE+ memory B cells extend previous 
observations.9, 12, 13 Importantly, our flowcytometric gating strategy enabled exclusion of 
IgE-binding cells from the true IgE-expressing B cells, which we confirmed by the presence 
of mature IgE transcripts. We showed that this occurs in children, and is independent of the 
allergic phenotype. A cause for the increased numbers of circulating IgE+ memory B cells 
could be the chronic inflammation. This is specifically thought to occur in patients with 
atopic dermatitis, and to some extent also in asthma. Here we found increased numbers 
of both CD27+ and CD27- IgE-expressing memory B cells in allergic patients. It has been 
shown that CD27- IgE+ memory B-cells display a limited proliferation history and lower SHM 
levels in their immunoglobulin genes9, which suggest that they originate from mucosal 
tissue, analogous to CD27-IgA+ memory B-cells.14 This is supported by previous detections 
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of IgE transcripts and Sμ-Sε switch circles in nasal tissue of patients with allergic rhinitis 
and in bronchial tissue of patients with allergic asthma.8, 15 Several studies have shown 
that sensitized individuals who are exposed to allergens via nasal tissue or the respiratory 
tract, display a substantial increase in systemic serum IgE levels, thus indicating the direct 
activation of an established local pool of IgE memory cells with defined specificities as an 
underlying mechanism.16
We did not observe a correlation between IgE+ memory B-cell and Th2 cell numbers, but 
we did find a positive correlation between Th2 cells and IgE+ plasmablasts. Previous studies 
show that type 2 innate lymphoid cells (ILC2) might play an important role in the local CSR 
towards IgE.17, 18 Furthermore expansions of ILC2 populations have been observed in allergic 
disease and are known to produce type 2 cytokines and ILC2 cells facilitate sensitization to 
local, but not systemic Th2 inducing allergen exposures.19 Next to that, T follicular helper 
(Tfh) cells have been linked to IgE class switching through the production of IL-4.20, 21 Tfh 
cells express the B-cell follicle homing receptor CXCR5 and mainly reside in germinal centers. 
Thus possibly ILC2 cells might be important in local IgE CSR, Tfh cells in germinal center 
IgE CSR, whereas Th2 cells are important in plasma cell differentiation. In future studies 
it would be interesting to study ILC2 cells in mucosal tissue and correlate these to IgE+ 
memory B-cell numbers.
It is uncertain if circulating IgE+ memory B-cells sustain the underlying allergy, but in 
vitro stimulated IgE+ memory B-cells can differentiate into IgE+ plasma cells.9 Therefore 
it is possible that increased circulating IgE+ memory B-cells actively contribute to allergic 
disease.22 To achieve desensitization and possibly even cure allergic disease, it might 
therefore be important to develop therapies to reduce IgE+ memory B-cells. Omalizumab 
treatment in humans has shown to decrease serum IgE in patients with IgE-mediated 
asthma23, however it mainly targets soluble IgE. This is not the case for Quilizimab, which 
only recognizes surface-expressed IgE on B cells11, and has shown to deplete IgE producing 
B-cells in mouse studies.24 Although human clinical trials with Quilizimab reduced IgE 
serum levels for 6 months after treatment cessation, the effects on clinical parameters were 
variable.25, 26 Our present findings can possibly contribute to patient selection and treatment 
monitoring of anti-IgE treatment.
AUTHOR CONTRIBUTIONS
JJH, JCdJ, JJMvD and MCvZ designed research. JJH and LR performed research. JJH, LR and 
MCvZ analyzed data. NJA, SGP, JCdJ and GJD evaluated and included patients in the study. 
JJH and MCvZ wrote the paper, and all authors commented on the paper and approved 
the final version.
69
Cellular characteristics of IgE+ B-cells in children with allergic disease
ACKNOWLEDGEMENTS
The authors would like to thank Mr. S.J.W. Bartol for technical support and Ms. M. Hoozemans 
for assisting with practical work. Furthermore, we would like to thank the nurses at 
KinderHaven for assistance in blood withdrawal of participating children.
This work was performed in part in the Department of Immunology in the context of the 
Molecular Medicine Postgraduate School of the Erasmus MC, and was financially supported 
by Grant S698 from the Sophia Children’s Hospital Fund (SKF) to JJH, NJA, JJMvD, JCdJ and 
MCvZ. MCvZ is supported by an NHMRC Senior Research Fellowship (APP1117687).
3
70
Chapter 3
REFERENCES
1. Aranda A, Mayorga C, Ariza A, Dona I, Rosado A, Blanca-Lopez N, et al. In vitro evaluation of 
IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011; 66:247-54.
2. Hamilton RG, Adkinson NF, Jr. 23. Clinical laboratory assessment of IgE-dependent 
hypersensitivity. J Allergy Clin Immunol 2003; 111:S687-701.
3. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting 
plasma cells. Nat Rev Immunol 2015; 15:160-71.
4. Davies JM, Platts-Mills TA, Aalberse RC. The enigma of IgE+ B-cell memory in human subjects. 
J Allergy Clin Immunol 2013; 131:972-6.
5. Steinberger P, Bohle B, di Padova F, Wrann M, Liehl E, Scheiner O, et al. Allergen-specific IgE 
production of committed B cells from allergic patients in vitro. J Allergy Clin Immunol 1995; 
96:209-18.
6. Eckl-Dorna J, Pree I, Reisinger J, Marth K, Chen KW, Vrtala S, et al. The majority of allergen-
specific IgE in the blood of allergic patients does not originate from blood-derived B cells or 
plasma cells. Clin Exp Allergy 2012; 42:1347-55.
7. Horst A, Hunzelmann N, Arce S, Herber M, Manz RA, Radbruch A, et al. Detection and 
characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency 
with IgE serum titre. Clin Exp Immunol 2002; 130:370-8.
8. KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) 
IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J 2000; 15:491-7.
9. Berkowska MA, Heeringa JJ, Hajdarbegovic E, van der Burg M, Thio HB, van Hagen PM, et al. 
Human IgE(+) B cells are derived from T cell-dependent and T cell-independent pathways. J 
Allergy Clin Immunol 2014; 134:688-97 e6.
10. Heeringa JJ, Hajdarbegovic E, Thio HB, van Zelm MC. Systemic B-cell abnormalities in patients 
with atopic dermatitis? J Allergy Clin Immunol 2016; 138:317-8.
11. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, et al. Targeting 
membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces 
IgE production. Sci Transl Med 2014; 6:243ra85.
12. Wong KJ, Timbrell V, Xi Y, Upham JW, Collins AM, Davies JM. IgE+ B cells are scarce, but 
allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis. 
Allergy 2015; 70:420-8.
13. Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Xiangyu P, Kunjravia N, et al. Diverse 
activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis 
but not in patients with psoriasis. J Allergy Clin Immunol 2016; 137:118-29 e5.
14. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, 
et al. Human memory B cells originate from three distinct germinal center-dependent and 
-independent maturation pathways. Blood 2011; 118:2150-8.
15. Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, et al. Class switch 
recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. 
J Allergy Clin Immunol 2007; 119:213-8.
71
Cellular characteristics of IgE+ B-cells in children with allergic disease
16. Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, et al. Antigens drive memory 
IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 2007; 142:133-
44.
17. Kim HY, Umetsu DT, Dekruyff RH. Innate lymphoid cells in asthma: Will they take your breath 
away? Eur J Immunol 2016; 46:795-806.
18. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells--how did we miss them? Nat Rev 
Immunol 2013; 13:75-87.
19. Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, et al. Group 2 innate lymphoid 
cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. J 
Allergy Clin Immunol 2014; 133:1142-8.
20. King IL, Mohrs M. IL-4-producing CD4+ T cells in reactive lymph nodes during helminth 
infection are T follicular helper cells. J Exp Med 2009; 206:1001-7.
21. Kobayashi T, Iijima K, Dent AL, Kita H. Follicular helper T cells mediate IgE antibody response 
to airborne allergens. J Allergy Clin Immunol 2017; 139:300-13 e7.
22. Mitre E, Nutman TB. IgE memory: persistence of antigen-specific IgE responses years after 
treatment of human filarial infections. J Allergy Clin Immunol 2006; 117:939-45.
23. Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-
mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72:306-20.
24. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, et al. Antibodies specific for a segment of 
human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest 2010; 
120:2218-29.
25. Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, et al. A randomized 
trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin 
Immunol 2016; 138:1730-2.
26. Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, et al. A randomized trial of 
the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. 
Respir Res 2016; 17:29.
3
72
Chapter 3
SUPPLEMENTAL DATA
Supplemental Materials and Methods
Flow cytometry of blood samples
White blood cell (WBC) counts were determined with a Coulter cell counter (Beckman 
Coulter) within 24 hours of blood sampling. Absolute counts of CD45+ leukocytes, CD3+ 
T-cells and CD19+ B-cells were obtained with a diagnostic lyse-no-wash protocol using 
TruCount tubes (BD Biosciences, San Jose, Calif). For detailed 11-color flow cytometry, red 
blood cells were lysed with NH4Cl prior to incubation of 2 million nucleated cells for 15 
minutes at room temperature in a total volume of 100μL. After preparation, cells were 
measured on a 4-laser LSRFortessa flow cytometer (BD Biosciences) using standardized 
settings. Data were analyzed with FACSDiVa software V8.0 (BD Biosciences). Our previously 
published sequential flowcytometric gating strategy was applied to identify IgE+ B-cells.
Molecular analysis of IGH gene rearrangements
RNA was isolated from post-Ficoll mononuclear cells with a GenElute mammalian RNA 
kit (Sigma-Aldrich, St Louis, Mo) and reverse transcribed to cDNA with random primers 
(Invitrogen Life technologies). Alternatively, IgE+ plasma cells (CD19+CD38hiCD27+IgE+) 
were single cell sorted on a FACSAria III (BD Biosciences) into 96-well PCR plates (VWR 
European, Radnor, PA) containing ice-cold 0.5x PBS, 10mM DTT (Invitrogen, Carlsbad, Calif) 
and 8 U RNAsin® (Promega, Madison, Wis). Total RNA from these single cells was reversed 
transcribed into cDNA using 5μM random hexamer primers (Applied Biosystems, Foster 
City, Calif), 0.5% Triton X (Sigma-Aldrich, St Louis, Mo), 1x first strand buffer (Invitrogen), 
1.25mM dNTPs, 10mM DTT (Invitrogen), 16 U RNAsin® (Promega) and 70 U SuperScript® III 
reverse transcriptase (Invitrogen).
IGHV gene rearrangements were amplified in a semi-nested multiplex PCR approach 
using 4 different IGHV-family specific leader forward primers in combination with IGHE-
specific reverse primers (first PCR: 5’-CATCACCGGCTCCGGGAAGTAG-3’; second PCR: 
5’-ACGGAGGTGGCATTGGAGGGAAT-3’). PCR products were cloned into a pGEMT easy vector 
(Promega, Madison WI), amplified by colony PCR, and sequenced on an ABI Prism 3130XL 
(Applied Biosystems, Foster City, CA). The sequences were analyzed with the IMGT database 
(www.imgt.org) and BASELINe program (selection.med.yale.edu/baseline) to quantify 
somatic hypermutations (SHM) and selection for replacement mutations.
Statistical analysis
Frequencies and absolute cell numbers had a non-Gaussian distribution. Therefore, all 
results were expressed as median (interquartile range) if applicable and were analyzed using 
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the Mann-Whitney U test. Linear regression was used to study the strength of association 
between cell-subsets. Spearman rho was used to define if the correlation was significant. 
All indicated P-values were two-tailed and considered statistically significant if values were 
lower than 0.05. Statistical analysis was performed using GraphPad Prism software, version 
6 (GraphPad Software, La Jolla, Calif).
Supplemental Table 1. Patient characteristics
Control Asthma
Asthma with food 
allergy and/or 
atopic dermatitis
Food allergy and/or 
atopic dermatitis
(n=15) (n=68) (n=48) (n=33)
Gender – n (%)
Male 7 (47%) 46 (68%) 31 (65%) 20 (61%)
Female 8 (53%) 22 (32%) 17 (35%) 13 (39%)
Age – mean yr (range)
11.1 (6-16) 11.4 (6-17) 10.9 (6-16) 9.0 * (6-15)
Sensitization to aero-allergens – n (%)
HDM n.d. 51 (75.0%) 28 (58.3%) 0 (0.0%)
Pollen n.d. 46 (67.6%) 31 (64.6%) 18 (54.5%)
Dander n.d. 43 (63.2%) 28 (58.3%) 13 (39.4%)
Sensitization to food allergens – n (%)
Milk n.d. 3 (4.4%) 11 (22.9%) 6 (18.2%)
Eggs n.d. 3 (4.4%) 13 (27.1%) 8 (24.2%)
(shell)fish n.d. 0 (0.0%) 9 (18.8%) 1 (3.0%)
Fruits n.d. 1 (1.5%) 4 (8.3%) 0 (0.0%)
Peanut n.d. 7 (10.3%) 23 (47.9%) 10 (30.3%)
Nuts n.d. 3 (4.4%) 25 (52.1%) 18 (54.4%)
Wheat n.d. 0 (0.0%) 6 (12.5%) 2 (6.1%)
Soy n.d. 1 (1.5%) 5 (10.4%) 2 (6.1%)
Serum immunoglobulins – mean IU/ml (range)
Total IgE n.d. 782 (6-9,082) 2561 (13-13,452) 1,346 (252-9,140)
HDM, house dust mite; n.d. not determined
* significantly lower than Asthma and Asthma with FA and/or AD (P<0.01)
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Supplemental Figure 1 Flowcytometry gating strategy for leukocyte subsets and T helper 
subsets. A. Analysis of leukocyte subsets using antibodies listed in Supplemental Table 2 
(Leukocyte subsets). B. Analysis of T-helper subsets using antibodies listed in Supplemental 
Table 2 (T-cell subsets)
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Supplemental Figure 2. Absolute counts of neutrophils, eosinophils, basophils and monocytes 
per microliter of blood. Each dot represents one individual and red lines indicate median values. 
Statistical analysis was performed with Mann Whitney U test. *P<0.05, **P<0.01
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ABSTRACT
Background Comel-Netherton syndrome (NS) is a rare autosomal disease, characterized by 
severe skin conditions, hair shaft defects, atopic diathesis and increased susceptibility for 
infections.
Objective Detailed clinical and immunological analysis of the cohort of NS patients in the 
Netherlands with the aim to identify if there is an immune defect underlying recurrent 
infections.
Methods Phenotypes were scored for skin severity, specific hair shaft defect, atopy and 
infections. Patients’ blood samples were collected for quantification of serum Ig levels, 
specific antibodies against Streptococcus pneumoniae and allergen-specific IgE, as well 
as detailed immunophenotyping of blood leukocyte and lymphocyte subsets with 
flowcytometry.
Results 14 patients were included with age range 3-46 years and varying degrees of skin 
involvement. All patients presented with atopic symptoms (food allergy, n=13; hay fever, 
n=10; asthma, n=7). Recurrent skin infections were common, particularly in childhood (n=12). 
Absolute numbers of lymphocytes, lymphocyte subsets and serum immunoglobulin levels 
were al l within nomal ranges. Low levels of specific antibodies against S. pneumoniae were 
found in 10 of the evaluated 11 patients.
Conclusion Multidisciplinary evaluation of our national cohort showed no evidence for a 
severe systemic immunodeficiency We hypothesize that in Dutch NS patients the increased 
risk for infections results from the skin barrier disruption and that increased allergen 
penetration predisposes to allergic sensitization.
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INTRODUCTION
Comel-Netherton syndrome (NS) (OMIM #256500) is a severe genodermatosis typically 
characterized by chronic skin inflammation (ichtyosis and scaly erythroderma), specific 
hair shaft defects (trichorrhexis invaginata) and atopic diathesis with elevated serum IgE 
levels.1, 2 The disease is caused by mutations in the SPINK5 gene (serine protease inhibitor 
of kazal type 5) encoding LEKTI (lympho-epithelial kazal type related inhibitor), which is 
expressed in the stratified epithelium of the skin, the mucosa and in the Hassal corpuscles 
of the thymus.3-6
The consequence of LEKTI deficiency is a loss of inhibition of serine proteinases such 
as plasmin, trypsin, subtilisin A, cathepsin G and elastase.7-11 This particularly leads to 
unopposed activity of kallikrein-related peptidase 5 (KLK5), which activates KLK7, KLK14 and 
elastase 2 (ELA2).12-14 This leads to increased degradation of corneodesmosomal cadherins 
through increased degradation of desmoglein 1, increased desmosome cleavage and 
reduced filaggrin proteolytic processing.15-17 The result is an abnormal skin homeostasis 
and detachment of the stratum corneum, which contributes to a defective skin barrier and 
thereby enabling microbe and allergen penetration.18 KLK5 also activates protease-activated 
receptor 2 (PAR-2) which is expressed on the surface of keratinocytes.19 Observations from 
SPINK5 knock-out mouse embryos indicate a KLK5-Par2 cascade, leading to enhanced 
production of thymic stromal lymphopoietin (TSLP), a T-helper 2 (Th2) related cytokine, 
enhancing the allergic predisposition.20 Furthermore, Par-2 leads to increased expression 
of TNF-α, IL-8 and ICAM-1, thereby augmenting an inflammatory process.21
The effects of defective LEKTI expression in the thymus and its effect on T-cell maturation 
are less well described. However, apart from dermal and allergic inflammation, the disease 
has also been associated with immunodeficiency and increased susceptibility to skin-, 
respiratory tract and systemic infections.22-25 Although recurrent skin infections with S. aureus 
can be related to altered skin homeostasis, some have attributed these observations to 
intrinsic immune defects, with improvement after intravenous immunoglobulin treatment.22 
Described immune defects include decreased numbers of natural killer (NK) cells, an 
immature phenotype of NK cells with reduced lytic function, reduced numbers of memory 
B cells and reduced responses to pneumococcal vaccinations.22-26 Although a premature 
senescent state of T-cells has been proposed, there have been no reports on dysfunctional 
T-cell properties. This is likely due to the fact that NS is a rare disease, the described patient 
cohorts are small (mostly 2-9 patients) and mainly consist of children.
To examine the potential immunodeficiency in NS, we actively recruited all known 
patients in the Netherlands for detailed clinical and immunological examinations including 
skin phenotype, allergic manifestations and blood leukocyte immunophenotyping.
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METHODS
Study design and patient characteristics
The study was designed as a cross-sectional study. All known sixteen patients with NS in the 
Netherlands were invited to participate in the study. Patients were actively recruited through 
the Erasmus University Medical Centre Rotterdam, an acknowledged national expert center 
for patients with NS, through the patients association and by social media. Patients were 
diagnosed based on the presense of germline mutations in SPINK5, LEKTI-deficiency in 
skin biopsy and/or trichorrhexis invaginata (ISRCTN12831121).27 Patients were included after 
obtaining written informed consent and with approval of the Medical Ethical Committee of 
the Erasmus MC (MEC-2013-026), which complies with the Helsinki declaration. Control blood 
samples were obtained from healthy volunteers amongst department staff (MEC-2016-022).
All patients received questionnaires about their medical and psychological wellbeing, 
including medical history, (daily) medication use, daily skin appearance, growth rate, 
frequency of infections, hospital admissions and (food)allergies. Subsequently patients 
were invited for blood sampling and a multidisciplinary evaluation by a the (pediatric-) 
dermatologist and (pediatric-) immunologist of our Netherton team.
Skin assessment and recurrent infections
To objectively score skin lesions, the body surface area (BSA in %), total lesional sign score 
for NS (TLSS-NS) and the investigator’s global assessment for NS (IGA-NS) (Supplemental 
Table 1) were used.28-30
Recurrent infections were defined as follows: recurrent skin infections: > 1 per year; 
recurrent respiratory infections > 3 per year for adults, > 6 per year for children; recurrent 
ear nose and throat (ENT) infections > 2 per year; recurrent gastro-intestinal infections > 
1 per year.
Immunoglobulin serology
Specific IgE for inhalation and food allergens were determined using ImmunoCAP and/
or the Immuno Solid-phase Allergen Chip (ImmunoCAP ISAC, Phadia, Uppsala, Sweden), 
according to manufacturer’s instructions.
Total IgM, IgG and IgA serum levels were measured by immunonephelometry with 
a Siemens BN II nepholometer according to manufacturer guidelines. Specific antibody 
titers against S. pneumoniae were analyzed using a Luminex assay according to a protocol 
adapted from Borgers et al.31
Vaccination response
Patients were immunized using a polysaccharide vaccine against S. pneumoniae 
(Pneumovax). Eleven out of 14 patients received Pneumovax vaccine and 4 to 6 weeks 
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after immunization specific antibody titers against S. pneumonia were measured and 
compared to pre-immunization titres. A 4-fold increase in titres reaching at least 1.00 μg/
mL in a minimum of 7 of the 13 measured serotypes (type 1,3,4,5,6A,6B,7F,9V,14,18C,19A,19
F,23F) 4 to 6 weeks after immunization was determined adequate.32, 33
Flowcytometric immunophenotyping of blood leukocytes
Absolute numbers of granulocytes, monocytes, lymphocytes, as well as NK-cells (CD16+/
CD56+), T-cells (CD3+) and B-cells (CD19+) were obtained with a diagnostic lyse-no-wash 
protocol using commercial Trucount tubes (BD Biosciences, San Jose, Calif). For detailed 
11-color flow cytometry,34 red blood cells were lysed with NH4Cl prior to incubation of 1 
million nucleated cells with antibody cocktails for 15 minutes at room temperature in a 
total volume of 100μL. After preparation, cells were measured on a 4-laser LSRFortessa 
flow cytometer (BD Biosciences) using standardized settings.35 Data were analyzed with 
FACSDiva software V8.0 (BD Biosciences).
Statistical analyses
Frequencies and absolute cell numbers were assumed a non-Gaussian distribution. All 
results are expressed as median values with interquartile range if applicable. Results were 
analyzed using the non-parametric Mann-Whitney U test. All P-values are two-tailed and 
were considered statistically significant if values were lower than 0.05. Statistical analysis 
was performed using GraphPad Prism software, version 6 (GraphPad Software, La Jolla, CA).
RESULTS
In the present study we evaluated 14 patients with NS in the Netherlands (6 males, 8 females). 
All known patients with NS in the Netherlands (n=16) were invited, however due to private 
circumstances two patients refused to participate. Ages ranged from 3 to 46 years (median, 
24 years), including four children, which were all female (Table 1).
Phenotypes
Ten patients were born with generalized erythroderma and two patients developed 
erythroderma within several hours after birth (Table 1). The skin severity varied between 
patients: six patients had an affected Body Surface Area (BSA) of 100% and 5 patients of 
>50% with a median IGA-NS score of 3 (IQR 3-4). All patients had trichorrhexis invaginata. 
Seven out of 14 patients noticed improvement of their skin over time with a median of 6.5 
years. All patients reported daily invalidation on a scale 1 to 10 (median 5; IQR 3-6), a daily 
pain numerical rating scale (NRS) median of 7.0 (IQR 2.8-8.0) and pruritus NRS median of 
4.0 (IQR 3.0-7.5) (Supplemental Table 1).
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When compared to the normal growth chart for children and the average height for 
adults (data of the Netherlands Organization for Applied Scientific Research), patients 
seemed to be smaller than the average population (Supplemental Table 2). Three patients 
had a length within 1 SD of the general population. All 4 children had normal weight-length 
ratios. Eight out of 10 adults had a normal BMI between 18.5 and 25; two patients were 
overweight with a BMI above 25 (Supplemental Table 2).
Atopic syndrome
Ten out 14 patients reported hay fever and 7 patients reported asthma. All but one patient 
reported reactions to food (especially nuts, cow milk, eggs and fish) with symptoms 
occurring within two hours after intake (nausea, stomach pain or edema of the nasopharynx) 
(Table 1 and Supplemental Table 3). Most patients had refused double blind food 
provocation tests due to clear acute reactions. Therefore, additional laboratory tests were 
performed to confirm IgE sensitization. Eleven out of the 12 tested patients had elevated 
total immunoglobulin E (IgE) above 100 IE/ml and one patient had a normal IgE level of 22 
IE/ml (Table 1). All 11 patients tested, had IgE sensitization to food allergens (Supplemental 
Table 3).
Treatment
All 14 patients used emollients for daily skin treatment, and 12 out of 14 patients needed 
topical corticosteroids, ranging from hydrocortisone acetate to clobetasol proprionate. One 
patient used tacrolimus ointment and one patient used coal tar. Three patients received 
treatment with oral antihistamines and all received treatment with inhalation medication. 
At the time of study inclusion, none of the patients received systemic immunosuppressive 
treatment.
Immunological evaluation
A manifest amount of infections were reported in all but one patient, particularly recurrent 
skin infections are a common problem, with a median of 4.1 infections requiring treatment 
with antibiotics every year (IQR 2.8-5.0; Table 2). Seven patients reported recurrent ENT 
infections since early childhood for which repetitive antibiotic treatments were required. 
In one patient, recurrent ENT infections persisted throughout adulthood. Several patients 
reported the need of regular cleaning of the external auditory meatus every 4 weeks to 
prevent external ear infections. Before the age of 6 years patients did not report frequent 
respiratory infections. Of the 12 patients above the age of 6 years, 7 patients suffered from 
recurrent skin infections in the previous 12 months. One patient reported recurrent gastro-
intestinal infections as a child, none reported these during adulthood. Similarly, one patient 
reported severe systemic infections during childhood, but none were reported during 
adulthood. No patients described a period of persistent fever after vaccinations (Table 2).
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The peripheral immune compartment in Netherton syndrome
None of the 13 tested patients showed an overt antibody deficiency. All patients had 
normal to high levels of IgG and IgA, and only 2 patients had reduced IgM serum levels 
(Table 2). Still, in 10 of 11 tested patients, levels of specific antibodies against S. pneumoniae 
were low after Pneumovax vaccination (i.e. less than a 4-fold increase in titres reaching at 
least 1.00 μg/mL in a minimum of 7 of the 13 measured serotypes) (Table 2).
Figure 1. Absolute numbers of leukocytes and leukocyte subsets in healthy individuals and in 
adult patients with NS. Each symbol represents an individual with red lines indicating median 
values. Normal ranges are depicted in grey shades. Statistics, Mann-Whitney U test; *, p<0.05; 
****, p<0.0001.
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Patients with NS have higher numbers of granulocytes
Blood leukocytes and their subsets were studied in 9 of the 10 adult patients (Figure 1). 
One patient had a leukocyte count above the normal range, which was caused by an 
elevated granulocyte count. Compared to the healthy individuals, patients with NS had a 
significantly higher granulocyte count (P 0.04). Absolute numbers of total lymphocytes and 
monocytes were in the normal range. Within the granulocyte subset, mainly the numbers of 
neutrophils seemed higher, although this was not significantly different from controls. Two 
patients had an increased eosinophil count. All patients had a normal basophil count, yet 
the median count was significantly lower than that of the control group (P=0.02). Numbers 
of plasmacytoid dendritic cells (pDCs) were dramatically decreased in the patient group 
(P<0.001). Within the lymphocyte subset one patient had an increased B-cell count and one 
patient had an increased T-cell count, yet as a group the median T-cell count was significantly 
lower than that of healthy controls (P=0.04). In our study cohort, NK-cell numbers were quite 
diverse, but statistically different from the control group. Still one patient had increased 
NK-cell numbers, whereas two patients had reduced NK-cell numbers.
Patients with NS have lower IgM-only memory B-cell numbers and increased 
IgE+CD27- memory B-cell numbers
Within the B-cell compartment we studied naive, memory and effector B-cell subsets 
(Figure 2). Absolute numbers of naive B-cell subsets (transitional B-cells and naive mature 
B cells) were comparable to that of healthy controls. In the memory compartment, median 
cell numbers of IgM-only memory B-cells (IgM+IgD-CD27+) were significantly lower than 
that of healthy controls (P=0.03), whereas cell numbers of other memory B-cell subsets 
(IgM+IgD+CD27+ Natural Effector B-cells, IgG+ and IgA+ memory B-cells) were comparable 
to those of healthy controls (Figure 2A). In contrast, the median cell number of IgE+CD27- 
memory B-cells was significantly higher in the patient group (Figure 2B; P=0.01). Plasma 
blast numbers seemed much lower in patients with NS. One patient had a high plasma 
blasts count, therefore as a group there was no significant difference between patients 
and controls.
Patients with NS have lower Th1 cell numbers
Since LEKTI is highly expressed in the thymus, the primary organ for T-cell development, 
we performed detailed analysis of the T-cell compartment (Figure 3). Although total T-cell 
numbers were significantly lower in the total group of patients as compared to controls, 
all patients but one, had T-cell numbers still within the normal range. In line with this, total 
CD4+ and CD8+ T-cells, as well as numbers of naive, central memory and effector memory 
subsets within CD4+ and CD8+ T-cells were not different between patients and controls 
(Figure 3A and B).
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Within the T-helper subset, numbers of Th1 cells were significantly lower in patients 
with NS, whereas Th2 cell numbers were not affected (Figure 3C). In addition, Th17 cell 
numbers were not different between patients and controls. Next to that also regulatory 
T-cell numbers were comparable between patients and controls (Figure 3C).
Figure 2. Absolute numbers of B-cell subsets in healthy individuals and in adult patients 
with NS. A. Absolute numbers of naive and memory B-cell subsets and plasma cells. Columns 
indicate median values with interquartile range. B. Absolute numbers of IgE+ memory B-cells. 
Each symbol represents an individual with red lines indicating median values. Statistics, Mann-
Whitney U test; *, p<0.05
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Figure 3. Absolute numbers of T-cell subsets in healthy individuals and in adult patients with NS. 
A. of total CD8+ T-cells and CD8+ Tnaive, Tcm, TemRO and TemRA. B. total CD4+ T-cells and CD4+ 
Tnaive, Tcm, TemRO and TemRA. Columns represent median values with interquartile range. C. 
counts of regulatory T-cells, Th1, Th2 and Th17 T-cells. Each symbol represents an individual with 
red lines indicating median values. Statistics, Mann-Whitney U test; *, p<0.05
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DISCUSSION
In this case series, 14 of the 16 known NS patients in the Netherlands were evaluated for their 
clinical phenotypes, atopic diathesis and immunological characteristics. To our knowledge 
this is the first described national NS patient cohort. Their history and clinical presentation 
are an illustration of the differences in the spectrum in patients with NS concerning clinical 
features, disease severity and follow-up.26
Immunological evaluation of our patients showed no evidence for a severe systemic 
immunodeficiency, even in the more severely affected patients. This in contrast to other 
studies 22, 26 Although low titers of specific antibodies against S. pneumoniae were measured, 
the current evaluation could not confirm the presence of a clinically relevant humoral 
immunodeficiency, based on the fact that patients did not suffer from an increased number 
of severe infections caused by encapsulated bacteria, which we see in antibody deficient 
patients.22 Functional assays evaluating potential NK-cell disturbances were not performed, 
however NK-cell numbers were not affected, thus this does not explain the difference 
between our observations with previous studies. An explanation might be that due to 
the national recruitment we experienced less selection bias resulting in more diversity in 
our cohort hence giving a better reflection of the whole spectrum of NS, at least in the 
Netherlands. The dramatically decreased numbers of pDCs can be explained by the fact 
that these cells are highly sensitive to corticosteroid therapy.36
All patients in the Dutch cohort were below the age of 50 years. We hypothesized that NS 
patients may have an accelerated aging of the immune system due to the severe skin barrier 
defect and/or by the defective LEKTI expression in the thymus. This was not confirmed by 
our data as the numbers of naive T-cells as well as effector T-cells were within normal range. 
This study does not explain the young age of the adult patients.
The increased manifestation of skin and ENT infections, especially in childhood, observed in 
our cohort may still imply an immune dysregulation according to the guidelines of European 
Society for Immunodeficiencies (ESID).37 Although in our cohort it is not known by which 
pathogens the infections were caused. As patients were born erythroderm, the observed 
change in skin phenotypes in some patients from erythroderma into Ichthyosis linearis 
circumflexa (ILC) are in line with previous described NS patients. Our cohort includes less 
severely affected NS patients and half of our patients reported improvement of their skin 
with age (median age 6.5 years). This might explain why less skin infections were reported 
in adults. We also hypothesized an impact of natural maturation of the immune system. 
In general, an increased susceptibility to infections during childhood has previously been 
described in healthy children, especially for respiratory infections and nasal immune 
responses in the first 2 years of life.38 The recurrent ear infections in children and adults 
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with NS might also be caused by obstruction of the external auditory canal as a result of 
excessive skin scaling.
Evaluation of atopic manifestations showed a remarkable high percentage of sensitization 
to food allergens, which is in line with previous observations.39 The increased risk of an 
atopic constitution corresponded with an elevated total IgE in 11 of the 12 tested patients 
as well as increased IgE+ memory B-cell numbers. Similar observations have been described 
in patients with atopic dermatitis.40 As described, the impaired epidermal skin barrier 
may open aberrant routes of entrance for allergens.41, 42 Combined with a different local 
immune response with enhanced risk of Th2 imprinting could lead to further sensitization 
to (food-) allergens.20, 41, 43 In our cohort food allergies for nuts, cow milk, eggs and fish 
were most common. The types of allergens do not differ from the general population in 
which 90% of the allergic responses to food are caused by cow’s milk, soy, eggs, wheat, 
peanuts, tree nuts, fish and shellfish.44-47 This suggests that the role of the skin barrier and 
sub-epithelial environment with a more Th2 profile might be greater than assumed for the 
atopic constitution in NS.
Strengths and limitations
To our knowledge this national cohort of 14 NS patients is the largest described until now.22, 
23, 26, 39, 48-53 Because of active recruitment we assume less selection bias and greater diversity 
in severity in our cohort. For example, some patients (n=2) were not in care before active 
recruitment and received their topical treatment from their general practitioner. Another 
strength is the multidisciplinary approach of this study. Evaluation of anamnestic information 
was partially based on retrospective data and could be considered as a limitation.
Clinical implications: Evaluation of patients with Netherton syndrome in the Dutch cohort 
showed no evidence for a severe systemic immunodeficiency. Rather it seems more likely a 
severe skin disease due to a local impaired skin barrier with an increased risk for infections 
and sensitization to food allergens, combined with reduced maturation of the immune 
system at a young age especially at a young age.
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SUPPLEMENTAL DATA
Supplemental Table 1. Numerical scores for pain and pruritus
patient NRS pain NRS pruritus
1 1 4
2 7 4
3 7 4
4 9 10
5 2 missing
6 7 8
7 8 3
8 2 3
9 5 8
10 9 4
11 3 2
12 4 6
13 8 9
14 7 2
NRS: numerical ratings scale (score 1-10)
Supplemental Table 2. Patients’ height and weight
patient child/adult age sex growth (in SD) length (cm) BMI
1 adult 43 M < -2 SD 170 23.88
2 adult 46 F -1 SD and 0 SD 163 30.49
3 adult 21 M < -2 SD 173 20.05
4 child 9 F < -2 SD 121 17.76
5 child 8 F < -2 SD 92 34.26
6 adult 24 F -2 SD and 1 SD 160 19.92
7 adult 22 F -1 SD and 0 SD 165 22.04
8 adult 24 M unknown 173 21.72
9 adult 36 M -1 SD and 1 SD 172 21.97
10 child 6 F -1 SD and 0 SD 102 15.19
11 child 3 F < -2 SD 99 16.32
12 adult 39 M unknown 178 22.72
13 adult 43 F -2 SD and 1 SD 172 20.28
14 adult 36 M -1 SD and 1 SD 189 26.32
SD: standard deviation; BMI: body mass index
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ABSTRACT
Background: Treatment of atopic dermatitis (AD) is focused on topical anti-inflammatory 
therapy, epidermal barrier repair and trigger avoidance. Multidisciplinary treatment in both 
moderate maritime and alpine climates can successfully reduce disease activity in children 
with AD. However, it remains unclear whether abnormalities in B- and T-cell memory 
normalize and if this differs between treatment strategies.
Objective: To determine whether successful treatment in maritime and alpine climates 
normalises B- and T-lymphocytes in children with moderate to severe AD.
Methods: The study was performed in the context of a trial (DAVOS trial, registered at Current 
Controlled Trials ISCRTN88136485) in which eighty-eight children with moderate to severe 
AD were randomized to 6 weeks of treatment in moderate maritime climate (outpatient 
setting) or in the alpine climate (inpatient setting). Before and directly after treatment, 
disease activity was determined with SA-EASI and serum TARC, and T- and B-cell subsets 
were quantified in blood.
Results: Both treatment protocols achieved a significant decrease in disease activity, 
which was accompanied by a reduction in circulating memory Treg, transitional B-cell and 
plasmablast numbers. Alpine climate treatment had a significantly greater effect on disease 
activity and was accompanied by a reduction of blood eosinophils, and increases in memory 
B-cells, CD8+ TemRO, CD4+ Tcm and CCR7+ Th2 subsets.
Conclusions and clinical relevance: Clinically successful treatment of AD induces changes 
in blood B- and T-cell subsets reflecting reduced chronic inflammation. In addition, 
multidisciplinary inpatient treatment in the alpine climate specifically affects memory 
B-cells, CD8+ T cells and Th2 cells. These cell types could represent good markers for 
treatment efficacy.
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INTRODUCTION
Atopic dermatitis (AD) is a common inflammatory skin disease, which affects up to 10-20% of 
children with a lifetime prevalence estimated at 15-30%.1{Bieber, 2010 #1337;Odhiambo, 2009 
#1348;Leung, 2003 #1757}(1)(1, 2) The underlying pathogenesis of AD is multifactorial and 
includes environmental factors, genetic predisposition, skin barrier dysfunction, and altered 
local and systemic immune responses.2-6 It remains unclear if reported abnormalities in the 
immune response are the cause of the disease, a result of reduced skin barrier function, or 
a combination of both. Still, it is generally accepted that AD is characterized by a skewing 
towards T-helper 2 (Th2) responses with increased immunoglobulin (Ig)E serum levels and 
eosinophilia.6, 7
The main principles in AD treatment are based on epidermal barrier repair with anti-
inflammatory topical treatment, emollients, antimicrobial therapy and trigger avoidance.5,8 
Only in more severe cases, or when insufficient control of AD is achieved, systemic 
immunosuppressive treatment may be required.5, 8-11 Treatment in the alpine climate has 
been used in children with AD and asthma for decades,12 with long term improvement 
in disease control and health related quality of life.13 On the short term, disease activity 
has been shown to decrease significantly, which is accompanied by a significant reduction 
in eosinophils and fractional exhaled nitric oxide (FeNO).13 Despite the rationale of these 
treatments to dampen abnormal immune responses, data on underlying immunological 
effects are scarce.14, 15
In the acute phase of AD, dermal and epidermal lesions are predominated by Th2 
cells and Th2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13.16, 17 This is also reflected in 
peripheral blood with increased numbers of CD4+ T-cells producing IL-4 and IL-13.18-22 In 
children, this increase specifically concerns T cells expressing the cutaneous lymphocyte 
antigen (CLA).23 In addition, expansions of CLA+ Th22 cells have been observed in adults 
with severe AD.23 During chronic stages of the disease, T-helper cell skewing changes, 
with an increase of Th1 cells, which is referred to as the biphasic T-cell polarization.24 The 
production of IL-22 induces epidermal hyperplasia through their effect on keratinocytes, 
whereas Th2 cytokines induce barrier disruption.17, 25 Furthermore, regulatory T-cells (Tregs) 
are consistently found to be increased in blood of patients with AD.26-28 Possibly, this is 
caused by chronic inflammatory signals, because numbers decline with treatment and 
correlate well with disease severity.29, 30
Under influence of the Th2 cytokines IL-4 and IL-13, activated B cells can undergo Ig class 
switching to IgE.31 Indeed IgE-producing plasmablasts are increased in AD,32 and elevated 
total and allergen-specific IgE serum levels are a hallmark of the disease. These B-cell 
responses also result in higher numbers of IgE+ memory B-cells in blood of patients with 
AD.32, 33 Furthermore, numbers of transitional B-cells, which are attributed to have regulatory 
capacities through the production of IL-10, have been reported to be increased in AD.32 Still 
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it has been shown that dupilumab, an antibody blocking IL-4/IL-13 receptors, has equal 
potency in treatment of either extrinsic AD (with increased IgE levels) as intrinsic AD (without 
increased IgE levels). This can be explained by data showing that Th2 cytokines diminish 
the expression of barrier proteins such as filaggrin, loricrin, involucrin and antimicrobial 
peptides34. Hence, this illustrates the clinical and immunological diversity of the disease.
Despite these insights into T-cell and B-cell abnormalities in disease, data about the 
effects of treatment on the immune response in patients with AD are limited. Most studies 
evaluated lesional skin biopsies and focused on T-cell subsets.35-40 Evaluation of alpine 
climate treatment has been focused on a reduction in eosinophil numbers, but data on 
T- and B-cell subsets are limited.14, 15
Here we investigate blood T- and B-cell subsets in children with moderate to severe 
AD before and after an intensive 6-week treatment protocol. Specifically, we compared 
the effects of two personalized integrative multidisciplinary treatment protocols: inpatient 
treatment in the alpine climate and outpatient treatment in moderate maritime climate 
(DAVOS trial).41 Here we report on the identification of common and treatment-specific 
effects on blood B- and T-cell subsets.
METHODS
Study design
This study is part of the DAVOS trial, ISRCTN88136485, which is a pragmatic randomized 
controlled trial for children with moderate to severe, difficult to treat AD. A detailed 
description of the study design has been published previously.41 In short, patients were 
enrolled between September 2010 and October 2014 and randomized to either a 6 week 
personalized integrative multidisciplinary inpatient treatment at a high altitude clinic in 
Switzerland (alpine climate) at 1,560 meters (intervention, NAD group), or to a 6 week 
personalized integrative multidisciplinary outpatient treatment program in the Netherlands 
at sea level (moderate maritime climate) (control, WKZ group). Patients were assessed before 
the start of treatment (T0) and within 72 hours after the end of the 6 week treatment (T1). 
The study assessments, including blood sampling, were all performed in the Netherlands. 
The trial design was in line with current health care practice in the Netherlands, which is 
outpatient whenever possible, whereas alpine climate treatment is always provided in an 
inpatient setting.
During the 6 week inpatient treatment period, children in the NAD group had weekly 
individual treatment sessions with a pediatrician, a psychologist (alternating with the 
psychomotor therapist) and a physiotherapist (if needed). A nurse monitored correct 
application of topical treatment in individual sessions with each child twice daily. In these 
individual sessions health education was provided with a varying weekly theme. During 
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their stay at the high altitude clinic, children attended an integrated school. Prior to outdoor 
activities, sun cream was applied on exposed skin to protect for high UV exposure when 
necessary. Children in the WKZ group visited the outpatient clinic on a weekly basis for 6 
weeks. They had three consultations with the dermatologist, five consultations with the 
dermatological nurse, three consultations with the pediatric allergist and three consultations 
with the psychologist. In the third week, separate group consultations were scheduled for 
the children and their parents about coping with AD and compliance.
Participants
Dutch children and adolescents with difficult to treat AD were eligible for participation in 
the trial. We defined difficult to treat as use of at least a class 3 topical corticosteroid and 
not being able to step down, or current use of systemic immunosuppressive treatment, or 
repeated treatment with potent topical corticosteroids or systemic immunosuppressive 
treatment, or a history of use of systemic treatment, or a significant impact of AD on the 
child’s or the families quality of life, or seemingly unresponsive to conventional therapy 
according to current guidelines. All patients and their parents provided written informed 
consent for participation in the trial, which was reviewed and approved by the Medical Ethics 
Committee of the University Medical Center Utrecht, the Netherlands (reference 09-192/K).
Clinical outcome measures
Data regarding gender, age, asthma, allergic rhinitis, food allergy and use of topical or 
systemic medication during the treatment period were extracted from electronic patient 
files in the Wilhelmina Children’s Hospital. Disease severity was measured with the objective 
Self-Administered Eczema Area and Severity Index (SA-EASI) by the research nurse prior to 
(T0) and after 6 weeks of treatment (T1).42
Blood measurements
Total lymphocyte and eosinophil counts were determined with a Coulter cell counter 
(Beckman Coulter) within 24 hours of blood sampling. Serum Thymus- and activation- 
regulated chemokine (TARC) levels were measured with an Enzyme-Linked Immuno 
Sorbent Assay. Total serum IgE levels were measured with an ImmunoCAP 250 (Phadia) 
on T0. Peripheral blood mononuclear cells (PBMCs) of all patient samples were isolated by 
Ficoll-plaque density centrifugation, stored in liquid nitrogen, and used for 11-color flow 
cytometry. For this, one million PBMCs were incubated with antibody cocktails against 
B-cell or T-cell markers for 15 minutes on room temperature in 100μL total volume. Flow 
cytometric analyses were performed on a 4-laser LSRFortessa (BD Biosciences) using 
standardized measurement settings,43 and data were analyzed using FacsDiva V8.0 (BD 
Biosciences). The absolute lymphocyte counts obtained from fresh samples were used to 
calculate absolute numbers of the CD3+ T-cell and CD19+ B-cell subsets.
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Statistical analysis
Statistical analysis was performed in SPSS version 21.0 (IBM Corp, Armonk, NY). The course 
of AD disease activity after treatment was determined by assessing the SA-EASI score on 
T1 versus T0 with the Paired Samples T-test. Changes in the absolute counts of T- and B-cell 
subsets after treatment in the total cohort or within the NAD and WKZ groups were analyzed 
with the Wilcoxon Signed Rank Test. Differences in kinetics of the T- and B-cell subsets 
before and after treatment between the NAD and WKZ groups were analyzed with Analysis 
of covariance. This analysis was corrected for possible pre-existing differences between the 
groups on T0 and the use of systemic medication during the treatment period. Systemic 
medication was defined as a dichotomous variable, with patients classified as using systemic 
medication when they had used prednisone and/or cyclosporine at any point during the 
six-week treatment period. P-values of <0.05 were considered statistically significant. Data 
analysis was supervised by a senior statistician.
RESULTS
Study subjects
A total of 88 patients were enrolled in the Davos trial (Supplementary Figure 1).13 Of these, 
79 started treatment; 38 in the alpine climate (NAD) and 41 in moderate maritime climate 
(WKZ). Two patients (both WKZ) did not complete treatment, and data from one or more 
blood samples were lacking from 13 patients. This resulted in a total of n=64 patients in this 
study: NAD group, n=31; WKZ group, n=33 (Supplementary Figure 1). Patient characteristics 
of children with missing blood samples did not differ from the study group. Patient gender 
and age were equally distributed in both groups; 51.6% males in the NAD group and 51.5% 
males in the WKZ group with a mean age of 12.7 years in both groups (Table 1). Most 
patients (85.9%) had one or more additional allergic comorbidities (Table 1). The use of 
topical corticosteroids before the start of treatment was similar between the groups, with 
most patients using a class III corticosteroid. In addition, 4 patients (12.1%) in the WKZ group 
used cyclosporine at T0, whereas none did in the NAD group (Table 1).
Disease activity decreases after treatment
In the total study cohort (n=64), we observed a reduction of the SA-EASI score. The median 
score of 34.4 out of 96 before the start of treatment (T0) decreased to a median score of 
6.0 after treatment (T1) (P <.001; Figure 1A). SA-EASI scores before treatment were similar 
between both treatment groups (median score NAD 31.4; WKZ 39.15, P 0.82). Both treatments 
resulted in significantly reduced SA-EASI scores at T1, yet the decrease was significantly 
greater in the NAD group than in de WKZ group (P <.01). This resulted in a significantly 
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Table 1. Baseline Patient Characteristics
Characteristics Total group
(n = 64)
NAD group
(n = 31)
WKZ group
(n = 33)
Gender
Male n (%) 33 (51.6) 16 (51.6) 17 (51.5)
Female n (%) 31 (48.4) 15 (48.4) 16 (48.5)
Age (years) mean 
± SD 
(range)
12.7 ± 2.4
(8 – 18)
12.7 ± 2.4
(8 – 16)
12.7 ± 2.5
(8 – 18)
SA-EASI (<17 mild; 
18-46 moderate; >47 
severe)
mean ± 
SD
(range)
37.2 ± 19.9
(3.8 – 79.8)
36.7 ± 20.8
(5.4 – 79.8)
37.6 ± 19.3
(3.8 – 77.0)
Other atopic diseases
Asthma n (%) 55 (85.9) 27 (87.1) 28 (84.8)
Allergic rhinitis
Food allergy
n (%)
n (%)
55 (85.9)
43 (67.2)
27 (87.1)
21 (67.7)
28 (84.8)
22 (66.7)
Sensitization profile†
Birch n (%) 51 out of 60 (85.0) 24 out of 31 (77.4) 27 out of 29 (93.1)
Timothy n (%) 46 out of 60 (76.7) 23 out of 31(74.2) 23 out of 29 (79.3)
Mugwort n (%) 32 out of 60 (53.3) 17 out of 31 (54.8) 15 out of 29 (51.7)
House dust mite n (%) 54 out of 60 (90.0) 28 out of 31 (90.3) 26 out of 29 (89.7)
Cat n (%) 46 out of 59 (78.0) 22 out of 31 (71.0) 24 out of 28 (85.7)
Dog n (%) 55 out of 60 (91.7) 26 out of 31 (83.9) 29 out of 29 (100)
Common food allergens n (%) 57 out of 62 (91.9) 22 out of 31 (71.0) 25 out of 31 (80.6)
Topical corticosteroid use on T0
No topical medication n (%) 1 (1.6) 0 (0.0) 1 (3.0)
Hydrocortisone n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Triamcinolone/Emovate/
Tacrolimus
n (%) 3 (4.7) 1 (3.2) 2 (6.1)
Cutivate/Elocon n (%) 23 (35.9) 16 (51.6) 7 (21.2)
Betnelan/Betamethasone n (%) 33 (51.6) 13 (41.9) 20 (60.6)
Dermovate n (%) 4 (6.3) 1 (3.2) 3 (9.1)
Systemic medication use on T0
† for these parameters some patients had missing values
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Table 1. Continued.
Characteristics Total group
(n = 64)
NAD group
(n = 31)
WKZ group
(n = 33)
No systemic medication n (%) 59 (92.2) 29 (93.5) 29 (87.9)
Prednisone n (%) 1 (1.6) 1 (3.2) 0 (0.0)
Cyclosporine n (%) 4 (7.8) 0 (0.0) 4 (12.1)
serum TARC
(<510 pg/ml)
median
(range)
1080.5
(170.0 – 14100.0)
1149.0
(170.0 – 7217.0)
861.0
(339.0 – 14100.0)
Eosinophils
(0.03-0.35x 109/L)
median
(range)
0.62
(0.10 – 1.80)
0.61
(0.18 – 1.37)
0.51
(0.10 – 1.80)
Total IgE
(<700 U/ml )
median
(range)
2849.0
(150.0 - 17260.0)
2872.0
(150.0 - 16718.0)
2614.0
(150.0 - 16718.0)
† for these parameters some patients had missing values
Figure 1. Six weeks of multidisciplinary treatment both in an alpine climate (NAD) and at 
moderate maritime climate (WKZ) decrease disease severity with only the former resulting in 
lower blood eosinophil numbers. A. Self-Administered Eczema Area and Severity Index (SA-EASI). 
B. Thymus and activation regulated chemokine (TARC). C. Eosinophils. D. Total lymphocytes E. 
Total T-cells F. Total B-cells. T0, baseline; T1, 6 weeks. Each dot represents one individual, and red 
lines median values. Dashed lines with grey surface indicate reference values. Statistical analysis 
between the groups was performed with the Wilcoxon signed rank test, analysis between the 
groups was performed with analysis of covariance. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
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lower median SA-EASI score in the NAD group at T1 (median of 3.2) than in the WKZ group 
(median 11.9) (Figure 1A).
Serum TARC levels varied considerably but correlated significantly with the SA-EASI 
score on T0 and T1 (Supplemental Figure 2). TARC levels also decreased after treatment, 
but were differently affected by treatment protocols (Figure 1B). A significant decrease was 
observed in the NAD group with a median of 1149.0 pg/ml at T0 and a median of 610 pg/ml 
at T1 (P <.01), whereas the serum TARC levels were not significantly lower after treatment 
in the WKZ group.
Reduction of eosinophils and increase in T-cells after alpine climate treatment
Numbers of blood eosinophils decreased after alpine climate treatment; from a median 
of 610 cells/μL at T0 to 250 cells/μL at T1 (P <.001) (Figure 1C). The reduction in eosinophil 
numbers in the NAD group was accompanied by a significant increase in lymphocyte 
numbers, from a median of 2040 cells/μL at T0 to 2380 cells/μL at T1 (P <.01) (Figure 1D). 
This effect was significantly different from the WKZ group, in which both eosinophil and 
lymphocyte numbers did not change after treatment (Figure 1C and D). Within total 
lymphocytes, specifically T-cells were affected in the NAD group with an increase from 
a median of 1236.9 cells/μL before treatment to 1345.7 cells/μL after treatment (P <.01) 
(Figure 1E). Total B-cell numbers did not change following either treatment (Figure 1F). 
Although patients were randomized to a treatment protocol, the total lymphocyte counts 
were significantly different between the WKZ and NAD groups at T0 (P <.05). This difference 
could not be explained by patient characteristics or technical work-up as these were similar 
between both groups. Therefore, we corrected for pre-existing differences between the 
groups on T0 in our statistical analysis.
Blood T- and B-cell subsets are affected by treatment
To study the immune system in more detail we focused on total and treatment-group 
specific effects on subsets within the T-cell and B-cell lineages. Within the CD3+ T-cell 
compartment, naive (Tnaive), central memory (Tcm), CD45RA- effector memory (TemRO) 
and CD45RA+ effector memory (TemRA) populations were defined in both the CD4+ and the 
CD8+ lineages (Supplemental Figure 3).44 Naive T cell numbers were not affected by therapy. 
After treatment, absolute numbers of CD8+ TemRO T-cells were increased in the NAD group 
(median at T0 of 108.2 cells/μL and median at T1 of 123.5 cells/μL; P <.05) (Supplemental 
Figure 3A). Other CD8+ T-cell subsets were not affected by treatment.
Treatment affects Th2 and memory Treg cells
CD4+ Tcm were differentially affected by treatment (P <.05); the absolute numbers 
decreased slightly in the WKZ group (from a median of 189 cells/μL to 167.2 cells/μL; P 
=0.5), and significantly increased in the NAD group (median T0 136.9 cells/μL and median 
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T1 171.9 cells/μL; P <.01) (Supplemental Figure 3B). Other memory CD4+ T-cell subsets did 
not significantly change with treatment in either of the treatment groups (Supplemental 
Figure 3B).
Next, we studied if Th subsets were affected by treatment. Th1, Th2 and Th17 cells were 
defined within the CD45RA- memory compartment based on differential expression of 
the chemokine receptors CCR4, CCR6 and CXCR3 (Figure 2A and B).45 Whereas no effects 
of treatment were found on Th1 and Th17 cells, numbers of Th2 cells were significantly 
different after treatment. Importantly, treatment of the WKZ group in moderate maritime 
climate reduced Th2 cell numbers (from a median of 84.9 cells/μL to 75.8 cells/μL; P <.05), 
whereas alpine climate treatment of the NAD group resulted in a (non-significant) increase 
of Th2 cells (from a median of 78.5 cells/μL to 89.0 cells/μL; P 0.09) (Figure 2A). As a result, 
the treatments also had significantly different effects on the Th1/Th2 cell ratios between 
the WKZ and the Davos group (P <.05) (Figure 2A). To further investigate the increase in Th2 
cells after alpine climate treatment we analyzed the expression of the lymphoid homing 
receptor CCR7. We found that CCR7+ Th2 cells attributed most to the increase of peripheral 
Th2 cells in the NAD group (Figure 2C), in line with the total increase in CD45-CCR7+ Tcm 
cells (Supplementary Figure 3). The reduction of Th2 cells in the WKZ group was the result 
of a decrease of both the CCR7+ and CCR7- subsets (Figure 2C).
Figure 2. Decreased Th2 cell numbers following treatment at moderate maritime climate. A. 
Flowcytometric analysis of Th1 and Th2 cells. B. Flowcytometric analysis of Th17 cells. C. Absolute 
counts of the CCR7- and CCR7+ Th2 cell subsets. Each dot represents one individual, and red lines 
median values. Statistical analysis between the groups was performed with the Wilcoxon signed 
rank test, analysis between the groups was performed with analysis of covariance. *P<0.05, 
**P<0.01
Regulatory T cells were studied based on the phenotype CD4+CD25+CD127- (Figure 
3A).45 Numbers of total Tregs decreased slightly but not significantly after treatment 
(Figure 3B). However, numbers of CD45RA- memory Tregs significantly decreased following 
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treatment, irrespective of the type of treatment (P <.01; Figure 3D), whereas numbers of 
naive Tregs did not change after treatment (Figure 3C).
Figure 3. Reduction in memory regulatory T-cells (Tregs) following treatments both at moderate 
maritime and in an alpine climate. A. Gating strategy for detection of Tregs B. Absolute counts 
of total Tregs. C. Absolute counts of naive Tregs (Treg CD45RA+) D. Absolute counts of memory 
Tregs (Treg CD45RA-). Each dot represents one individual and red lines median values. Statistical 
analysis between the groups was performed with the Wilcoxon signed rank test, analysis 
between the groups was performed with analysis of covariance. *P<0.05, **P<0.01
Decreased transitional B-cell and plasmablast numbers after treatment
Within CD19+ B-cells, multiple naive and memory B-cell subsets and plasmablasts 
were defined (Figure 4A and 5A). Numbers of CD21low and naive mature B-cells did not 
change after treatment (Figure 4B). However, numbers of transitional B-cells (P <.01) and 
plasmablasts (P <.05) were significantly reduced in the total cohort (Figure 4B). From the 
plasmablast subsets, only IgE+ plasmablasts significantly decreased after alpine climate 
treatment (Supplemental Figure 4). Transitional B-cell numbers were also solely affected by 
high alpine treatment (NAD; P <.01), whereas the slight decreases in plasmablast numbers 
were not significant when treatments were analyzed separately. When comparing alpine 
climate treatment and moderate maritime climate, an opposing effect on natural effector 
B-cell numbers was found (P <.05), with treatment at maritime climate leading to a decrease 
and alpine climate leading to an increase (Figure 5B).
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Figure 4. Reduced numbers of blood transitional B-cells and plasmablasts following treatment. 
A. Flow cytometric gating strategy of major B-cell subsets. B. Absolute counts of major B-cell 
subsets. Each dot represents one individual, and red lines median values. Statistical analysis 
within the groups was performed with the Wilcoxon signed rank test, analysis between the 
groups was performed with analysis of covariance. *P<0.05, **P<0.01, ***P<0.001
Increased IgM, IgG and IgA memory B cell numbers following alpine climate 
treatment
Within the memory B-cell compartment, we defined 8 distinct subsets based on differential 
expression of the 5 Ig isotypes and CD27 (Figure 5A).33, 46, 47 Of these 8 subsets, only numbers 
of IgG+CD27+ memory B cells were significantly increased after treatment (P <.05). This effect 
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was significantly greater following alpine climate treatment than treatment at maritime 
climate (P <.05). In addition, alpine climate treatment led to significantly increased numbers 
of Natural Effector (P <.05), IgA+CD27- (P <.05) and IgA+CD27+ (P <.05) memory B cell 
subsets, as compared to maritime climate treatment (Figure 5B-E). No effects were found on 
either CD27+ or CD27- IgE-expressing memory B cells. Thus, treatment resulted in reduced 
transitional B cells and plasma cells, whereas alpine climate treatment specifically led to 
slightly increased numbers of IgA and IgG memory B cells. A summary of the significant 
effects of treatment on the various outcomes are displayed in Table 2.
Figure 5. Increased numbers of CD27-IgG+, CD27+IgG+ cells and CD27-IgA+ memory B-cell 
numbers following treatment in alpine climate. A. Flow cytometric gating strategy of memory 
B-cell subsets. B. Absolute counts of CD27+IgM+IgD+ Natural Effector B-cells. C. Absolute counts 
of IgM-only B-cells D. Absolute counts of CD27- and CD27+ IgG memory B-cells. E. Absolute 
counts of CD27- and CD27+ IgA memory B-cells. F. Absolute counts of CD27- and CD27+ IgE 
memory B-cells. Each dot represents one individual, and red lines median values. Statistical 
analysis between the groups was performed with the Wilcoxon signed rank test, analysis 
between the groups was performed with analysis of covariance. *P<0.05
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Table 2. Summary of significant effects after treatment
Parameter WKZ NAD Different effects between groups
SA-EASI ? ? *
TARC - ?
Eosinophils - ? *
T-cell subsets
Total CD3+ T-cells - ? *
CD8+ - ?
CD8+ TemRO - ?
CD4+ Tcm - ? *
Memory Tregs ? ?
Th2 ?  - *
Th2 CCR7- ?  -
Th2 CCR7+ ? ? *
B-cell subsets
Transitional - ?
IgA+CD27- memory - ? *
IgG+CD27- memory - ?
IgG+CD27+ memory - ? *
IgE+ plasmablasts - ?
? indicates significant increase; ? indicates significant decrease; - indicates no change; 
* indicates significant different effect between groups after treatment
WKZ, outpatient treatment at moderate maritime climate; NAD inpatient treatment at 
alpine climate
DISCUSSION
We here report that clinically successful treatment protocols of children with atopic 
dermatitis, either at maritime climate (outpatient treatment) or at alpine climate (inpatient 
treatment), differentially affect the immune system. Reduced disease activity after 6 
weeks of treatment quantified by SA-EASI in both groups, and by serum TARC levels after 
alpine climate treatment, was accompanied by a decrease in circulating memory Tregs, 
transitional B-cells and plasmablasts. Moreover, 6 weeks of alpine climate treatment resulted 
in significantly lower disease activity scores and blood eosinophil counts than treatment in 
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moderate maritime climate, and was associated with higher numbers of Th2 and memory B 
cells (for summary of significant effects see Table 2). Thus, inpatient alpine climate treatment 
appears to have unique effects on the patient’s immune system.
A notable reduction was found in memory Treg cell numbers following therapy, 
irrespective of the treatment protocol. Patients with AD have increased numbers of Tregs in 
blood as compared to healthy controls.26-28, 48 Furthermore, Treg numbers positively correlate 
with AD disease activity.30 It is thought that the increase in Treg numbers is a response to the 
chronic inflammation, and the numbers go down upon suppression.29, 49 Although it cannot 
be excluded that therapy induces a Treg influx into the skin and thereby locally reduces 
skin inflammation. Still, considering the decrease in disease activity following treatment 
in our patients, the reduction in Treg numbers seems a reflection of successful treatment. 
Although it is not entirely sure if Tregs migrate to skin. Hence, Treg cell numbers could be 
a good general marker for treatment evaluation.
In addition to Tregs, transitional B-cells and plasmablasts also decreased after treatment. 
Transitional B-cells are recent bone marrow emigrants that can further develop into naive 
mature B-cells.46 These functionally immature cells respond poorly to IgM stimulation and 
can exert regulatory functions via the production of IL-10, thereby dampening immune 
responses and inflammation.50, 51 Transitional B-cells are reported to be expanded in patients 
with AD, although reports on this are not conclusive.32, 47 Similar to memory Tregs, the 
decline in transitional B-cells can be the result of a decrease in disease activity. It remains 
to be studied if treatment directly affects survival of transitional B cells or the B-cell output 
from the bone marrow.
Plasmablasts are antibody producing cells that are mostly short-lived and can be 
precursors to long-lived plasma cells. Although our measurements were performed 
after freezing and thawing of cells, which could affect plasmablast numbers, there 
are no indications that study samples are differently affected by this. In the case of AD, 
where high levels of allergen specific IgE is one of the hallmarks of the disease, plasma 
cells are potentially important contributors to the disease.32 Blood plasma cell numbers 
increase during active immune responses, as illustrated by acute infections and following 
vaccinations.52, 53 Our finding that plasmablast numbers decrease upon treatment are in 
line with the previously established correlation with active inflammation. In addition, we 
stained plasmablasts for IgE, IgA and IgG and found that the largest reduction was found 
in IgE+ plasmablasts. However, since surface immunoglobulin staining of plasmablasts is 
controversial the latter result must be interpreted with some caution, although other studies 
also report high numbers of IgE+ plasmablasts in patients with AD.32
Besides the common effects of treatment, we also observed several differences in B- and 
T- cell subsets between the two treatments. The significantly larger decreases in SA-EASI 
and serum TARC levels after alpine climate treatment were accompanied by an increase 
in total CD3+ T-cells. This was mainly due to increased numbers of CD8+ TemRO T-cells 
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and T-helper 2 cells. As these are memory T cell subsets, their increased numbers could 
reflect increased maturation following an immune response. However, this is unlikely as 
the patients showed decreased disease activity and inflammation. An alternative cause for 
their increased numbers in blood is their re-localization from tissue. The skin harbors large 
numbers of immune cells, and especially Th2 cell numbers are increased in AD lesions.16 In 
addition, CD8+ T-cells have been found to infiltrate lesional skin of patients with AD.54, 55 This 
can even result in decreased numbers of blood CD8+ T-cells and a higher CD4/CD8 ratio 
than healthy controls.56 The increase of CD8+ TemRO and CD4+ Th2 cells following alpine 
climate treatment could reflect the normalization of AD skin lesions and redistribution of 
the memory T cells to the peripheral blood.57-59
Another hypothesis could be that these patients with chronic AD were skewed towards 
Th1 dominance prior to treatment. Following treatment in the alpine climate with reduced 
disease provoking allergens, this chronic Th1 response may have subsided and the immune 
system could have reverted to the original state that was prone to Th2 predominance.60 Due 
to the reduced allergenic pressure in the alpine climate the Th2 response is minimal and 
markers of the Th2 response, such as TARC and eosinophils, are reduced. This hypothesis 
would also explain the lack of long term differences between alpine climate treatment and 
the outpatient treatment program at moderate maritime climate.13 Treatment in the NAD 
group may have dampened inflammation, but not have reset the immune system. Rather, 
our results show that the immune response remained skewed towards Th2, which could 
underlie the renewed inflammation upon return to maritime climate with higher allergen 
exposure.
In addition to memory T cells, alpine climate treatment also resulted in increased 
memory B-cell numbers. IgA+CD27-, IgG+CD27- and IgG+CD27+ memory B-cells were 
significantly increased, and the effects on natural effector and IgA+CD27+ memory B cells 
were significantly different from treatment at moderate maritime climate. Since almost 80% 
of our patient population was additionally diagnosed with asthma, it could be speculated 
that the IgA+ memory B-cells may have migrated from the lungs into the peripheral 
circulation after clinical improvement of asthma. This is supported by additional analyses 
demonstrating that improvement of asthma, measured as lower exhaled nitric oxide levels, 
correlated with an increase of IgA+CD27- and IgA+CD27+ memory B-cells in peripheral 
blood. Yet, we here did not directly investigate any skin homing markers on B-cell subsets. 
Importantly, despite the observed effects on memory B cells, IgE+ B-cells were not affected 
by either treatment. As the CD27-IgE+ subset has been shown to be significantly increased 
in patients with AD,33 the current data suggests that these numbers are not normalized 
following intensive treatment for 6 weeks. Since the favorable outcome of alpine climate 
treatment on disease severity did not persist until 6 months after treatment,13 our observed 
effects on the immune system are most likely a result of reduced disease activity rather than 
a cause for reduction in disease severity.
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However explanatory studies are needed to identify the main responsible factor for the 
observed improvement since there was a difference in treatment setting in both study arms. 
Beneficial factors ascribed to treatment in the NAD group are the inpatient setting and the 
characteristics of the alpine climate, which include reduced air concentrations of allergens 
and pollutants and a higher exposure to UV radiation.61 In asthma, and to a lesser extent 
AD, reduced allergen exposure has been linked to a decrease in peripheral eosinophilia.62-67 
Indeed also in our study, after treatment, blood eosinophils were significantly lower in the 
NAD group. Furthermore, UV radiation exposure can lead to immunosuppressive effects, 
and specifically can activate local apoptosis in T and B-cells and result in decreased cytokine 
productions involved in lymphocyte activation and trafficking.68-70 However, direct sunlight 
exposure to the skin was limited and patients were protected with sun cream.
Both treatment protocols involved intensive treatment by multidisciplinary teams of 
healthcare professionals, and resulted in decreased disease activity scores after 6 weeks of 
treatment with sustained beneficial effects lasting for >6 months.13 Based on the observed 
immunological changes and the greater clinical improvement in the alpine climate 
treatment group, in this study alpine climate treatment seems a more effective treatment 
on the short-term. In the present study we did not investigate the long-term effects on 
the immune compartment, but it would be interesting to study the effects 6 weeks and 6 
months after treatment completion and observe if alpine climate treatment led to an altered 
peripheral immune system.
Conclusion
Intensive treatment of children with moderate to severe AD affected blood T- and B- cell 
subsets. In addition to changes in Treg, transitional B cells and plasmablasts upon treatment 
in both a moderate maritime and an alpine climate, the latter also resulted in additional 
changes in circulating CD8+ TemRO, Th2 and memory B-cells.
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SUPPLEMENTAL DATA
Supplemental Figure 1. Flowchart of patient selection. 232 patients were screened for eligibility. 
84 patients were randomized to one of the treatment arms. Finally, 64 patients were included 
for analysis; 31 in the NAD group and 33 in the WKZ group.
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Supplemental Figure 2. Correlation between serum Thymus- and activation- regulated 
chemokine (TARC) levels and Self-Administered Eczema Area and Severity Index (SA-EASI) scores 
on T0 (A) and T1 (B). Each dot represents one individual; black lines indicate linear correlations. 
Correlation was calculated with Spearman R.
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Supplemental Figure 3. CD8+ and CD4+ naive and memory T-cell subsets. A. Representative 
plots of the flow cytometric analysis of CD8+ naive T-cells (CD8+ Tnaive), CD8+ central memory 
T-cells (CD8+ Tcm), CD8+ effector memory CD45RA- T-cells (CD8+TemRO) and CD8+ effector 
memory CD45RA+ T-cells (CD8+TemRA). B. Representative plots of the flow cytometric analysis 
and absolute counts of CD4+ Tnaive, CD4+ Tcm, CD4+TemRO and CD4+TemRA. Each dot 
represents one individual, and red lines median values. Statistical analysis between the groups 
was performed with the Wilcoxon signed rank test, analysis between the groups was performed 
with analysis of covariance. *P<0.05, **P<0.01
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Supplemental Figure 4. Plasmablast subsets. A. Representative plots of the flow cytometric 
analysis of plasmablasts B. IgG+ plasmablasts C. IgA+ plasmablasts D. IgE+ plasmablasts 
Statistical analysis between the groups was performed with the Wilcoxon signed rank test, 
analysis between the groups was performed with analysis of covariance. *P<0.05
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ABSTRACT
Background Treatment for atopic rhinitis is mostly aimed to relieve symptoms, only allergen 
specific immunotherapy (SIT) is targeted to resolve allergic sensitization. This results in 
prolonged desensitization, also when treatment has stopped. The immunomodulatory 
effects of SIT have been mainly attributed to increased regulatory T-cell function and 
increased serum IgG4, yet little is known about the effect on the memory B-cell compartment 
and its relation to various T-cell subsets.
Methods We here included 24 patients with atopic rhinoconjunctivits and performed a 
longitudinal analysis of the peripheral immune compartment before and during SLIT for 
grass pollen allergy. With flowcytometry on peripheral blood we analyzed the direct effects 
of a 4-month treatment regimen and the long term effects of two courses of treatment 
over 2 years on circulating IgE+ and IgG4+ memory B-cells, allergen-specific Ig levels and 
Th and Treg cell frequencies.
Results SLIT induced a direct increase in pollen-specific serum IgG4 accompanied by an 
increase in the frequency of IgG4+ memory B-cells, whereas no effect was observed on the 
IgE+ memory B-cell compartment. Furthermore, SLIT resulted in an increase in the frequency 
of regulatory T-cells. This was associated with clinical improvement of allergic complaints.
Conclusion Our data provides evidence for long lasting effects of sublingual immunotherapy 
on the memory compartment of the immune system. Increased numbers of regulatory 
T-cells lead to a higher frequency of IgG4+ memory B-cells and a beneficial shift in the 
IgG4+/IgE+ memory B-cell ratio, reflecting the increased IgG4/IgE antibody fraction in 
serum, which results in a favorable outcome.
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INTRODUCTION
Rhinoconjunctivitis and other IgE-mediated allergies are an increasing disease burden to 
the world population 1. Most therapies intended to treat allergies are directed to relieve 
symptoms, but allergen-specific immunotherapy (SIT) is one of the few therapies aimed 
to resolve allergic sensitization. Subcutaneous immunotherapy (SCIT) and sublingual 
immunotherapy (SLIT) have both been proven to be an effective treatment for grass pollen 
induced rhinoconjuntivitis 2, 3. The therapeutic effect is maintained until after the treatment 
has stopped 4-6, it can prevent the onset of new sensitizations 7, and it has the ability to reduce 
the development of asthma in patients with allergic rhinitis 8. The immunomodulatory 
properties of SIT affect local and systemic immune responses, with an effect on the number 
and function of effector cells, antigen presenting cells (APCs), T cells and B cells 9, 10.
Allergic patients display sensitization by means of allergen specific IgE bound to 
effector cells, such as mast cells and basophils 11. The underlying mechanism is thought to 
be a shifted T-cell balance towards a T helper 2 (Th2) phenotype, and these cells produce 
interleukin (IL)-4, IL-5 and IL-13 that direct allergen-specific B-cells to produce IgE 12. Effective 
immunotherapy has been shown to reverse the Th2 dominance, and to result in anergy of 
allergen-specific T-cells 13, 14, induction of regulatory T-cells (Treg) 15-17 and production of 
blocking antibodies of the IgG isotype 18, 19. Specifically, TGF-β and IL-10 produced by Tregs 
are pivotal for the successful immune deviation in immunotherapy 20, 21.
The tolerogenic functions of IL-10 are extensive, but mainly encompass the inhibition of 
mast cell activity 22, suppression of IL-5 production by Th2 cells 23 and cell death induction in 
eosinophils 24. Furthermore, IL-10 in combination with IL-4 and IL-13 directs immunoglobulin 
class switching of B-cells to IgG4 instead of IgE 25. Indeed, one of the known effects of SIT 
is an increase in allergen-specific serum IgG4 and an increased serum IgG4/IgE antibody 
ratio that is associated with successful outcome 26.
SCIT and SLIT have distinct immunomodulatory capacities that appear related to the 
different routes of administration. Sublingual administration results in fewer side effects, but 
shows less profound clinical and immunological efficacy than subcutaneous administration 
2, 27. SLIT treatment results in increased numbers of Foxp3+ Tregs both in the oral epithelium 
and in peripheral blood 19, 28. Further systemic alterations are more diverse. Some studies 
report an initial increase in IgE serum levels, followed by a decrease after 1 month 29. 
Furthermore, IgG4 and IgA serum levels are reported to increase directly after the start 
of therapy 29, 30. However, other studies detected no systemic alterations with regard to 
allergen-specific lymphoproliferation, cytokine secretion or Ig serum levels 31, 32.
Since immunotherapy has been attributed to have long lasting beneficial effects, it is 
of specific interest to understand if this is the result of changes in immunological memory, 
i.e. memory B and T-cells. We here addressed this in 24 patients with moderate to severe 
seasonal allergic rhinitis, who were studied longitudinally before and during SLIT for grass 
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pollen allergy. We analyzed the direct effects of a 4-month treatment regimen and the long 
term effects of two courses of treatment over 2 years on circulating IgE+ and IgG4+ memory 
B-cells, allergen-specific Ig levels and Th and Treg cell frequencies.
METHODS
Study design
Using an open label longitudinal design, 30 subjects were included for treatment with the 
5 grass pollen mix Oralair® sublingual tablets for a period of 4 months. The treatment with 
Oralair® involved placing the tablet under the tongue until complete dissolution (for at 
least 2 minutes) and then swallowing it. Treatment started 4 months before the grass pollen 
season (T1; May) and stopped at the start of the pollen season (T2; September). Grass pollen 
count data were collected to confirm the duration of the pollen season (School of Botany, 
University of Melbourne). The total treatment duration was approximately 4 months with 
a follow-up study visit 8 months after completion of the first year of treatment (T3) and 
8 months after completion of the second year of treatment (T4). The treatment regimen 
was composed of an initiation treatment (first month of treatment, including a 3-day dose 
escalation) and a continuation treatment (second month onwards) as follows: First month 
(initiation treatment): day 1 – 1 tablet 100 IR (index of reactivity); day 2 - 2 tablets 100 IR; 
day 3 to day 30 – 1 tablet 300 IR. Month 2-4 (continuation treatment): day 31 to day 120–1 
tablet 300 IR. Blood samples were collected at T1, T2, T3 and T4 (Fig 1).
Patient samples
Patients were recruited from the Allergy Clinics, The Alfred, Melbourne, Australia and had 
well-characterized moderate to severe seasonal allergic rhinitis due to ryegrass pollen (RGP) 
allergy and with positive RGP-specific IgE (CAP-Pharmacia score ≥ 1), with or without mild 
stable asthma. Patients were stratified for disease severity according to current symptoms 
and presence of asthma. Exclusion criteria were a co-existing immunodeficiency, previous 
immunotherapy within the last five years, ongoing immunotherapy with other allergens and 
treatment with continuous oral corticosteroids. Subjects on treatment with β-blockers were 
excluded as ß-blockers can impair the response to treatment in the event of anaphylaxis. 
The use of usual medications for allergic rhinitis was permitted, including antihistamines 
and topical corticosteroids. Alfred Hospital Research and Ethics Committee approval and 
written informed consent from each patient were obtained prior to the start of inclusion.
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Quantification of allergen-specific IgE and IgG4
Serum was separated from clotted blood for analysis of total and RGP-specific IgE levels 
using the Pharmacia CAP system by the Alfred Pathology service and for RGP-specific IgG4 
antibodies by in-house ELISA as described previously 33.
Flowcytometry
Peripheral blood mononuclear cells (PBMCs) were isolated within 24hrs of blood collection 
by Ficoll-plaque density centrifugation and stored in liquid nitrogen. One million thawed 
PBMCs were incubated with antibody cocktails against B-cell or T-cell markers for 15 minutes 
on room temperature in 100μL total volume. Flow cytometric analyses were performed 
on a 4-laser LSRFortessa (BD Biosciences) and data were analyzed using FacsDiva V8.0 (BD 
Biosciences).
Statistical analysis
Differences in kinetics in disease scores, Ig serum values and of B- and T-cell subsets before, 
during and after treatment were analyzed with the Wilcoxon Signed Rank Test. All analyses 
were two-tailed and were considered statistically significant if P-values were lower than 
0.05. Statistical analysis was performed using GraphPad Prism software, version 6 (GraphPad 
Software, La Jolla, CA).
RESULTS
Patient characteristics
Twenty-eight patients were included in the study, with a mean age of 35 and a range 
between 18-59 years. There was an equal gender distribution between males (n=15) and 
females (n=13). All patients had detectable RGP-specific IgE levels, with a mean CAP-
Pharmacia score of 437U/ml (Table 1). Blood samples for flowcytometric analysis were 
obtained from n=24 patients at T1, n=21 at T2, n=23 at T3 and n=14 at T4.
SLIT has a positive effect on symptoms and disease scores
To study the clinical effects of SLIT we measured symptom and disease scores. Before the 
start of treatment patients had a median symptom score of 14 and a median disease score of 
8 (out of 10). After the first year of treatment patients experienced fewer symptoms after the 
hay fever season (median symptom score 4, p <0.05), which was also reflected in a decreased 
disease score (median 4, p<0.05) (Fig 1B and C). After the second year of treatment the 
symptom score remained low (median 4), whereas the disease score continued to decrease 
(median 2) (Fig 1B and C). Thus SLIT resulted in beneficial clinical outcomes after 1 and 2 
years of treatment.
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Increased IgG4 serum levels and IgG4+ memory B-cell frequencies after 4 
months SLIT
To study the direct effects of SLIT on the immune system, we analyzed immunoglobulin 
serum levels and B- and T-cell subsets before and directly after the first four months of 
therapy. We observed that after 4 months of immunotherapy all patients showed an increase 
in RGP-specific serum IgG4 from a median of 0.37g/L before treatment (T1) to 1.16g/L after 
treatment (T2) (Fig 2A). This was accompanied by a significant increase in the frequency of 
Table 1. Patient characteristics
Patient Gender Age RGP SPT Total IgE Rye RAST Disease score Follow up
(yrs) (mm) (U/mL) (VAS scale 1-10) T2 T3 T4
1 M 19 6 1000 68,9 6,5 + + +
2 F 37 10 328 100 8,7 + + +
3 M 32 10 409 54,4 9 + + -
4 M 38 20 298 69,1 9,8 + + +
5 M 21 20 886 100 9 + + -
6 F 55 5 6 0,43 7 + + -
7 F 18 10 14 4,8 2 + + -
8 M 48 7 38 2,72 3 + + -
9 M 29 5 191 3,95 9 + + +
10 M 34 10 35 13,6 8 + + +
11 F 19 15 3271 100 2 + + +
12 F 34 6 293 100 7 + + +
13 F 23 5 336 100 10 + + -
14 M 37 7 138 64,4 6 + + +
15 F 34 7 690 100 10 + + -
16 F 29 15 144 100 8 + + -
17 M 42 6 64 16,7 2 + + +
18 F 59 3 1212 6,7 7 - + +
19 F 53 10 202 34,1 9,5 + + -
20 M 37 7 35 16 9 - + +
21 F 39 6 576 100 5 + + +
22 M 25 9 60 10,7 7,5 + + -
23 F 40 10 153 63,9 10 - - +
24 M 40 12 114 21,2 10 + + +
n=21 n=23 n=14
RGP, rye grass pollen; SPT, skin prick test; RAST, radioallergosorbent test; VAS, visual analogue 
scale
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IgG memory B-cells expressing IgG4 (Fig 2B). The increase in IgG4+ memory B-cells was not 
directly correlated to the increase in RGP-specific serum IgG4 (Fig 2A). SLIT did not change 
IgE+ memory B-cell frequencies. Still the increase in IgG4+ memory B-cells resulted in a 
significantly higher IgG4+/IgE+ memory B-cell ratio following 4 months of treatment (Fig 
2D). Nearly all other B-cell subsets, including transitional, naive mature, memory B cells 
and plasma blasts remained unchanged after 4 months of SLIT, except for a decrease of 
IgA+CD27+ memory B-cells. Thus, 4 months SLIT quite specifically affected allergen-specific 
IgG4 serum levels and the frequencies of IgG4-expressing memory B cells.
Figure 1. Study design and clinical outcomes A. Treatment scheme. B. Symptom score. C. Disease 
score. T= timepoint. Each dot represents one individual, and red lines median values. Statistical 
analysis was performed with Mann Whitney U test. *P<0.05, ****P<0.0001
Because IgG4 class switch recombination is regulated by Th cells and their cytokines, we 
subsequently analyzed the patients’ T-cell compartments. Within the CD4 and CD8 T-cell 
subset, naive T-cell frequencies were increased after 4 months of SLIT. This was accompanied 
by a decrease in the frequency of central memory T-cells (Tcm) within CD4+ T-cells and a 
decrease in effector memory RO (TemRO) in CD8+ T-cells. Since these are relative changes, 
the latter two observations may be indirect observations due to the increased numbers of 
naive T-cells. Within CD4+ T-cells, frequencies of Th1, Th2, Th17 and Tregs did not change 
after 4 months of SLIT (Fig 2E). Furthermore, within the Treg subset there was no change 
in ratio of those with a naive over a memory phenotype. However, follicular helper T-cell 
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(Tfh) frequencies were decreased following SLIT. Thus, the increase in IgG4+ B-cells is not 
accompanied by direct changes in Th subsets or regulatory T-cells.
Figure 2. 4 months of SLIT affects serum IgG4 levels and numbers of circulating IgG4-expressing 
memory B cells and Tfh cells. A RGP specific serum IgG4 B. Relative percentage of IgG4 memory 
B cells within the IgG memory B-cell compartment C.Correlation between increase in serum 
IgG4 and percentage of IgG4+ memroy B-cells D. IgE+ B cells E. Thelper and regulatory subsets. 
Each dot represents one individual; red lines indicate median values; and red line in panel C 
indicates linear correlations. Statistical analysis was performed with Mann Whitney U test. 
*P<0.05, ****P<0.0001. Correlation was calculated with Spearman R.
SLIT has persistent long term effects on IgG4 memory B-cells and regulatory T 
cells.
In addition to direct effects, we studied the long term treatment effects of SLIT, i.e. one year 
after start of the first treatment course (T3) and 1 year after the second (T4). SLIT resulted 
in higher RGP specific serum IgG4 levels after the first year of treatment (T3) with a further 
increase after the second year of treatment (T4) (Fig 3A). The frequencies of IgG4+ memory 
B-cells were not significantly different between T1 and T3, these were significant between 
T1 and T4 (Fig 3A). SLIT had no long term effects on IgE+ memory B-cell frequencies nor on 
total serum IgE levels and IgE Rye RAST (Fig 3B). The remainder of the B-cell compartments 
remained mostly similar during treatment follow-up, including the IgA+CD27+ memory 
B-cells which were found to be decreased after 4 months of SLIT. Two courses of SLIT did 
result in increased frequencies of IgG+CD27- memory B-cells and decreased marginal zone 
B-cell frequencies.
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Figure 3. Persistent increase in IgG4 and late rise in Tregs after two 4-month SLIT courses. A. 
Serum IgG4 and percentage of IgG4+ memory B-cells. B. Serum IgE and percentage of IgE+ 
memory B-cells. C. Naïve and memory CD4+ and CD8+ T-cells. D. Thelper and regulatory subsets. 
Each dot represents one individual; red lines indicate median values.. Statistical analysis was 
performed with Mann Whitney U test. *P<0.05, **P<0.01, ****P<0.0001.
During the two-year follow up, we did not observe changes in naive and memory subsets 
with the CD4 and CD8 T-cell lineages (Fig 3C). However, within the CD4 T cell lineage, Th1 
cell frequencies had decreased after the first year of treatment and continued to decrease 
after 2 years of treatment (Fig 3D). In contrast, Th2 and Th17 cell frequencies remained stable 
(Fig 3D). Furthermore, SLIT resulted in a significant increase of regulatory T cells after two 
years of treatment (Fig 3D). This observation was not specifically attributed to either naive 
or memory Tregs. The decrease of Tfh cells observed directly after SLIT was not sustained 
after 2 years of therapy.
In conclusion, low dose allergen exposure during 4 months of SLIT resulted in fast changes in 
B-cell responses leading to increased serum IgG4 levels and IgG4-expressing memory B cells. 
These effects were lasting and gradually increased after two rounds of treatment. In contrast, 
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changes in the T-cell compartment occurred later with decreased Th1 and increased Treg 
frequencies becoming apparent 2 years after start of treatment.
DISCUSSION
In the study presented here, we show that sublingual immunotherapy to pollen allergy 
not only has long term beneficial clinical effects, but also results in sustained systemic 
effects on the immune system. SLIT induced a direct increase in pollen-specific serum 
IgG4 accompanied by an increase in the frequency of IgG4+ memory B-cells. Furthermore, 
SLIT resulted in an increase in the frequency of regulatory T-cells. Both observations were 
associated with favorable immunological properties by deviating the exaggerated Th2 
response from an IgE phenotype towards an IgG4 phenotype.
Currently, SLIT is recommended for courses of 7 months starting 4 months prior to the 
start of the hay fever season and this has been shown to result in significantly improved 
symptom and disease scores 2. Yet long treatment regimens are costly and prone to poor 
treatment compliance 34. As patients will be exposed to pollens during hay fever season, we 
reasoned that 4-month treatment regimens prior to start of hay fever season might suffice 
to induce clinical effects. Indeed, based on our outcome of symptom and disease scores 
this approach seemed highly effective. Possibly during season treatment is not necessary 
for the desired effect, although we did not investigate this with a second treatment group 
here. Prolonged treatment (duration>12 months) has also shown to have a beneficial effects 
on symptom and medication scores 35. The fact that some immunological effects only 
developed after the second treatment year, or in the case of RGP specific serum IgG4 levels, 
continued to rise after consecutive treatment, substantiates these observations.
In particular we here observed an increase in RGP specific IgG4. Previously allergen-
specific immunotherapy, either SCIT or SLIT, has already been demonstrated to result in 
increased allergen-specific IgG4 serum levels 36, 37. Moreover it has been postulated as one 
of the explanations for the beneficial effects of immunotherapy and has been observed 
as natural effect in bee-keepers exposed to bee-venom for prolonged periods 38, yet the 
desensitizing effect in immunotherapy is not entirely clear. Increased allergen specific IgG4 
can directly compete for allergen, but it is also thought to have blocking activity on IgE-
mediated responses 39. Furthermore the IgG4 antibody has been attributed to have immune 
dampening effects, since it can only weakly bind to both C1q and Fcγ receptors 40, 41. Still, 
increased RGP specific IgG4 would suggests that the direct competition for allergen is the 
main mechanism in our study cohort.
The source of increased serum IgG4 levels are IgG4 producing plasma cells. Here we did 
not investigate numbers of (Ig specific) plasma cells since these mainly reside in tissue, rather 
than in blood, however we did look at plasma blast numbers, which can be found in blood. 
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However total plasma blast frequencies were not affected by SLIT. To further characterize 
plasma blasts for the production of specific Ig’s is difficult, since they only display weak 
membrane immunoglobulin expression and phenotyping can be unreliable. However in 
the differentiation from naïve B-cell to plasma cell, B-cells can also develop into memory 
B-cells, which have long lasting memory characteristics and can differentiate into plasma 
cells in subsequent responses 42.
Indeed we observed that SLIT results in increased frequencies of IgG4+ memory B-cells, 
whereas there was no effect on frequencies of IgE memory B-cell subsets. The latter 
observation can explain the absence of a decline in IgE serum levels which has also been 
observed by others 35, 43, 44. Since we observed the increase in IgG4+ memory B-cells after 
4 months of treatment with SLIT, and before the pollen season, this effect can be directly 
attributed to the treatment with Oralair. Our observation that frequencies of IgG4+ memory 
B-cells remain to be increased, can be an explanation for the long lasting effects attributed 
to immunotherapy 4-6.
In line with previous data, we observed an increase in regulatory T-cells after 
immunotherapy. The cytokines IL-4 and IL-13 are the most important regulators of 
immunoglobulin class switch recombination (CSR) to IgE, and these are predominantly 
produced by Th2 cells. In addition to Th2 cytokines, CSR to IgG4 is also regulated by IL10 
which is secreted by Tregs. Previous studies have observed the new generation of allergen-
specific Tregs, as well as a clonal expansions of allergen specific Tregs 39, 45. In our study we 
could not attribute the increase in Tregs to either naïve or memory Tregs. The underlying 
mechanism inducing the increase in Tregs possibly originates in the mucosal surface. These 
are the tissues exposed to the low dose allergen treatment regimen and substantial evidence 
supports a role for local dendritic cells in the induction of Treg cells 46, 47. To investigate this 
mechanism was outside the scope of our study, but a shift towards a local immune response 
might explain the decreased frequency of Tfh cells observed directly after SLIT.
Surprisingly we did not observe a change in Th2 cell frequency, yet rather a decrease in 
Th1 cells. Decreases in both subsets have been described as a result of immunotherapy, but 
solely reduced frequencies of Th1 cells seems to be in contrast with the described skewing 
if the immune system away from the Th2 phenotype. In some cases the suppression of 
Th2 cells was found to be transient, yet here patients received a second treatment before 
the next pollen season. Still, maintained numbers of Th2 cells can be explained by the 
fact that the Th2 cytokines IL4 and IL13 are required for the CSR towards IgG4 and thus in 
combination with IL10, can still lead to immune tolerance.
Concluding, our data provides evidence for long lasting effects of sublingual 
immunotherapy on the memory compartment of the immune system. Increased numbers 
of regulatory T-cells lead to a higher frequency of IgG4+ memory B-cells and a beneficial 
shift in the IgG4+/IgE+ memory B-cell ratio, reflecting the increased IgG4/IgE antibody 
fraction in serum, which results in a favorable outcome.
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ABSTRACT
Background IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition 
affecting various organs and has a diverse clinical presentation. Fibrosis and accumulation 
of IgG4+ plasma cells in tissue are hallmarks of the disease and IgG4-RD is associated with 
elevated IgG4 serum levels. However, disease pathogenesis is still unclear and these cellular 
and molecular parameters are neither sensitive nor specific for diagnosis of IgG4-RD.
Objective We here sought to develop a flowcytometric gating strategy to reliably identify 
blood IgG4+ B-cells to study their cellular and molecular characteristics and investigate 
their contribution in disease pathogenesis.
Methods Sixteen patients with histologically confirmed IgG4-RD, 11 patients with sarcoidosis 
and 30 healthy individuals were included for 11-color flowcytometric analysis of peripheral 
blood for IgG4-expressing B cells and T-helper (Th) subsets. In addition, detailed analysis 
of activation markers and chemokine receptors was performed on IgG4-expressing B cells 
and IgG4 transcripts were analyzed for somatic hypermutations.
Results Cellular and molecular analyses revealed increased numbers of blood IgG4+ memory 
B-cells in patients with IgG4-RD. These cells showed reduced expression of CD27 and CXCR5 
and increased signs of antibody maturation. Furthermore, IgG4-RD patients, but not patients 
with sarcoidosis, had increased numbers of circulating plasma blasts and CD21low B-cells, as 
well as Th2 and regulatory T-cells, indicating of a common disease pathogenesis in IgG4-RD.
Conclusion These results provide new insights into the dysregulated IgG4 response in 
patients with IgG4-RD. A specific “peripheral lymphocyte signature” observed in patients 
with IgG4-RD, could support diagnosis and treatment monitoring.
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INTRODUCTION
IgG4 related disease (IgG4-RD) is defined as a systemic fibro-inflammatory condition that can 
affect potentially any organ, but predominating the retroperitoneal space, thyroid, pancreas, 
salivary glands and orbital tissue 1, 2. The pathology is characterized by fibrosis and infiltration 
of IgG4-producing plasma cells of the affected organs 3, 4. As a result, a tumor-like swelling 
of the involved organ can occur, which causes organ dysfunction and, if left untreated, can 
lead to organ failure. Furthermore, AA amyloidosis can develop in IgG4-RD, emphasizing the 
need for prompt diagnosis and treatment of the disease 5. Previously, diseases with IgG4+ 
plasma cell infiltrates were defined predominantly by organ involvement, and only since 
2012 these diverse manifestations have been recognized as one disease entity 3, 4.
The pathogenesis of IgG4-RD remains poorly understood. It is thought to be triggered 
by organ damage, resulting from e.g. a bacterial infection with molecular mimicry or 
from an underlying autoimmune process 1. In patients with pancreatic involvement, auto-
antibodies directed against self-antigens have been observed 6, 7. Importantly, IgG4+ 
plasma cell infiltrates are not monoclonal 8, and serum IgG4 in patients is polyclonal with 
reactivity to multiple antigens 9. The function of IgG4 antibodies remains elusive, because 
these display weak or negligible binding to both C1q and Fcγ receptors 10, 11. Furthermore, 
IgG4 molecules have the exclusive ability to exchange Fab-arms, thus creating monovalent 
bispecific antibodies that can prevent the formation of immune complexes 12. Therefore, 
IgG4 has a presumed immune dampening effect, however its role in the pathogenesis of 
IgG4-RD is controversial 13.
Immunoglobulin class switching of B-cells to IgG4 is regulated by T helper 2 (Th2) 
cytokines and by IL-10, produced by regulatory T-cells 14, 15. Substantial evidence indicates 
that indeed Th2 cells and regulatory T-cells (Tregs) are involved in the pathophysiology 
of IgG4-RD 16-18. Affected tissues express higher messenger RNA (mRNA) levels of the Th2 
cytokines IL-4, IL-5 and IL-13 16, 17. Furthermore, isolated circulating CD4+ T-cells from patients 
predominantly produce Th2 cytokines 18, 19. Similarly, IL-10 and tissue growth factor β (TGF-β) 
transcripts are increased in affected tissues 16, and patients with IgG4-related autoimmune 
pancreatitis have increased frequencies of circulating Tregs 20, 21. More recently, in affected 
tissue and blood of IgG4-RD patients clonal expansions of CD4 effector memory T(EM) cells 
have been identified, which potentially drive fibrosis and IgG4 production 22, 23.
Clinically, IgG4-RD manifestations can mimic those of many infectious, inflammatory 
and malignant disorders 24-30. Therefore, diagnosis of IgG4-RD can be challenging, often 
leading to a delay in start of proper treatment. The gold standard for diagnosis is histology 
28, 31. Characteristic lymphoplasmacytic infiltrates, rich in IgG4 positive plasma cells, storiform 
fibrosis (cartwheel arrangement of fibroblasts) and obliterative phlebitis are seen in 
histological samples 28. An increase in serum IgG4 supports the diagnosis, but is found in 
only 50-70% of patients with histological proven IgG4-RD 32, 33. Recently, circulating plasma 
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blasts have been postulated as a more reliable marker for the disease, irrelevant of IgG4 
serum levels 34. However, the specificity of this marker is limited, because circulating plasma 
blasts are also increased in active infection, following vaccination and in other chronic 
diseases, such as systemic lupus erythematosus (SLE) 35-38.
Still the importance of B-cells in the pathophysiology of the disease is illustrated by 
recent observations demonstrating that B-cell depletion with rituximab is a promising 
therapy in IgG4-RD 39-42. As rituximab specifically binds CD20, it does not directly target 
IgG4+ plasma cells, which do not express CD20. Thus, the therapeutic effect could lie in 
depletion of memory B cells that are chronically stimulated to generate IgG4+ plasma cells. 
Furthermore, other chronically activated B cells might be involved in the disease through 
antigen presentation and cytokine production, such as CD21low B cells that are found to be 
expanded in diverse chronic inflammatory diseases 43.
Despite previously reported expansions of IgG4+ plasma cells, CD4 Tem, Th2 cells and 
Treg cells in affected tissue, little is known about the pathogenesis of IgG4-RD. Therefore, 
we developed a new flow cytometric approach, which enabled us to study IgG4-expressing 
B cells and their pathogenic contribution to the disease. Our insights into IgG4-expressing 
B cells in combination with abnormalities in B and T-cell subsets reveal abnormal systemic 
immune regulation, which are valuable for the improvement of diagnosis and treatment 
of IgG4-RD.
METHODS
Patients.
Patients with IgG4-RD and patients with sarcoidosis were recruited following signed 
informed consent from the Immunology outpatient clinic at the Erasmus Medical Center 
Rotterdam and from the Rotterdam Eye Hospital, the Netherlands. All patients were >18 years 
and were diagnosed based on clinical, serological and histopathological findings. All IgG4-
RD patients met the IgG4-RD diagnostic guidelines, including histological confirmation 28, 
and did not have a known history of an immunodeficiency or any auto-inflammatory disease 
other than IgG4-RD. All but two patients with sarcoidosis had tissue biopsy confirmed 
disease with typical presence of non-caseating granulomatous inflammation. In two patients 
the diagnosis was based on clinical presentation and supportive serological parameters 
(angiotensin converting enzyme and soluble interleukin-2 receptors) in combination with 
radiological imaging. Healthy controls were recruited from healthy individuals selected 
from department staff, and the control group was age- and gender-matched to the patient 
cohort. None of the healthy individuals showed signs of active inflammatory disease. This 
study was performed according to the Declaration of Helsinki and was approved by the 
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Medical Ethics Committee of Erasmus MC (ethics approval numbers MEC-2014-476, MEC-
2015-200 and MEC-2017-084).
Histopathology.
All patients with IgG4-RD were histologically diagnosed. The haematoxylin and eosin 
stainings were analyzed at the Department of Pathology of the Erasmus Medical 
Center Rotterdam by a trained pathologist with experience in diagnosing IgG4-RD. The 
deparaffinized formalin-fixed paraffin embedded sections of the tissue (4 mm thick) were 
stained using a BenchMark automated immunostainer (Ventana, Tucson, AZ, USA) with the 
Ultraview Universal diaminobenzidine detection kit (Ventana). Mouse anti-human IgG (clone 
A57H, 1:200, Dako, Carpinteria, CA, USA) and mouse anti-human IgG4 (clone HP6025, 1:600, 
Invitrogen Zymed, Camarillo, CA, USA) were used for immunohistochemical staining and 
were applied to the sections for 32 min. The amount of IgG4+ plasma cells per high-power 
field (0.28 mm2) and the IgG4/IgG ratio were measured.
IgG serology.
IgG subclass serum levels were measured by immunonephelometry using a Siemens BN II 
nepholometer according to manufacturer guidelines. A possible prozone effect for IgG4 
levels was excluded through dilution of serum samples until reliable values were obtained 44.
Flow cytometry of blood samples.
Patients and controls were included over a time period of three years. To ensure consistency 
in flowcytometry, standardized sample preparation, antibody staining and flowcytometer 
instrument settings were used 45. In short, absolute counts of CD3+ T-cells, CD19+ B-cells 
and CD16+/CD56+ NK-cells were obtained with a diagnostic lyse-no-wash protocol using 
commercial Trucount tubes (BD Biosciences, San Jose, Calif). For detailed 11-color flow 
cytometry, red blood cells were lysed with NH4Cl prior to incubation of 1 million nucleated 
cells for 15 minutes at room temperature in a total volume of 100μL. After preparation, cells 
were measured on a 4-laser LSRFortessa flow cytometer (BD Biosciences) using standardized 
settings. Data were analyzed with FACSDiva software V8.0 (BD Biosciences).
Molecular analysis of immunoglobulin heavy chain (IGH) gene 
rearrangements.
RNA was isolated from post-Ficoll mononuclear cells with a GenElute mammalian RNA 
kit (Sigma-Aldrich, St Louis, Mo) and reverse transcribed to cDNA with random primers 
(Invitrogen Life technologies). IGHV gene rearrangements were amplified in a semi-nested 
multiplex PCR approach using 4 different L-VH-family forward primers 46 in combination with 
IGHG4-specific (5’GGGCATGATGGGCAYGGGGGACCATA; first round) and IGHG-consensus 
(5’CACGCTGCTGAGGGAGTAG; second round) reverse primers. PCR products were cloned 
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into a pGEMT easy vector (Promega, Madison WI), amplified by colony PCR, and sequenced 
on an ABI Prism 3130XL (Applied Biosystems, Foster city, CA). The sequences were analyzed 
with the IMGT database (www.imgt.org) and BASELINe program (selection.med.yale.edu/
baseline) 47, 48.
Statistical analysis
Frequencies and absolute cell numbers were assumed a non-Gaussian distribution. All results 
are expressed as median values with interquartile range if applicable. Results were analyzed 
using the non-parametric Mann-Whitney U test. Linear regression was used to study the 
strength of association between cell-subsets with Spearman r to measure significance. All 
P-values are two-tailed and were considered statistically significant if values were lower than 
0.05. Statistical analysis was performed using GraphPad Prism software, version 6 (GraphPad 
Software, La Jolla, CA). Principal component analysis (PCA) was performed with Infinicyt 
software (Cytognos, Salamanca, Spain). Specificity and sensitivity were calculated with SPPS 
software (IBM SPSS statistics 21.0, Armonk, NY)
RESULTS
Patient characteristics.
A total of 16 patients with IgG4-RD were included with a mean age of 56 years (range 
18-79 yrs) and a male:female ratio of 2:1 (Table I). All patients were confirmed to have IgG4-
RD based on the Boston consensus, with typical histopathologic characteristics and the 
presence of IgG4-producing plasma cells in affected tissue (Fig 1). Twelve out of 16 patients 
had increased serum IgG4 levels (mean 5.06g/L; range 0.27-25.25g/L). Four of these patients 
had an additional increase in serum IgG1 or IgG2 levels, and one patient with normal serum 
IgG4 had increased levels of IgG1 and IgG3 (see Repository Table E3). Six patients showed 
signs of active disease based on clinics and increased CRP (C-reactive protein) and/or ESR 
(erythrocyte sedimentation rate) (Table I).
The majority of IgG4-RD patients were treatment naive (no prior treatment), three 
patients had received immunomodulatory medication in the past (medication had been 
stopped for at least 6 months prior to inclusion) and only two patients received low dose 
prednisone (Table I). Most patients had normal counts of blood leukocytes and lymphocytes 
(Supplemental Table 1). Increased lymphocytes resulted from high T-cell counts, often in 
combination with high B- and/or NK cell numbers. One of the two patients treated with 
prednisone had decreased numbers of B- and T-cells. In the analysis of the distribution of 
IgG subclasses within the total IgG memory B-cell compartment we analyzed material from 
15 of the 16 patients.
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Figure 1. Representative hematoxylin and eosin (H&E) and IgG4 stainings of tissue sections of 
affected organs in patients with IgG4-RD. A. and B. Pericardial tissue of patient 15 demonstrating 
lymphoplasmacytoid fibrosis and obliterative phlebitis. C. and D. Orbital tissue of patient 6 with 
lymphoid infiltration. E. and F. Lung tissue of patient 10 with lymphoplasmacellular infiltrates. 
All images are 200X magnification.
Of the eleven patients with sarcoidosis, one patient used plaquenil. All other patients 
were therapy naive (Supplemental Table 2). All patients had normal leukocyte counts, 
although some patients had slightly decreased or slightly increased T-cell or B-cell counts. 
One patient had an increased IgG4 serum level accompanied with an increased IgG1 serum 
level. One patient had a slightly decreased IgG4 serum level and from one patient IgG serum 
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levels were not determined. Five patients showed signs of active disease based on CRP and/
or ESR (Supplemental Table 2).
Table 1. Characteristics of patients with IgG4-RD
patient gender
age
(yr) organs affected
medication
at inclusion
time until
diagnosis
treatment started
after inclusion
CRP
(<10mg/L)
ESR
(20mm/h)
1 F 60 orbita n.i.m. 14 years prednisone, meth-
otrexate, cyclospo-
rine, infliximab
14 40
2 F 67 orbita n.i.m. 8 years dexamethasone 1.1 1
3 M 63 orbita, lymph 
node, lung, 
prostate
prednisone 3 years prednisone, ritux-
imab, methotrexate
0.9 5
4 M 54 orbita prednisone 10 years prednisone 1.9 9
5 F 53 orbita n.i.m. 3 years unknown 1.7 n.d.
6 M 60 orbita, lymph 
node
t.n. 5 years prednisone, metho-
trexate
0.7 16
7 M 44 orbita t.n. 12 years prednisone 0.4 1
8 F 59 skin t.n. 5 months hydroxochloro-
quine
6.0 11
9 M 18 lymph node, 
lung, cerebra
t.n. 1 month dexamethasone, 
azathioprine
50 107
10 F 62 pancreas, 
lymph node, 
lung
t.n. 3 months prednisone 6 2.4
11 M 74 lymph node, 
salivary gland, 
lung
t.n. 5 months prednisone, azathi-
oprine
0.8 37
12 M 53 mesenterium t.n. 20 years prednisone, azathi-
oprine, rituximab
84 119
13 M 62 thyroid gland t.n. 1 year prednisone 1.9 6
14 M 32 serous mem-
brane
t.n. 3 months prednisone 18.7 8
15 M 79 lymph node, 
pancreas
t.n. 1 year - 6.4 90
16 M 60 bile duct, 
lymph node
t.n. 2 weeks prednisone, metho-
trexate
4 0.7
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; n.i.m., no immunomodulatory 
medication for at least 6 months prior to inclusion; t.n., treatment naïve; n.d., not determined
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Immunophenotypical analysis of IgG4-expressing B-cells.
The hallmark of IgG4-RD is the accumulation of IgG4-producing plasma cells in affected 
tissue. To study whether patients had systemic abnormalities in IgG4-expressing B cells, 
we developed a reliable flow cytometric gating strategy to distinguish cells expressing one 
of the four IgG subclasses (Fig 2A). Within total CD19+ B cells, CD27+CD38hi plasma blasts 
were electronically gated and studied for expression of IgG1, 2, 3 and 4. However, surface 
Ig levels were too low to detect. Therefore, we next focused our attention on CD38dimIgM-
IgD- memory B cells. These contained presumed memory B cell subsets that expressed 
either IgG1, IgG2 or IgG3, and within the triple negative fraction, a sizeable IgG4-expressing 
subset could be identified (Fig 2A).
To confirm the activated nature and memory phenotype of all IgG+ B-cell subsets 
we studied the expression of B7 family members CD80 and CD86 and the TNF receptor 
superfamily member transmembrane activator and CAML interactor (TACI). All four IgG-
subclass expressing B-cell subsets showed higher expression of the activation markers than 
naive B-cells (Fig 2B), fitting with an activated memory B-cell phenotype.
Figure 2. Identification and immunophenotyping of IgG subclass expressing memory B-cells. 
A. Stepwise flowcytometric gating strategy to identify IgG1+, IgG2+, IgG3+ and IgG4+ memory 
B-cells. B. Expression of activation and memory markers on B-cell subsets. Shaded grey 
histograms represent naive B-cells, light blue represent IgG1+ memory B-cells and dark blue 
represent IgG4+ memory B-cells. Each dot represents one individual, red lines indicate medians. 
Statistical analysis between the groups was performed with the Mann Whitney U test. *p<0.05
Increased CD21low B-cells and plasma blasts, but reduced IgM+IgD+ memory 
B cells in patients with IgG4-RD.
To study systemic abnormalities in IgG4-expressing B cells, we performed extensive 
immunophenotyping of B-cells in 16 patients with IgG4-RD and compared these with 
30 age-matched healthy controls (Fig 3A). The median numbers of transitional and naive 
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mature B cells were not different between patients and controls. Of the six major memory 
B cell subsets, only the IgM+IgD+ memory B cells were significantly affected in patients 
(reduced; P<0.05) (Fig 3B). In contrast, the numbers of CD21low B-cells (CD19+CD38dimCD21low), 
and plasma blasts (CD19+CD38+CD27+) were significantly higher in patients with IgG4-RD 
(both P<0.05).
Patients with IgG4-RD have increased numbers of IgG4+ memory B-cells.
Despite the normal total numbers of IgG+ memory B-cells, patients with IgG4-RD had 
significantly higher numbers of IgG4+ memory B-cells than controls (P<0.01) (Fig 3C). 
In addition, patients had reduced numbers of memory B cells expressing IgG1 (P<0.05), 
whereas IgG2 and IgG3 expressing B-cell numbers were similar to controls (Supplemental 
Figure 1A). When analyzed as fraction of total IgG-expressing memory B cells, the decrease in 
IgG1 and increase in IgG4 in patients with IgG4-RD became more apparent (both P<0.0001). 
Furthermore, IgG4-RD patients showed a significant increase in the fraction of IgG memory 
B cells expressing IgG2 (P<0.01). To study if there was a direct relation with serum IgG4 
levels, we performed linear regression analyses with the percentages and the absolute 
numbers of IgG4+ memory B-cells (Supplemental Figure 1B). These did not reveal significant 
correlations, indicating that the memory B cells and serum IgG4 levels were not directly 
related.
Since both IgG4-expressing B cells and CD21low B cells were significantly increased in 
IgG4-RD patients, we studied if these were related and investigated CD21low B cells expressing 
IgG4 (Supplemental Figure 1C). Indeed, patients carried significantly more CD21lowIgG4+ B 
cells (Supplemental Figure 1D) and these numbers were directly correlated to the total 
number of CD21low B cells (P<0.01) (Supplemental Figure 1E).
Cellular and molecular analysis of IgG4-expressing B-cells in patients with IgG4-RD.
To analyze the nature of the IgG4-expressing B-cell expansion in patients with IgG4-RD, 
we first studied the expression of CD27 (Fig 4A). In healthy controls, the frequencies of cells 
that expressed CD27 were highest within the IgG2 and IgG4 subsets, followed by IgG1 and 
IgG3 (Fig 4B). Thus, CD27 positivity was higher in cells utilizing IgG subclasses encoded by 
the downstream genes within the IGH locus (Cγ2 and Cγ4) (Fig 4C). In patients with IgG4-RD, 
significantly fewer IgG4+ B-cells expressed CD27 than IgG4+ B-cells from healthy individuals.
To study whether the expanded IgG4-expressing B cells could be normally involved in 
immune responses, we analyzed the expression levels of cytokine receptors and chemokine 
receptors involved in germinal center responses. IL21 receptor (IL21R) and IL4R as well as C-C 
chemokine receptor type 7 (CCR7) expression levels were similar between IgG4+ memory 
B-cells from healthy individuals and from patients with IgG4-RD (Fig 4D). In contrast, C-X-C 
receptor type 5 (CXCR5) expression was significantly lower on IgG4+ memory B-cells from 
patients.
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Figure 3. Composition of the blood B-cell compartment in healthy individuals and in patients 
with IgG4-RD. A. Model of peripheral B-cell maturation. B. Absolute numbers of naive and 
memory B-cell subsets and plasma cells. Columns indicate median values with interquartile 
range. C. Absolute numbers of IgG4+ memory B-cells. D. Distribution of IgG subclass memory 
B-cells within the total IgG memory B-cell compartment. E. Absolute numbers of CD21lowIgG4+ 
memory B-cells. Each dot represents one individual, red lines indicate medians. Statistical analysis 
between the groups was performed with the Mann Whitney U test. * p<0.05, ** p<0.01, **** 
P<0.0001
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Figure 4. Molecular characteristics of IgG4+ B-cells from healthy individuals and patients 
with IgG4-RD. A. Representative flowcytometry plots of CD27 expression on total B cells and 
IgG4+ B-cells from a healthy individual and from a patient with IgG4-RD B. Frequencies of IgG 
subclass memory B-cells expressing CD27. C. Schematic representation of the human IGH locus 
D. Expression of cytokine and chemokine receptors on IgG4+ B-cells. E. Representation of the 
membrane B-cell receptor (BCR) with the variable domain of the Ig heavy chain (V, D and J) and 
Ig light chain (V and J). Asterisks in the RNA represent mutations in the genes encoding the 
proteins of the BCR. F. Frequency of somatic hypermutation (SHM) in rearranged IGHV gene. G. 
Selection for replacement mutations in the CDR (red) and FR (blue) regions. Solid lines represent 
patients; dotted lines represent healthy controls. A selection strength of more than 0 is indicative 
of positive selection 48.
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To investigate the nature of the expanded IgG4+ memory B-cells in the pathogenesis 
of IgG4-RD, we studied somatic hypermutations (SHM) in the IGHV regions (Fig 4E). Such 
mutations are molecular signs of B-cell responses and affinity maturation 49. In agreement 
with previous studies, SHM frequencies in IgG4 transcripts of healthy adults were higher 
than in the more proximal-encoded IgG1 and IgG250, 51. The SHM levels in IgG4 transcripts 
of patients with IgG4-RD (7.89%) were similarly high as in healthy adults (7.98%; P=0.75) (Fig 
4F). To study if the mutations were driven by selection for antigen binding, we analyzed the 
selection for replacement mutations in the complementarity determining regions (CDR) with 
the Bayesian estimation of Antigen-driven SELectIoN program BASELINe 48. IgG4 transcripts 
from healthy controls did not show more replacement mutations than expected by random 
chance in the CDR regions, i.e. absence of positive selection (Fig 4G). In contrast, CDR regions 
of IgG4-RD patients did show positive selection for replacement mutations. Both groups 
showed normal negative selection for replacement mutations in framework (FR) regions that 
compose the structure of the variable domain. Thus, IgG4+ B-cells in patients with IgG4-RD 
show increased selection for replacement mutations in CDR regions. Patients and controls 
displayed high diversity in sequence and length of the CDR3 region, which is encode by 
the junction of the V, D and J genes. Still, patients showed significantly shorter IGH-CDR3 
regions in IgG4 transcripts than healthy individuals. Furthermore, IGHV usage seemed to 
differ between groups with increased usage of IGHV5-51 in patients with IgG4-RD and 
reduced IGHV3-39 usage, although this did not reach statistical significance (P=0.08).
Increased numbers of Th2 cells and Tregs in IgG4-RD.
The impaired expression levels of CXCR5 and absence of positive selection of SHM in 
IgG4+ B cells are suggestive of abnormal immune responses in patients with IgG4-RD. IgG4 
responses are mediated by IL-4 and IL-13, produced by Th2 cells, and IL-10, produced by 
Tregs. Therefore, we performed additional studies into Th subsets in our patients (Fig 5A). 
Flowcytometrc immunophenotyping of their blood T cells demonstrated normal overall 
numbers of naive, central memory and effector memory CD4 T cells. Still, patients with IgG4-
RD had significantly more circulating Th2 cells (CD45RA-CCR6-CXCR3-CCR4+; P<0.0001) and 
Tregs (CD45RA-CD127-CD25+; P<0.001) than healthy individuals (Fig 5B). Th1 cells seemed 
slightly lower, but this was not significant and numbers of follicular helper T cells (Tfh) 
and Th17 were not different. Linear regression showed a direct correlation between the 
numbers of IgG4+ memory B-cells and Th2 cells (P<0.01), but not for Tregs (P=0.24; Fig 
5C). CD21lowIgG4+ B cell numbers were similarly correlated with Th2 cells (P<0.05) and not 
with Treg numbers (P=0.49). IgG4 serum levels in patients did not correlate with Th2 nor 
Treg cell numbers. In contrast to the changes in Th subsets, patients with IgG4-RD had no 
differences in numbers of CD4+CD45RA+CCR7- TemRA cells, CD4+CD45RA-CCR7- TemRO 
cells, nor CD27- TemRO cells (CD4 CTL). Finally, naive CD8 T-cell numbers were decreased 
in IgG4-RD patients, in absence of effector memory expansions.
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Skewing of Th subsets towards Th2 is also observed in allergies and frequently 
accompanied by eosinophilia 52. However, we did not find increased numbers of eosinophils 
(SSChighCD45+CD16dimCD81+) in patients with IgG4-RD (Supplemental Figure 2), nor any 
differences in the other granulocyte subsets (neutrophils and basophils). In contrast, the 
numbers of plasmacytoid dendritic cells (SSClowCD45dimHLADR+CD123+), which are potent 
drivers of Th1 responses 53, were significantly lower in IgG4-RD patients. Thus, the increased 
numbers of IgG4-expressing B cells in IgG4-RD patients are accompanied by systemic 
reduction in Th1 immunity and increased Th2 and Treg cells.
Figure 5. Blood T-helper subsets. A. Representative plots from flow cytometric analysis. 
B. Absolute numbers of T-helper 1 (Th1), T-helper 2 (Th2), follicular helper T-cells (Tfh) and 
regulatory T-cells (Treg). C. Regression analysis of Th2 cells and IgG4+ B-cells and of Treg cells 
and IgG4+ B-cells. Each dot represents one individual, red lines indicate medians. Statistical 
analysis between the groups was performed with the Mann Whitney U test. * p<0.05, ** p<0.01. 
Correlation was calculated with Spearman R.
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Figure 6. Multi-parameter analysis and clustering of individuals based on blood lymphocyte 
subsets. A. Principal component analysis of peripheral blood lymphocyte subsets from healthy 
individuals (green), patients with sarcoidosis (blue) and patients with IgG4-RD (red). Each 
individual is represented by one dot, with indication of group median (large dot) together with 
1SD and 2SD. Following automated population separator (APS) based on the absolute counts of 
various subsets, PC1 and PC5 were selected to visualize separation between healthy individuals, 
patients with sarcoidosis and patients with IgG4-RD. The contribution of the top 5 components 
of each PC are listed. B. Scoring of blood samples based on a formula composed of the subsets 
that were significantly different between healthy individuals and patients with IgG4-RD. The 
percentage of IgG2+ B-cells and IgG4+ B-cells within total IgG B-cells are multiplied by the 
absolute numbers of Th2, Treg and IgG4+ B-cells and divided by the percentage of IgG1+ B-cells 
within total IgG+ B-cells multiplied with the absolute numbers of Th1 and IgG1+ B-cells. Red 
dotted line indicates a score of 100 considered as cut-off value.
IgG4+ memory B-cells and other lymphocyte subsets as a diagnostic tool for 
IgG4-RD.
Despite clinical indications and high serum IgG4 levels, diagnosis of IgG4-RD requires analysis 
of a tissue biopsy. Obtaining a biopsy can be difficult, is invasive, sample error sensitive and 
might not always be sufficiently discriminative from other immune-proliferative and auto-
inflammatory diseases. A specific marker in blood could be a valuable means to overcome 
these diagnostic challenges. However, the differences in B-cell and T-cell subsets we 
identified do not provide a clear discrimination between patients and controls. Therefore, 
we explored if a combination of measurements could be used as a disease marker. First, 
we performed a principal component analysis (PCA) on the absolute cell numbers of all B 
and T-cell subsets from healthy individuals and patients with IgG4-RD and visualized this 
with the automated population separation (APS) tool of the Infinicyt program 54. In this 
analysis we also included a group of patients with treatment naive sarcoidosis, another 
fibro-inflammatory disease. IgG4-RD resembles many immune proliferative diseases, yet 
patients with sarcoidosis did not show typical expansions of IgG4+ memory B cells, Tregs 
and Th2 cells. Of the first 5 principle components, component 1 (PC1) separated patients 
with IgG4-RD from patients with sarcoidosis and from healthy controls. (Fig 6A). This analysis 
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indicates the usefulness to combine multiple parameters for optimal discrimination between 
IgG4-RD patients and controls and potentially from other auto-inflammatory conditions 
with tissue fibrosis. Therefore, we continued to develop a score based on the B- and T-cell 
subsets that were most significantly different between IgG4-RD patients and both controls 
and patients with sarcoidosis (Fig 6B). Application of this scoring method to the 56 samples 
in our study resulted in 50 samples being correctly assigned as either non-IgG4-RD or IgG4-
RD (Fig 6B). The calculated sensitivity for this score was 93.3% (95% confidence interval, 
68.05% - 99.83%) and the calculated specificity was 87.8% (95% CI, 73.80% - 95.92%). Thus, 
IgG4-RD patients carry changes in their blood B- and T-cell subsets that together reflect a 
unique “lymphocyte signature”.
DISCUSSION
We here demonstrate significant expansions of IgG4-expressing B cells in blood of patients 
with IgG4-RD. These changes were directly related to the previously described expansion 
of CD21low B cells and are associated with expansions in plasma blasts, Th2 and Treg cells.
Increased numbers of circulating plasma blasts have been reported before in patients with 
IgG4-RD 8, 34. This is not a disease-specific effect as similar expansions have been observed 
in many chronic inflammatory diseases and in individuals with active infection or following 
vaccination 35-38. Thus, increased plasma blast numbers mostly reflect active humoral 
immune responses. Active inflammation is further supported by the increased numbers of 
CD21low B cells in our patients. These cells have been reported to be increased in multiple 
states of inflammation 43, 55, 56 and are thought to result from prolonged B-cell activity due 
to chronic activation by self-antigens 57. CD21 functions as a co-receptor for the BCR, and 
downregulation of its expression makes the cells anergic for chronic stimuli 58. We now 
demonstrated that the expansion of CD21low B cells is in part due to the expansion of IgG4+ 
population, which directly links it to the disease. The nature of chronic B-cell stimulation in 
IgG4-RD remains unclear. It is likely that auto-antigens are involved, as plasma blasts from 
patients with IgG4-RD produce immunoglobulins that react against human cell lysates 8.
Insights into IgG4-expressing B cells in patients with IgG4-RD are limited, most likely due 
to the lack of proper reagents to specifically detect and isolate these cells. To overcome 
this, we developed a flow cytometric approach to stain for IgG4-expressing B cells using 
newly available reagents and found that frequencies and absolute numbers of IgG4+ 
memory B-cells were increased in patients with IgG4-RD. However, in contrast to previous 
observations, these numbers were not correlated to IgG4 serum levels 59. Absence of 
correlation is most likely due to the fact that these cells were immunophenotypically 
memory B-cells 60, 61 rather than IgG4-producing plasma cells. Previously we observed similar 
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absence of correlation for IgE+ memory B-cell numbers and serum IgE levels in patients 
with atopic dermatitis 62.
On top of cell numbers, patients’ IgG4+ memory B cells were phenotypically different 
from those of healthy controls. A lower frequency of cells expressed CD27, which is the 
conventional marker for memory B-cells 63, 64. Furthermore, expression levels of CXCR5 were 
lower in patients. These differences could originate from a different maturation pathway for 
IgG4+ memory B cells in patients. Generation of IgG+ memory B cells in humans is critically 
dependent on T-cell help 65. Yet, it is unclear if T-cell help is needed for sequential switching 
to IgG4 of memory B cells expressing other IgG subclasses. The reduced expression of CXCR5 
on IgG4+ B-cells from patients could represent a reduced capacity for homing to B-cell 
zones in lymph nodes and would suggests that activation and differentiation of IgG4+ 
B-cells in patients occurs in peripheral tissue, rather than in lymphoid structures 66. Cytokines 
specifically inducing CSR to IgG4 have been found in IgG4-RD tissue biopsies 16. Moreover, 
expression of activation-induced cytidine deaminase (AID), the enzyme that triggers SHM 
and which is needed for CSR, was reported to be increased in tissue biopsies of IgG4-RD 
patients, conforming the ability of local CSR 15.
In addition to differences in IgG4+ memory B cells, we found systemic expansions of 
Th2 and Treg cells. Ig class switching to IgG4 is mediated by the cytokines IL4 and IL-10, 
which are predominantly produced by Th2 and Treg, respectively. This is referred to as 
“the modified T-helper 2 type response” 67, and has been reported in the context of the 
beneficial effects of immunotherapy in allergy, in which it favors CSR to IgG4 over IgE 68. 
Prolonged antigen exposure indeed leads to a serologic shift in the IgG4:IgG1 antibody ratio, 
as previously illustrated by natural immunization in bee keepers or during subcutaneous 
immunotherapy with grass pollen 69, 70. Previous observations in tissue and in blood have 
also linked the modified Th2 type response to IgG4-RD 16-18, 20, 69. Our data confirms such a 
response, with the observation of increased numbers of Th2 cells and Tregs in IgG4-RD and 
a positive correlation between Th2 cells and IgG4+ B-cells. In contrast to earlier observations 
we did not find an increase in Tfh cells 71. Yet, this finding supports the hypothesis that 
differentiation towards IgG4 in IgG4-RD takes place in peripheral tissue, rather than in 
follicles in lymphoid structures.
Despite significant differences in numbers of B- and T-cell subsets between patients and 
controls in the presented study, none of these were sufficiently discriminative to be used as 
biomarker. This included plasma blasts, which had recently been proposed as a biomarker 
for IgG4-RD 34. Importantly, the numbers of plasma blasts in our patients (median 3.36 cells/
μL) were in the same range as previously reported (median 4.70 cells/μL) 34, whereas plasma 
blast numbers were extremely low in controls of that study (0.10 cells/μL) 34. As plasma 
blasts in our study (median 1.70 cells/μL) were in the same range as reported by others, it 
is questionable if this subset is a reliable biomarker 72. Therefore, we propose to derive a 
biomarker based on the specific “lymphocyte signature” in peripheral blood of patients with 
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IgG4-RD. Combined analysis of various subsets has an advantage since it does not rely on 
one biomarker, rather it reflects the pathophysiology of the disease. Since IgG4-RD can affect 
various organs, the clinical presentation is diverse, yet PCA of the peripheral lymphocyte 
compartment illustrates that the underlying immune response is clearly distinct. This is 
confirmed by the fact that combined analysis with PCA not only distinguishes healthy 
from disease, but can also discriminate between different fibro-inflammatory conditions 
(i.e. sarcoidosis from IgG4-RD). Examples of scoring systems in medical practice are ample 
and systems medicine has been proven of value to study complex diseases and generate 
predictive models, although some caution is warranted 73, 74.
In conclusion, we here demonstrate that patients with IgG4-RD present with 
increased numbers of IgG4+ B-cells, CD21low B-cells and plasma blasts in blood. Molecular 
characteristics reveal that the latter expansion is a result of an ongoing immune response 
in affected tissue. Furthermore, this is characterized by increased numbers of Th2 cells 
and regulatory T-cells, known as the modified Th2 type response. This specific “peripheral 
lymphocyte signature” in patients with IgG4-RD indicates that patients suffering from 
IgG4-RD have a common disease pathogenesis and in the future, peripheral blood might 
be exploited as a non-invasive tool to employ for diagnosis and treatment monitoring in 
patients with IgG4-RD.
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SUPPLEMENTAL DATA
Supplemental Table 1. Basic immunological characteristics of patients with IgG4-RD
serum immunoglobulins (g/L) blood leukocytes and subsets (cells/μl)
Patient IgG1 IgG2 IgG3 IgG4 leukocytes lymphocytes T-cells B-cells NK-cells
1 8.61 6.8 0.4 2.12 6500 3480 2640 620 220
2 10.40 2.28 0.34 2.73 4500 2440 1930 400 70
3 5.24 2.36 0.38 5.96 7300 790 610 60 90
4 5.37 2.13 0.35 1.22 6200 1960 1640 200 120
5 4.59 3.16 0.62 0.27 12100 4470 3500 490 450
6 10.4 4.56 0.75 7.50 4800 1790 1480 110 180
7 6.49 2.49 0.32 1.85 7100 1650 1160 190 270
8 6.89 3.39 0.59 1.93 6500 2040 1510 270 220
9 25.1 5.12 0.96 12.8 5800 2360 1620 570 130
10 5.27 4.31 0.35 0.27 8800 2970 2140 430 370
11 10.4 2.93 0.32 5.75 7700 1280 1040 60 170
12 11.4 2.68 1.09 25.25 10200 4100 3300 280 440
13 6.85 4.66 0.23 2.76 5400 2280 1440 210 530
14 9.91 7.15 0,64 5.40 7600 1530 1130 110 260
15 19.30 2.27 2.28 1.13 7000 1710 1010 470 150
16 8.87 4.36 0.36 5.55 6800 1480 1150 60 160
normal 
range
4.9-
11.4
1.5-
6.4
0.2-
1.1
0.08-1.4
3500-
10000
1100-2500
700-
1900
100-
400
100-
400
Subnormal values are depicted in italics, supranormal values in bold font
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Supplemental Figure 1. A. Absolute counts of IgG1+, IgG2+ and IgG3+ memory B-cells. Each 
dot represents one individual, red lines represent median values. Statistical analysis between 
the groups was performed with the Mann Whitney U test; *P<0.05. B. Correlation between IgG4 
serum values and absolute numbers of IgG4+ memory B-cells and between percentages of 
IgG4+ B-cells within total IgG+ B-cells. Grey shaded area indicates the reference value for IgG4 
serum values. Correlation was calculated with Spearman R. C. Representative plots of the flow 
cytometric analysis of IgG subclass expressing CD21low B-cells D. Absolute counts of CD21low 
IgG4+ B-cells. Each dot represents one individual, red lines represent median values. Statistical 
analysis between the groups was performed with the Mann Whitney U test; *P<0.05, **P<0.01. E. 
Correlation between CD21low B-cells and IgG4+ CD21low B-cells in healthy controls and in patients 
with IgG4-RD.
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Supplemental Figure 2. A. Representative plots of the flow cytometric analysis of granulocyte 
subsets and plasmacytoid dendritic cells (DC) B. Absolute counts of neutrophils, basophils, 
eosinophils and plasmacytoid DC. Columns represent median values with interquartile range. 
Statistical analysis was performed with the Mann Whitney U test, *P<0.05.
7

8
CHAPTER 8
Local and systemic signs of chronic 
B-cell responses in IgG4-related 
disease
A. Faiz Karim, MD,1,2* Jorn J. Heeringa, MD,1* Jan A.M. van Laar, MD, PhD,1,2 Robert M. Verdijk, 
MD, PhD,3 Willem A. Dik, PhD,1 A. Dion Paridaens, MD, PhD,4 P. Martin van Hagen, MD, PhD,1, 
2 Menno C. van Zelm, PhD5
1 Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The 
Netherlands, 2 Department of Internal Medicine, Erasmus MC, University Medical Center, 
Rotterdam, The Netherlands, 3 Department of Pathology, Erasmus MC, University Medical 
Center, Rotterdam, The Netherlands, 4 Department of Ophthalmology, Department of Orbital 
Surgery Rotterdam, The Netherlands, and 5 Department of Immunology and Pathology, 
Central Clinical School, Monash University and Alfred Hospital, Melbourne, Victoria, Australia
* These authors contributed equally to this work.
J Allergy Clin Immunol. 2018 May;141(5):1958-1960
178
Chapter 8
We recently devised a method to examine IgG4+ B cells in blood and applied this to study 
patients with IgG4-related disease (IgG4-RD) with the implication of a non-invasive test.1, 2 
In our cohort of patients that all met the Boston criteria for IgG4-RD, IgG4+ memory B cell 
numbers were increased,2 as well as circulating plasma blasts, CD21low B cells, T-helper (Th)2 
and regulatory T cells (Treg) that were reported previously in other cohorts.3, 4 Together, 
these abnormalities were regarded as a specific “lymphocyte signature”, and we devised a 
combined score that could discriminate patients from controls with 93.3% sensitivity and 
87.8% specificity.2
The accumulation of IgG4-expressing B cells and plasma cells is thought to result from 
enhanced T-cell dependent germinal center responses in lymphoid and non-lymphoid 
tissue of affected patients. Indeed, of 16 previously reported2 and 3 newly included patients, 
17 (89%) had B-cell follicles in affected tissue (Fig 1A, Table 1, Fig 2). In contrast, we did 
not identify cellular or molecular signs of enhanced B-cell activation in blood. Rather, 
IgG4+ memory B cells showed a more anergic phenotype with significantly more of these 
cells lacking CD21 and CD27 expression, and having reduced expression levels of CXCR5, 
a chemokine receptor important for homing to B-cell follicles.2 Moreover, transcripts of 
these IgG4+ B cells did not show enhanced accumulation of somatic hypermutations (SHM). 
Additional SHM analysis on transcripts amplified with an IgG consensus primer revealed 
no increased SHM in the other IgG subclasses either, which is in contrast to patients 
with sarcoidosis (Fig 1B, Fig 3).5 Still, the frequency of IgG2 transcripts was significantly 
increased (Fig 3), fitting with our flowcytometry data2 and repeated immune responses.1 
This contrasted a previous study, where increased SHM were found in the FR3 and CDR3 
regions of IgG4 transcripts. It should be noted that FR3 and CDR3 form less than 1/3rd of 
the variable domain and that mutations in the CDR3 are notoriously difficult to define, 
because this includes the junctional regions between IGHV, IGHD and IGHJ genes with 
random nucleotide insertions and deletions from the V(D)J recombination process. Our 
analysis involved the strongly recommended approach for SHM analysis, which included 
the whole IGHV gene (>280 nt) including FR1, FR2 and FR3, and the CDR1 and CDR2.6 Thus, 
the patients in our original IgG4-RD cohort do show signs of chronic B-cell responses in 
affected tissue, whereas their circulating B cells have increased anergic properties.
Similar to Akiyama et al,7 we did not find a significant increase in absolute numbers 
of circulating follicular helper T (Tfh) cells in our original study,2 and this remained non-
significant upon inclusion of our 3 new patients (Fig 1C). The importance of Tfh subsetting 
is a relative new finding and was not yet exploited at the start of our original study. Given 
recent reports that underline the important role of Tfh subsets in IgG4-RD,7 we here 
analyzed Tfh1 and Tfh2 numbers in more detail and found the latter to be significantly 
increased as compared to controls (Fig 1C). However, circulating Tfh2 cell numbers were 
also significantly increased in patients with sarcoidosis, and are therefore less specific for 
IgG4-RD as circulating IgG4+ B cells, Treg cells and Th2 cells.
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Figure 1. B-cell follicles, somatic hypermutations and follicular helper T-cell subsets in patients 
with IgG4-RD. A. Immunohistochemical analysis of orbital tissue from patient 7 reveals the 
presence of CD79A positive B-cell follicles containing Bcl-6 positive, PD-1+ B follicular helper T(fh) 
cells. B. Somatic hypermutations (SHM) in IgG transcripts and IgG subclasses of adult controls, 
patients with IgG4-RD and patients with sarcoidosis. C. Numbers of Tfh, Tfh1 and Tfh2 cells in 
blood of controls, patients with IgG4-RD and patients with sarcoidosis. Black triangles denote 
newly included IgG4-RD patients. Statistics: Mann-Whitney U test, ** p <0.01, **** p <0.0001.
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Figure 2. Additional immunohistochemical analysis of orbital tissue From IgG4-RD patient 7 
with anti-IgG4, CD3, and Bcl-2.
Figure 3. Somatic hypermutation analysis in IgG transcripts. A. IgG transcripts were 
amplified with an IgG consensus primer from 6 IgG4-RD patients and the relative composition 
of IgG subclasses was compared to previously generated data from controls and from patients 
with sarcoidosis. Statistics, χ2 test. B. Somatic hypermutation levels in unique transcripts from 
6 controls, 6 IgG4-RD patients and 4 patients with sarcoidosis.
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SUPPLEMENTAL DATA
Methods
Histopathology
All patients with IgG4-RD were histologically diagnosed. The amount of IgG4+ plasma 
cells per hpf (0.28 mm2) and the IgG4/IgG ratio were measured (Table 1), and all patients 
met the Boston criteria for IgG4-RD. The hematoxylin and eosin stainings were analyzed 
at the Department of Pathology of the Erasmus MC Rotterdam by a trained pathologist 
with experience in diagnosing IgG4-RD. The deparaffinized formalin-fixed paraffin–
embedded sections of the tissue (4 mm thick) were stained using a BenchMark automated 
immunostainer (Ventana, Tucson, Ariz) with the Ultraview Universal diaminobenzidine 
detection kit (Ventana). Mouse antihuman IgG (clone A57H, 1:200; Dako, Carpinteria, Calif) 
and mouse antihuman IgG4 (clone HP6025, 1:600; Invitrogen Zymed, Camarillo, Calif) were 
used for immunohistochemical staining and were applied to the sections for 32 minutes. 
Additional stainings were performed with CD3 (2GV6, ready to use), CD79A (Sp18, ready to 
use), and Bcl-2 (Sp66, ready to use; all from Ventana) and Bcl-6 (G11GE/A8, 1:10) and PD-1 
(Nat105, 1:50; both from Cell Marque, Rocklin, Calif).
Molecular analysis of IgG transcripts
RNA was isolated from post-Ficoll mononuclear cells of IgG4-RD patients 5, 7, 8, 10, 11, and 12 
with a GenElute mammalian RNA kit (Sigma-Aldrich, St Louis, Mo) and reverse transcribed to 
cDNA with random primers (Thermo Fischer,Waltham,Mass). Rearranged IgGtranscripts were 
amplified in a multiplex PCR approach using 4 different IGHV-family leader forward primers 
in combination with an IGHG-consensus (59CACGCTGCTGAGGGAGTAG) reverse primer.
E1 PCR products were cloned into a pGEMTeasy vector (Promega, Madison,Wis), amplified 
by colony PCR, and sequenced by Micromon facility of Monash University on an Applied 
Biosystems 3730s DNA Analyzer (Thermo Fisher). Obtained sequences were analyzed using 
the IMGT database (http://www.imgt.org/IMGT_vquest/vquest) to assign the IGHV, IGHD, 
and IGHJ genes and alleles, and to identify SHMs. Of each unique clone, the position and 
frequency of mutations were determined within the entire IGHV gene (FR1-CDR1-FR2-CDR2-
FR3). SHMs were determined as variations on the best-matchedV-gene and represented as 
the percentage ofmutations of the total sequenced V-gene nucleotides. The IgG receptor 
subclasses were determined using the IGH reference sequence (NG_001019). All results of 
patients with IgG4-RD were compared with previously generated data sets of controls and 
of patients with sarcoidosis.
Flow cytometry
Stored PBMCs from controls, patients with IgG4-RD (2, 3, 6, 9, 15-19), and patients with 
sarcoidosis were thawed and prepared for detailed flow cytometric analysis of Th and Tfh 
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subsets. Two million PBMCs were incubated for 15 minutes at room temperature in a total 
volume of 100 mL with the following antibodies: CD4-BV510 (RPA-T4), CD25-BV421 (BC96), 
CD45RA-BV605 (HI100), CD127-APC (A019D5), CCR4-PE-Cy7 (L291H4), CCR6-PerCPCy5.5 
(G034E3; all from Biolegend, San Diego, Calif), CD3-BV711 (UCHT1), CD8-APC-H7 (SK1), CCR7-
PE-CF594 (150503), CXCR3-PE (1C6/CXCR3), and CXCR5-BB515 (RF8B2; all from BD Biosciences, 
San Jose, Calif). After preparation, cells were measured on a 4-laser LSRFortessa flow 
cytometer (BD Biosciences) using standardized settings. Data were analyzed with FACSDiva 
software V8.0 (BD Biosciences). Tfh cells were defined as CD31CD41CD45RA2CXCR51, and 
within this subset the Tfh1 cells were defined as being CCR62CXCR31CCR42 and Tfh2 cells 
as CCR62CXCR32CCR41.
Statistical analysis
SHM frequencies and both frequencies and absolute cell numbers were assumed a non-
Gaussian distribution. Results were analyzed using the nonparametric Mann-Whitney U test. 
IgG subclass distributions were analysed with the chi-square test. All P values are 2-tailed and 
were considered statistically significant if valueswere lower than .05. Statistical analysiswas 
performed usingGraphPad Prism software, version 7 (GraphPad Software, La Jolla, Calif).
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Is there a role for IgE in psoriasis?
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DISCUSSION
Abnormalities in serum antibody levels and specificities are hallmarks of many immune-
mediated diseases. Patients with allergic diseases such as asthma, atopic rhinitis, food allergy 
and atopic dermatitis, have typical increased total and allergen-specific IgE. Successful 
treatment with immunotherapy in such patients results in rises of total and allergen-specific 
IgG4. Despite the detailed insights into antibody levels and applications in diagnostic work-
up of patients, little is known about the cells that produce IgE and IgG4; i.e. memory B 
cells and plasma cells. The research presented in this thesis was conducted to expand our 
knowledge on IgE and IgG4 B-cell biology and to gain new insights into their maturation in 
healthy individuals and their possible role in the development of immune-mediated disease.
Through the development of a stepwise flow cytometric gating strategy we enabled 
the identification of IgE+ plasmablasts and two populations of IgE+ memory B-cells. The 
latter differ in CD27 expression, and detailed molecular characteristics of these subsets 
showed evidence for a T-cell independent origin of CD27-IgE+ memory B-cells and a T-cell 
dependent origin of CD27+IgE+ memory B-cells (Chapter II). Adults with atopic dermatitis 
as well as patients with Netherton disease, who have a reduced epidermal barrier function 
due to a mutation in the SPINK5 gene, displayed increased numbers of blood CD27-IgE+ 
memory B-cells (Chapters II, III and IV). Furthermore, children with various forms of allergic 
disease, i.e. asthma, atopic rhinitis, food allergy and atopic dermatitis, had increased 
numbers of circulating IgE+ memory B-cells and IgE+ plasmablasts, and the latter were 
directly correlated to Th2 cell numbers (Chapter III). Outpatient treatment at sea level and 
inpatient treatment at alpine climate had no effect on blood IgE+ B-cell numbers, but did 
result in a reduction of total plasmablast numbers, transitional B-cells and regulatory T(reg)-
cells. Next to that, therapy in an alpine climate resulted in a significantly greater reduction 
of disease activity and was accompanied by a reduction of blood eosinophils, and increases 
in memory B-cells, CD8+ TemRO, CD4+ Tcm and CCR7+ Th2 cells (Chapter V). For several 
forms of IgE-mediated allergy successful desensitization of patients can be achieved with 
allergen immunotherapy. Sublingual immunotherapy for grass pollen allergy did not affect 
IgE+ memory B-cells numbers, but did lead to an increase in IgG4+ memory B-cell numbers. 
The resulting increase of IgG4+/IgE+ B-cell ratio may provide an explanation for the 
desensitization and reduction of complaints following treatment (Chapter VI). IgG4 has been 
associated with successful desensitization in allergic individuals following immunotherapy. 
However, patients with IgG4-related disease had increased numbers of IgG4+ memory 
B-cells. Furthermore, patients with IgG4 related disease (IgG4-RD) have increased numbers 
of Th2 cells and Tregs. Together, these subsets make up a specific “peripheral lymphocyte 
signature”, which can be employed for diagnosis and treatment monitoring (Chapter VII).
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IgE B-cell memory
It has long been an enigma if IgE memory B-cells exist in man or if IgE memory function 
results from long-lived IgE producing plasma cells in bone marrow and circulating IgG+ 
memory B-cells which switch to IgE in secondary responses (1, 2). Experimental data from 
studies conducted in mouse models showed conflicting results and provided evidence for 
both models (3-6). In our studies presented in Chapter II, we showed that IgE+ B-cells can 
be reliably identified in peripheral blood of healthy individuals and in that of patients with 
atopic dermatitis. These cells lacked CD23 expression, excluding the possibility that the IgE 
positivity was the result of binding of soluble IgE to this low affinity FcεR. Moreover, mature 
IgE transcripts were detected by PCR-amplification and DNA sequencing from both bulk 
sorted IgE+ memory B-cells (Chapter II), and single cell sorted IgE+ plasmablasts and IgE+ 
memory B-cells (Chapter III). Importantly, both subsets showed phenotypic and molecular 
characteristics of memory B cells, and rapidly differentiated into IgE+ plasma cells upon in 
vitro stimulation with CD40 and IL-21. Thus in humans, there is a reservoir of circulating IgE+ 
memory B-cells with the ability to rapidly respond to antigenic stimulation.
Additional molecular characteristics of CD27+IgE+ memory B-cells showed evidence 
of T-cell dependent (TD) differentiation. In the typical germinal center reaction IL-4, IL-13, 
IL-21 and CD40 ligation is provided by follicular-helper T(fh)2 cells (7). However, CD27-IgE+ 
memory B-cells displayed molecular characteristics of T-cell independent (TI) maturation 
and switch regions showed evidence for more direct switch from naive IgM+ B-cells (Chapter 
II). TI maturation in CD27-IgE+ B-cells is supported by the fact that these cells could be 
detected in patients with a CD40 ligand deficiency in which there is an absence of cognate 
T-cell help due to the lack of direct B and T-cell interaction. Indeed next to T-cells also local 
basophils can be a source of IL-4. Cysteine proteases induce high IL-4 production by mouse 
basophils (8) and in vitro stimulation of human basophils with Der p 1 (i.e. a potent house 
dust mite (HDM) allergen) induces IL-4 secretion (9). The basophil derived IL-4 has been 
shown to control the function of innate lymphocyte type 2 cells (ILC2s) in lung inflammation 
(10), but may also provide the essential signals for local B-cells to undergo class switch 
recombination (CSR) to IgE. Furthermore, several studies have shown that ILC2 cells play an 
important role in the sensitization to allergen exposure through the production of IL-13 (11). 
IL-13 is mainly thought to prompt the migration of activated DCs towards draining lymph 
nodes, yet it may also play an important role in the local differentiation of naive B-cells 
towards IgE+ B-cells by providing the required signals for IgE CSR. This can be substantiated 
by studies which show that ILC2 cells facilitate the sensitization to local, but not to systemic 
allergen exposure (12).
Previous studies have already shown evidence for signs of CSR to IgE in B-cells within 
the bronchial and nasal mucosa of allergic individuals (13-17). Still, it would be interesting 
to directly observe IgE+ B-cells in local mucosal tissue and study their reactivity for certain 
allergens. We have already performed a pilot study to identify IgE+ memory B-cells with flow 
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cytometry in single-cell suspensions from nasal tissue of patients with nasal polyps (non-
allergic) and indeed we could detect CD27-IgE+ memory B-cells and IgE+ plasma cells (Figure 
1). Importantly, CD27+IgE+ memory B-cells were also present in single-cell suspensions of 
nasal tissue. Moreover, CD27-IgE+ memory B-cells could be identified in tonsils of children. 
Thus, there does not seem to be a clear distinction that CD27-IgE+ memory B-cells only 
differentiate in local mucosal tissue and that CD27+IgE+ memory B-cells only originate from 
germinal center reactions. Moreover IgE+ memory B-cells circulate through the periphery, 
which makes it difficult to exclude that these cells switch locally in the respective tissue. 
Still future studies performed with immunohistochemistry on tissue biopsies might identify 
which cells interact in mucosal tissue and play a role in peripheral IgE+ B-cell differentiation.
Figure 1 Frequencies of IgE+ B-cell subsets in human tissues. Blood and nasal tissue samples 
are from adults, tonsil samples are from children. All individuals are non-allergic, nasal tissues are 
from patients with chronic rhinosinusitis. Values are mean frequencies within total IgE+ B-cells 
from each individual, with 95%CI.
Disrupted skin barrier affects IgE+ B-cell differentiation through increased 
allergen exposure
The underlying pathogenesis of IgE-mediated allergic disease is multifactorial, with genetic, 
environmental and immunological factors contributing to the onset of disease (18-20). Yet, 
there are monogenetic diseases with allergic manifestations. One of these is Netherton 
syndrome (NS), a severe genodermatosis typically characterized by chronic skin inflammation 
(ichtyosis and scaly erythroderma), specific hair shaft defects (trichorrhexis invaginata) and 
atopic diathesis with elevated IgE serum levels. The disease is caused by mutations in the 
SPINK5 gene (serine protease inhibitor of kazal type 5) encoding LEKTI (lympho-epithelial 
kazal type related inhibitor) which is expressed in the stratified epithelium of the skin, the 
mucosa and in the Hassal corpuscles of the thymus (21, 22). Analogous to patients with AD, 
patients with Netherton disease displayed increased numbers of CD27-IgE+ memory B-cells 
in blood, whereas numbers of CD27+IgE+ memory B-cells were normal (Chapter IV). Most 
probably this is the result of increased allergen infiltration in the underlying epidermis, since 
the consequence of LEKTI deficiency is a loss of inhibition of serine proteinases. This leads 
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to an abnormal skin homeostasis and detachment of the stratum corneum, which in turn 
contributes to a defective skin barrier enabling microbe and allergen penetration. Previously, 
it has also been suggested that increased thymic stromal lymphopoietin (TSLP) contributes 
to the atopic diathesis. This hypothesis comes from observations of SPINK5 knock out 
embryos in mice, which indicate a KLK5-Par2 cascade leading to enhanced production 
of TSLP, which would in turn lead to increased DC activation and allergen presentation in 
lymphoid structures. Our observations rather support increased allergen penetration as 
a main cause of atopic sensitization, because specifically T-cell independent CD27-IgE+ 
memory B-cell numbers were increased, whereas T-cell dependent CD27+IgE+ memory 
B-cell numbers were not affected.
Alternatives to the IL4/IL13-driven pathway of IgE class switching?
Possibly there might also be alternatives to the IL4/IL13–IgE axis. Psoriasis, generally thought 
to be an auto-inflammatory disease of the skin, is mediated by T-helper (Th)1 and Th17 cells. 
DNA-LL37 complexes stimulate plasmacytoid (p)DC and myeloid (m)DC (23), which induce 
Th1 and Th17 cell differentiation through production of interleukin (IL)-12 and IL-23. IL-17A 
produced by Th17 cells is an important mediator in keratinocyte activation and proliferation 
(24). The efficacy of antibodies neutralizing IL-12/23 (ustekinumab) and IL-17A highlights the 
importance of the Th17 axis in psoriasis (25).
Unexpectedly, increased levels of serum Immunoglobulin E (IgE) have been reported 
in subsets of patients with psoriasis since the early 1980s (26-28). It has remained unclear 
whether the IgE in psoriasis induces similar responses as in allergic disease and might 
thereby contribute to disease pathogenesis. Yet, on top of increased serum IgE, lesional 
skin of patients with psoriasis contains more IgE and FcεRI bearing cells than non-lesional 
skin (29). These concerned especially mast cells, dermal Langerhans cells, epidermal DCs and 
macrophages. Following therapy with ustekinumab, the numbers of IgE and FcεRI bearing 
cells decreased. Although these findings can be merely a bystander effect of inflamed tissue, 
one could speculate about a Th2 independent pathway driving IgE responses.
Yet indeed, alternative to IL-4 and IL-13, IL-17A can promote IgE production by B-cells (30). 
Furthermore, autoreactive IgE has been identified in systemic lupus erythematosus (SLE), 
which can activate pDCs to secrete interferon-α (31). These observations would suggest a 
role for an IL-17 – IgE – pDC axis that contributes to self-destructive autoimmune responses 
(Figure 2). Most likely, the IgE response is not the primary mediator of pathogenesis, but 
is produced after the initial autoreactive IgG (32). Chronic stimulation of autoreactive IgG 
memory B cells could lead to secondary Ig class switching to IgE. The resulting soluble IgE 
will then be included in immune complexes and augment pDC responses by involving FcεRI. 
Current observations support such a mechanism for psoriasis as well (29). However, more 
functional studies would be needed to substantiate this. In contrast to atopic dermatitis, 
patients with psoriasis do not have increased numbers of IgE expressing B-cells (Chapter 
9
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II) (33). This could be a difference in etiology with most IgE in psoriasis being derived from 
sequential Ig class switching in the IgG memory reservoir. This could be investigated using 
in vitro stimulation of IgG memory B cells with Th17 cytokines. On top of total IgE, it would 
be important to establish if patients with psoriasis also have increased levels of autoreactive 
IgE, since anti-nuclear antibodies have been reported in patients with psoriasis (34). Finally, 
with the antigen-specific antibodies, functional studies can be performed to determine the 
effector cells in the skin. Are these the mast cells and basophils that mediate allergies, or 
the pDCs that are thought to be the main effector cells in SLE? Such detailed studies could 
help to unravel pathogenic processes in patients with psoriasis, to identify similarities and 
differences with other (auto-)immune diseases, and provide new targets for therapeutics.
Figure 2 Models for immunoglobulin (Ig) E responses in allergy and the nonclassical IgE 
response in psoriasis. (a) Allergen is taken up by dendritic cells (DC) and presented to naive 
T-cells, which differentiate into T-helper 2 (TH2) cells. Interleukin (IL)-4 and IL-13 induce class 
switching in naive B cells to IgE. Allergen-specific soluble IgE produced by plasma cells binds to 
FceRI on mast cells and basophils. Subsequent allergen exposure leads to cross-linking of cell-
bound IgE, resulting in allergic complaints. (b) Self-antigen is taken up by DC and presented to 
naive Tcells, which differentiate into TH17 cells. IL-17A induces class switching to IgE. Antigen–
IgG–IgE complexes can bind to plasmacytoid DC (pDC) and recognition of self-antigen leads to 
the production of interferon-a, augmenting the psoriatic immune reaction.
IgE+ B-cells as target for treatment and treatment monitoring of allergic disease
As shown Chapter III, median numbers of IgE+ B-cells in blood of patient groups with various 
forms of IgE-mediated allergies are significantly increased as compared to healthy children. 
However, the cell numbers in many patients did not fall outside the range of healthy controls 
and as a result there is some overlap in values between allergic individuals and non-allergic 
individuals. Next to that, neither circulating IgE+ plasmablast nor IgE+ memory B-cell 
numbers correlated with IgE serum levels. Possibly, serum IgE levels are dependent on the 
production of IgE by tissue residing plasma cells or by the capacity of mast cells, basophils 
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and eosinophils to bind free IgE. On the other hand, IgE serum levels are also not well 
correlated to disease severity. Therefore it will be interesting to study the reactivity of IgE+ 
memory B-cells and investigate if this can be directly correlated to reactivity testing of serum 
IgE with RAST or ISAC. Strategies to achieve this can be attained through single cell sorting 
and production of monoclonal antibodies, or through direct detection of allergen specific 
B-cells with labeled allergen extracts using flow cytometry.
Possibly, allergen specific IgE+ memory B-cells are more specific markers for allergic 
sensitization and these could be important targets for desensitization treatments possibly 
leading to a cure for allergic disease. Next to that, these could be used as easy tool for 
monitoring therapy success. As mentioned previously, memory B-cells can differentiate 
into plasma cells and thereby sustain the underlying sensitization. Therefore, targeting IgE+ 
B-cells with anti-IgE treatment might halt the persistent production of allergen-specific 
IgE. Already omalizumab (an anti-IgE antibody) is being used in patients with severe and 
difficult to treat asthma and it has shown to diminish the production of IgE (35). Omalizumab 
can recognize soluble IgE in serum, as well as membrane IgE on B cells. As omalizumab 
recognizes the domain that binds Fcε receptors, it cannot bind to FcεR-bound IgE and 
induce activation of target cells. However, as soluble IgE is more numerous than surface 
IgE on B cells, it is likely that in the majority of patients, the cells are not targeted and 
omalizumab will not affect IgE B-cell memory. This issue has been circumvented recently 
by the development of quilizimab. Quilizimab is an antibody directed at the M1’ domain 
of IgE and thereby targets a segment of membrane IgE which is not present in soluble IgE 
(Figure 3). In mice it has been shown to effectively reduce serum IgE as well as IgE producing 
plasma cells in vivo (36). However, in patients with chronic spontaneous urticaria and in 
patients with inadequately controlled allergic asthma, quilizimab did not result in clinically 
significant improvements (37, 38). Still in both studies quilizimab reduced median serum 
IgE levels. Probably detection of IgE+ memory B-cells can contribute to patient selection 
for whom quilizimab would lead to beneficial clinical outcome. Since quilizimab directly 
targets IgE expressing B-cells, pre-treatment screening and selecting patients with increased 
IgE-memory B-cell numbers or more specifically, selecting patients with increased allergen 
specific IgE-memory B-cell numbers, could identify patients benefiting quilizimab therapy. 
Next to that, monitoring of IgE+ B-cell numbers during therapy could aid in determining 
therapy efficacy.
The effect of different strategies treatments on peripheral B- and T-cell subsets
Most treatments for allergic disease are aimed at allergen avoidance or symptom relieve. In 
patients with food allergies this can be difficult but is often still feasible, whereas in patients 
with allergic asthma or atopic rhinitis this is often impossible. Local corticosteroid therapy 
to suppress immune mediated complaints or anti-histamines to specifically target mast cell 
and basophil mediators are then the first choice of therapy. Although these therapies can 
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Figure 3 Mechanism of anti IgE treatment. A. IgE is composed of various variable and constant 
domains (CH1-CH4). Next to that membrane IgE also consists of the (trans)membrane domains 
M1 and M2 and is associated with the transmembrane signaling molecules CD79a and CD79b. B. 
The anti-IgE antibody omalizumab binds to the CH3 domain of IgE, which is present on soluble 
and membrane-expressed IgE, but which is masked by Fcε receptors on cell-bound IgE. C. The 
anti-IgE antibody quilizimab binds the M1’ domain of surface IgE and therefore has the potential 
to target IgE expressing (memory) B-cells.
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have good clinical outcomes, they are targeted at symptom repression and not at curation 
of the underlying allergy. Still, little is known about the effect of treatment on the peripheral 
immune compartment in patients with allergic disease whereas this could be important for 
prediction of treatment outcome. In the studies presented in Chapters V and VI we describe 
the effects on the peripheral immune system induced by multidisciplinary treatment at 
sea level and at alpine climate in children with atopic dermatitis and the effects induced by 
sublingual immunotherapy (SLIT) in adults with atopic rhinitis.
Notably, a profound difference observed between these studies was the effect 
on regulatory T-cells. This can be explained by the nature of the studied interventions, 
since the treatments performed in Chapter V were aimed at disease control rather than 
curation, whereas the treatment of SLIT described in Chapter VI, was intended to specifically 
resolve the allergic sensitization. In the case of symptomatic treatment (partially through 
allergen avoidance) disease control is reflected by a reduction of inflammation. Since in a 
physiological state Tregs suppress inflammation, this can be immunologically translated in 
a decrease of Tregs upon symptomatic treatment. On the other hand, treatment of disease 
through disease reversion, such as intended by SLIT, is reflected by skewing of the underlying 
inflammatory response. This can explain the decrease in Tregs after multidisciplinary 
treatment at sea level or at alpine climate and the increase of Tregs after SLIT. As a result of 
increased Treg cell numbers, IgG4 serum values also increase after SLIT. Consequently it is 
not surprising that the initial observed reduction in disease severity after climate treatment 
was not maintained after treatment cessation, whereas disease and symptom scores after 
immunotherapy tended to keep improving.
Still, studies presented in Chapter V and Chapter VI were focused at analyzing peripheral 
blood, whereas allergic reactions are often experienced at local sites, i.e. the skin and the 
mucosa of the upper airways. Therefore in the future, it is also necessary to study the 
immunological changes in these tissues in addition to peripheral blood. Or to specifically 
analyze tissue homing markers on the relevant immune subsets in blood. For example, are 
the increased numbers of CCR7+ Th2 cells which were observed after 6 weeks of alpine 
climate therapy expansions from blood or rather a shift from tissue (i.e. skin) towards blood?
Deviation of the allergic response through immunotherapy
As mentioned before, we show in Chapter VI that grass pollen SLIT affects the underlying 
allergic response and that it leads to increased IgG4+ B-cell formation. IgG4 is proclaimed 
to have an immune dampening effect and thus leads an increased IgG4+/IgE+ B-cell ratio 
to a desensitizing effect which indeed, in our study, was accompanied by reduced allergic 
symptoms during the hay fever season. Based on our results it seems most probable that 
increased IgG4+ B-cells numbers are the result of the existing Th2 skewing, with production 
of IL4 and IL13, in combination with increased IL10 production from Tregs. Still it would be 
interesting to investigate how increased IgG4 production originates.
9
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Differentiation of IgG4+ B-cells from (IgM+) naïve B-cells can be the result of direct 
class-switch recombination (CSR) from IGHM or from indirect CSR through an IGHG (IgG+) 
or IGHA (IgA+) intermediate. Because the constant domain encoding IgE (i.e. IGHE) is located 
downstream of IGHG4, and since in the process of CSR the intermediate DNA is excised from 
the genome, CSR from IgE+ B-cells towards IgG4+ B-cells is not possible. It is therefore not 
surprising that SLIT has no effect on the numbers of IgE+ memory B-cells. The only constant 
domain located more downstream of IGHE is IGHA2, encoding IgA2+ B-cells. In our study 
we did not discriminate between IgA1+ or IgA2+ B-cells, but in future studies it might be 
interesting to investigate if immunotherapy induces an increase in IgA2+ B-cells. Previous 
studies have already shown an increase of allergen specific serum IgA2 after grass pollen 
immunotherapy.(39, 40)
Furthermore it would be interesting to sequence the switch-regions from sorted IgG4+ 
B-cells after immunotherapy. These regions, just upstream of each IGH constant domain, 
contain the remnants of the intermediate switch regions and can indicate whether the cell 
underwent direct or indirect CSR, perhaps revealing more about the exact mechanism of 
immunotherapy. Based on data from a recently published re-entry model (41), one would 
expect that allergen specific IgE+ B-cells would engage in secondary immune response after 
sequential exposures to allergen, as is the case in immunotherapy. Yet also in the natural 
environment, during hay fever season, allergic patients are continuously exposed against 
their cognate allergen, and then desensitization does not occur. This confirms that indeed 
route of allergen exposure and allergen doses are also important factors in the process of 
deviating the allergic immune response.
Next to that, it is not entirely clear how the IgG4 antibody induces the desensitizing 
effect. Increased allergen specific IgG4 can directly compete for allergen, reducing the 
allergen load, but it is also thought to inhibit IgE-mediated responses through FcγRIIb 
binding, which is expressed on mast cells and basophils.(42, 43) Ligation or co-ligation of 
FcγRIIb downregulates the FcεRI mediated mast cell degranulation.(44-46) We observed 
an increase in rye grass pollen (RGP)-specific IgG4 which would suggests that the direct 
competition for allergen is the main mechanism in our study cohort.
IgG4+ B-cells: a cell with two faces?
As mentioned before, IgG4 has been attributed to have immune dampening or regulating 
properties since it only has weak or negligible binding to both C1q and Fcγ receptors. Still 
in Chapters VII and VIII we showed that patients with IgG4-RD, a disease characterized 
by fibrosis and infiltration of IgG4-producing plasma cells of the affected organs, have 
elevated numbers of circulating IgG4+ B-cells. The debate remains if IgG4 in IgG4-RD is 
disease causing or a bystander effect of ongoing (uncontrolled) inflammation. We show 
that drivers of IgG4 B-cell development, i.e. Th2 cells and Tregs, are also increased, therefore 
IgG4+ B-cells do not necessarily need to be intrinsically aberrant to undergo (excessive) 
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proliferation. Moreover, no genetic mutations have been reported which would confirm 
fundamental defects in IgG4 biology. In principle, IgG4 has the most affinity for the inhibiting 
FcγRIIb, yet cross-linking of IgG4 might induce stimulating effects on the target cell. Next 
to that, in other diseases IgG4 has been specifically linked to disease pathogenesis. (47, 48). 
Nonetheless it would be interesting to sort IgG4+ B-cells from patients and study their 
replication history via KREC. This would give an indication if indeed extensive replication and 
thereby possible ongoing inflammation is the cause of increased IgG4. Also the generation 
of monoclonal antibodies of single cell sorted IgG4+ B-cells and subsequent reactivity 
testing could learn us more about underlying disease pathogenesis and specific triggers 
for B-cell stimulation. Previous studies showed that expanded plasmablast numbers in IgG4-
RD, which were largely IgG4+, are mainly oligoclonal, and that re-emerging plasmablasts 
after rituximab therapy were clonally distinct from those prior to treatment (49). This would 
indicate that not a specific antigen is responsible for IgG4+ B-cell expansions but rather the 
underlying stimuli.
CONCLUDING REMARKS
Based on current knowledge from literature and studies presented in this thesis, induction of 
allergic disease is initiated by increased allergen exposure in mucosal or epithelial tissue. This 
triggers the release of cytokines which favors IgE B-cell development and allergen specific 
IgE synthesis. It is very well conceivable that in each allergic individual different underlying 
mechanisms are causative for the onset of disease, e.g. a slightly reduced barrier function in 
one individual, a genetic tendency for Th2 skewing in another individual or high exposures 
to allergens in a third individual. Still the identification, characterization and observation of 
active contribution to disease of IgE+ B-cells in allergic individuals opens new possibilities 
for disease monitoring and, more important, the development of treatment strategies aimed 
at treating allergic sensitization. 9
200
Chapter 9
REFERENCES
1. Donohoe PJ, Heddle RJ, Sykes PJ, Fusco M, Flego LR, Zola H. IgE+ cells in the peripheral blood 
of atopic, nonatopic, and bee venom-hypersensitive individuals exhibit the phenotype of 
highly differentiated B cells. J Allergy Clin Immunol. 1995;95(2):587-96.
2. Dullaers M, De Bruyne R, Ramadani F, Gould HJ, Gevaert P, Lambrecht BN. The who, where, 
and when of IgE in allergic airway disease. J Allergy Clin Immunol. 2012;129(3):635-45.
3. Lafaille JJ, Xiong H, Curotto de Lafaille MA. On the differentiation of mouse IgE(+) cells. Nat 
Immunol. 2012;13(7):623; author reply -4.
4. Talay O, Yan D, Brightbill HD, Straney EE, Zhou M, Ladi E, et al. IgE(+) memory B cells and 
plasma cells generated through a germinal-center pathway. Nat Immunol. 2012;13(4):396-404.
5. Wesemann DR, Magee JM, Boboila C, Calado DP, Gallagher MP, Portuguese AJ, et al. Immature 
B cells preferentially switch to IgE with increased direct Smu to Sepsilon recombination. J 
Exp Med. 2011;208(13):2733-46.
6. Xiong H, Dolpady J, Wabl M, Curotto de Lafaille MA, Lafaille JJ. Sequential class switching is 
required for the generation of high affinity IgE antibodies. J Exp Med. 2012;209(2):353-64.
7. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses 
and autoimmunity. Nat Rev Immunol. 2005;5(11):853-65.
8. Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M, et al. IL-33-mediated innate response 
and adaptive immune cells contribute to maximum responses of protease allergen-induced 
allergic airway inflammation. J Immunol. 2013;190(9):4489-99.
9. Phillips C, Coward WR, Pritchard DI, Hewitt CR. Basophils express a type 2 cytokine profile on 
exposure to proteases from helminths and house dust mites. J Leukoc Biol. 2003;73(1):165-71.
10. Motomura Y, Morita H, Moro K, Nakae S, Artis D, Endo TA, et al. Basophil-derived interleukin-4 
controls the function of natural helper cells, a member of ILC2s, in lung inflammation. 
Immunity. 2014;40(5):758-71.
11. Halim TYF, McKenzie ANJ. New kids on the block: group 2 innate lymphoid cells and type 2 
inflammation in the lung. Chest. 2013;144(5):1681-6.
12. Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, et al. Group 2 innate lymphoid 
cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. J 
Allergy Clin Immunol. 2014;133(4):1142-8.
13. Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q. S epsilon S mu and S epsilon 
S gamma switch circles in human nasal mucosa following ex vivo allergen challenge: evidence 
for direct as well as sequential class switch recombination. J Immunol. 2003;171(7):3816-22.
14. Coker HA, Durham SR, Gould HJ. Local somatic hypermutation and class switch recombination 
in the nasal mucosa of allergic rhinitis patients. J Immunol. 2003;171(10):5602-10.
15. Snow RE, Djukanovic R, Stevenson FK. Analysis of immunoglobulin E VH transcripts in a 
bronchial biopsy of an asthmatic patient confirms bias towards VH5, and indicates local clonal 
expansion, somatic mutation and isotype switch events. Immunology. 1999;98(4):646-51.
201
General discussion
16. Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, et al. Class switch 
recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. 
J Allergy Clin Immunol. 2007;119(1):213-8.
17. Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, et al. Allergen drives class 
switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol. 2005;174(8):5024-32.
18. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-94.
19. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45-56.
20. Yu W, Freeland DM, Nadeau KC. Food allergy: immune mechanisms, diagnosis and 
immunotherapy. Nat Rev Immunol. 2016;16(12):751-65.
21. Bitoun E, Micheloni A, Lamant L, Bonnart C, Tartaglia-Polcini A, Cobbold C, et al. LEKTI 
proteolytic processing in human primary keratinocytes, tissue distribution and defective 
expression in Netherton syndrome. Hum Mol Genet. 2003;12(19):2417-30.
22. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, 
encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141-2.
23. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
24. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is 
essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy 
Clin Immunol. 2012;130(1):145-54 e9.
25. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 
cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. 
Nat Med. 2015;21(7):719-29.
26. Ding Y, Yi X, Yu N. Serum IgE levels are increased in patients with generalized pustular 
psoriasis. Clin Exp Dermatol. 2013;38(5):549-52.
27. Hajdarbegovic E, Nijsten T, Westgeest A, Habraken F, Hollestein L, Thio B. Decreased 
prevalence of atopic features in patients with psoriatic arthritis, but not in psoriasis vulgaris. 
J Am Acad Dermatol. 2013;68(2):270-7.
28. Negosanti M, Fanti PA, Gasponi A, Orlandi G, Liverani L, Tosti A. IgE serum levels in psoriasis. 
Dermatologica. 1981;163(6):474-5.
29. Yan KX, Huang Q, Fang X, Zhang ZH, Han L, Gadaldi K, et al. IgE and FcepsilonRI are highly 
expressed on innate cells in psoriasis. Br J Dermatol. 2016;175(1):122-33.
30. Milovanovic M, Drozdenko G, Weise C, Babina M, Worm M. Interleukin-17A promotes IgE 
production in human B cells. J Invest Dermatol. 2010;130(11):2621-8.
31. Henault J, Riggs JM, Karnell JL, Liarski VM, Li J, Shirinian L, et al. Self-reactive IgE exacerbates 
interferon responses associated with autoimmunity. Nat Immunol. 2016;17(2):196-203.
32. Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of antibodies 
to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic 
lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295(21):1149-54.
33. Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Xiangyu P, Kunjravia N, et al. Diverse 
activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis 
but not in patients with psoriasis. J Allergy Clin Immunol. 2016;137(1):118-29 e5.
34. Singh S, Singh U, Singh S. Prevalence of autoantibodies in patients of psoriasis. J Clin Lab 
Anal. 2010;24(1):44-8.
9
202
Chapter 9
35. Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-
mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011;72(2):306-
20.
36. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, et al. Antibodies specific for a segment 
of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest. 
2010;120(6):2218-29.
37. Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, et al. A randomized 
trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin 
Immunol. 2016;138(6):1730-2.
38. Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, et al. A randomized trial of 
the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. 
Respir Res. 2016;17:29.
39. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, et al. Grass pollen 
immunotherapy induces an allergen-specific IgA2 antibody response associated with 
mucosal TGF-beta expression. J Immunol. 2007;178(7):4658-66.
40. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass 
pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and 
elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory 
activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 
2010;40(4):598-606.
41. de Jong BG, H IJ, Marques L, van der Burg M, van Dongen JJ, Loos BG, et al. Human IgG2- 
and IgG4-expressing memory B cells display enhanced molecular and phenotypic signs of 
maturity and accumulate with age. Immunol Cell Biol. 2017;95(9):744-52.
42. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev 
Immunol. 2008;8(1):34-47.
43. van de Veen W, Akdis M. Role of IgG4 in IgE-mediated allergic responses. J Allergy Clin 
Immunol. 2016;138(5):1434-5.
44. Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol. 2002;14(6):698-704.
45. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol. 
2006;117(6):1214-25; quiz 26.
46. Halova I, Ronnberg E, Draberova L, Vliagoftis H, Nilsson GP, Draber P. Changing the threshold-
Signals and mechanisms of mast cell priming. Immunol Rev. 2018;282(1):73-86.
47. Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 
subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci. 2001;26(1):55-
61.
48. Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, et al. The distribution 
of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in 
pemphigus patients and their first-degree relatives. Br J Dermatol. 2000;143(2):337-42.
49. Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al. De novo 
oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related 
disease. J Allergy Clin Immunol. 2014;134(3):679-87.
203
General discussion
9

PART VI
ADDENDUMVI
206
Addendum
ABBREVIATIONS
AD  atopic dermatitis
AID  activation induced cytidine deaminase
APC  antigen presenting cell
APRIL  proliferation inducing ligand
BAFF  B-cell activating factor
BCR  B-cell receptor
BM  bone marrow
BSA  body surface area
CD  cluster of differentiation
CDR  complementarity determining regions
CLA  cutaneous lymphocyte antigen
CRP  C-reactive protein
CSR  class switch recombination
CXCR  C-X-C chemokine receptor
ELA2  elastase 2
ESID  European Society for Immunodeficiencies
ESR  erythrocyte sedimentation rate
FA  food allergy
FeNo  fractional exhaled nitric oxide
FLG  filaggrin gene
FWR  frame work region
GC  germinal center
GWAS  genome wide association studies
Hep  histamine equivalent prick
ICAM1  intercellular adhesion molecule 1
Ig  immunoglobulin
IGA-NS  investigator’s global assessment for Netherton syndrome
IgG4-RD  IgG4 related disease
IgκREHMA Igκ restriction enzyme hot-spot mutation assay
IL  interleukin
ILC  innate lymphoid cell
ISAC  immune solid-phase allergy chip
IQR  interquartile range
KLK5  kallikrein-related peptidase 5
KREC  Kappa-deleting Recombination Excision Circle
LEKTI  lympho-epithelial kazal type related inhibitor
MHC  Major histocompatibility complex
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Abbreviations
NK  natural killer
NS  Netherton syndrome
PAR2  protease-activated receptor 2
PBMC  peripheral blood mononuclear cells
PCA  principal component analysis
PCR  polymerase chain reaction
pDC  plasmacytoid dendritic cell
RGP  rye grass pollen
SA-EASI  self-administerd eczema area and severity index
SCIT  subcutaneous immunotherapy
SHM  somatic hypermutation
SIT  specific immune therapy
SLE  systemic lupus erythematosus
SLIT  sublingual immunotherapy
SNPs  single-nucleotide polymorphisms
SPINK5  serine protease inhibitor of kazal type 5
STAT  signal transducer and activator of transcription
TACI  transmembrane activator and CAML interactor
TD  T-cell dependent
TFH  T-follicular helper
TH  T helper
TI  T-cell independent
TLR  toll-like receptor
TLSS-NS  total lesional sign score for Netherton syndrome
TNF  tumor necrosis factor
TSLP  thymic stromal lymphopoietin
208
Addendum
SUMMARY
Allergies such as asthma, rhinitis, atopic dermatitis and food allergy are common diseases 
in both children and adolescents, but also affect many adults. The disease presentation 
can range from mild complaints such as itch and sneezing to life-threatening episodes 
demonstrated by anaphylactic shock. Immunoglobulin (Ig)E plays an important role in 
allergic disease. IgE is the antibody which can bind to non-pathogenic allergens such 
as pollens, house dust mite or peanut epitopes and thereby elicits the allergic reaction. 
Although serum IgE has been widely used in the diagnosis of allergic disease, still very 
little is known about the cells producing IgE as these are scarce and difficult to detect. 
A small subset of B-lymphocytes, i.e. memory B cells, express surface IgE and terminally 
differentiated B-cells, plasma cells, can secrete IgE. In this thesis, I developed new assays 
to examine IgE+ B cells and plasma cells in cellular and molecular detail, and assessed 
how these were different between healthy individuals and patients with allergic disease. 
Moreover, I adapted these assays to assess IgG4-expressing B cells, as this IgG4 isotype is 
associated with amelioration of allergic disease following immunotherapy, while also a being 
a major disease marker in patients with the chronic inflammatory condition IgG4-related 
disease (IgG4-RD).
In our first study, presented in Chapter 2, we developed a novel flowcytometric gating 
strategy enabling the identification of IgE+ B-cells in peripheral blood. We show that based 
on immunophenotypic properties these cells could be characterized as IgE+ memory B-cells, 
which either express the classical memory surface molecule CD27, or lack CD27 expression. 
Cell sorting of both IgE+ memory B-cells subsets and subsequent analysis of their molecular 
characteristics (i.e. proliferation history, somatic hypermutation status and Ig switch region 
properties), revealed that CD27+IgE+ memory B-cells displayed characteristics of a T-cell 
dependent maturation, whereas CD27-IgE+ memory B-cells seemed to differentiate through 
a T-cell independent pathway. This was confirmed in patients with a CD40L mutation, in 
whom cognate T and B-cell interactions are defective, as they carried CD27-IgE+ memory 
B-cells. Finally, adults with atopic dermatitis had increased numbers of peripheral blood 
CD27-IgE+ memory B-cells compared to healthy individuals and compared to patients with 
psoriasis, whereas numbers of CD27+IgE+ memory B-cells were comparable between these 
groups. This resulted in the conclusion that T-cell independent, possibly local development 
of IgE is enhanced in allergic patients.
To further investigate cellular characteristics of IgE+ B-cells in allergic diseases we 
performed a cross-sectional study in patients with different allergic diseases, which is 
presented in Chapter 3. Here we collected blood of children with asthma, food allergy and 
atopic dermatitis and determined numbers of IgE+ B-cells and of other cells which play 
an important role in the allergic reaction, such as Th2 cells and eosinophils. The results 
from this study confirmed our previous results that CD27-IgE+ memory B-cell numbers 
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are increased in patients with allergic disease as compared to non-allergic individuals. 
In contrast to previous results in adults, allergic children also had increased numbers of 
CD27+IgE+ memory B-cells. Moreover numbers of CD27+IgE+ memory B-cells were directly 
correlated to Th2 cell numbers, which illustrates the T-cell dependent differentiation 
pathway of these cells.
To further investigate a possible enhanced differentiation of IgE+ B-cells in local 
tissue, we investigated the lymphocyte compartment of patients with increased allergen 
exposure as the result of a disease with an impaired barrier function. Therefore, in Chapter 
4, we studied IgE+ B-cells in patients with Netherton syndrome, which is characterized by 
mutations in the SPINK5 gene and results in a reduced skin barrier function. Conform adults 
with atopic dermatitis, these patients had increased numbers of CD27-IgE+ memory B-cells 
in peripheral blood, but normal numbers of CD27+IgE+ memory B-cells as compared to 
healthy individuals. As a result almost all patients had increased IgE serum levels and all 
patients had complaints of atopic manifestations. Thus increased allergen exposure as a 
result of barrier defects in local tissue, seems to specifically enhance the differentiation of 
CD27-IgE+ memory B-cells, leading to allergic sensitization. This observation emphasizes 
the importance of an intact (mucosal) barrier.
Next we wanted to study the effect of treatment on the lymphocyte compartment and 
specifically on IgE+ memory B-cells. In Chapter 5 we studied the effect of different treatment 
strategies on the peripheral immune compartment in patients with allergic disease. Children 
with moderate to severe atopic dermatitis were randomized to either an intensive outpatient 
treatment in the Netherlands at sea level, or were assigned to an in-patient treatment in 
an alpine climate environment in Davos, Switzerland. Both protocols consisted of a 6-week 
multidisciplinary treatment with blood withdrawal before and directly after the 6-week 
treatment period. The results showed a clinical benefit after both treatments with reduced 
disease activity, objectified by allergic serum markers such as serum TARC and eosinophil 
numbers. However, in-patient treatment in an alpine climate setting resulted in significant 
better outcomes directly after the treatment period. Although numbers of various peripheral 
immune subsets changed after treatment, IgE+ B-cell numbers did not change. Possibly 
this indicates why the beneficial treatment effect did not sustain until 6 months after the 
treatments had finished. Still, both treatment protocols resulted in a reduction of circulating 
memory Tregs, transitional B-cells and plasma blast numbers.
A different treatment approach for allergic disease is desensitization through 
immunotherapy. With this treatment, low doses of the relevant allergen are exposed to, for 
example, mucosal tissue of the mouth. In Chapter 6 we studied the effect of desensitization 
through sublingual immunotherapy (SLIT) on circulating IgE+ B-cells and other B- and T-cell 
subsets. In our study the clinical benefit of SLIT is confirmed. Additionally, our data showed 
that IgE+ B-cell numbers were not affected, but that IgG4+ B-cell numbers increased and 
that through this, the IgE+/IgG4+ ratio decreases. This treatment effect may account for the 
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beneficial clinical effects we observed, since IgG4 is in principal thought to have immune 
dampening properties. Moreover, since these cells are memory cells, the favorable treatment 
outcomes may last for a longer period, which were also observed in our study.
As mentioned above, IgG4 is mainly presumed to have immune dampening effects. 
However increased IgG4 serum levels and tissue infiltration of IgG4 producing plasma cells 
are also seen in IgG4-RD, a disease further characterized by fibrosis and dysfunction of the 
affected organ. In Chapter 7 we further investigated this fibro-inflammatory condition and 
investigated the contribution of IgG4+ B-cells to disease pathogenesis. Our data showed 
increased numbers of blood IgG4+ memory B-cells in patients with IgG4-RD, with reduced 
expression of CD27 and CXCR5 and increased signs of antibody maturation. Furthermore, 
IgG4-RD patients had increased numbers of circulating plasma blasts and CD21low B-cells, 
as well as increased numbers of Th2 and regulatory T-cells. This specific “peripheral blood 
lymphocyte signature” we observed, may also be exploited to further support the diagnosis 
of IgG4-RD, which is now always dependent on an invasive tissue biopsy.
In addition to the previous study, we demonstrate in Chapter 8 that patients with IgG4-
RD had B-cell follicles in affected tissue and active responses are reflected by increased 
blood Tfh2 cell numbers. However patients do not show cellular or molecular signs of 
enhanced B-cell activation in blood. Rather, IgG4+ memory B cells display a more anergic 
phenotype. Furthermore, transcripts of IgG4+ B cells do not show enhanced accumulation 
of somatic hypermutations. Therefore, the exact role of IgG4+ memory B-cells in IgG4-RD 
remains to be clarified.
In conclusion the results of the studies presented in this thesis demonstrate that IgE 
producing B-cells can be identified in peripheral blood and that IgE+ memory B-cells with 
a T-cell independent maturation pathway are increased in patients with allergic disease. 
Furthermore, treatment does not directly affect IgE+ memory B-cells but immunotherapy 
does lead to increased numbers of IgG4+ B-cells resulting in a beneficial IgE/IgG4 ratio and 
a favorable treatment outcome. IgG4+ memory B-cells however, can also be increased in 
the context of a chronic inflammatory disease. Whether these cells also directly contribute 
to the disease pathogenesis is not entirely clear.
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SAMENVATTING
Allergieën zoals astma, hooikoorts, atopische dermatitis (allergisch eczeem) en 
voedselallergie zijn veelvoorkomende ziekten bij zowel kinderen als adolescenten, maar 
treffen ook veel volwassenen. De aandoeningen kunnen variëren van milde klachten zoals 
jeuk en niezen tot levensbedreigende episoden zoals anafylactische shock. Bij allergische 
aandoeningen speelt Immunoglobuline (Ig) E een belangrijke rol. Immunoglobulines van 
verschillende klassen zoals IgM, IgG, IgA en IgE zijn antistoffen die door het immuunsysteem 
geproduceerd worden en in principe gericht zijn tegen bacteriën, virussen of parasieten. 
Je immuunsysteem kan vervolgens immuniteit ontwikkelen door het aanmaken van zgn. 
B-geheugencellen die er voor zorgen dat je bij een volgende blootstelling aan hetzelfde 
desbetreffende virus of bacterie sneller en sterker reageert. Bij een allergie daarentegen, 
wordt door het immuunsysteem IgE geproduceerd dat kan binden aan onschuldige stoffen 
zoals pollen, huisstofmijt of pinda en hierdoor kan een allergische reactie ontstaan. De 
meting van de hoeveelheid vrije, in het bloed circulerende, IgE wordt daarom veel gebruikt 
bij de diagnose van allergieën. Er is echter nog steeds weinig bekend over de cellen die IgE 
produceren, vooral omdat deze schaars zijn en moeilijk kunnen worden aangetoond. Deze 
IgE+ B-cellen bestaan uit B- geheugencellen, die IgE in de vorm van een B-cel receptor 
tot expressie brengen op hun celmembraan; en uit gedifferentieerde B-cellen, genaamd 
plasmacellen, die IgE kunnen uitscheiden. In dit proefschrift hebben we nieuwe testen 
ontwikkeld om deze IgE+ B-geheugencellen en plasmacellen op cellulair en moleculair 
niveau te onderzoeken en hebben daarmee onderzocht op welke manier deze cellen 
verschillen tussen gezonde personen en patiënten met een allergie. Daarnaast hebben we 
deze testen toegepast om B-cellen die IgG4 tot expressie brengen te onderzoeken, omdat 
het IgG4-isotype (een van de isotypes binnen de IgG klasse) geassocieerd is met verbetering 
van allergische aandoeningen na immunotherapie. Daarentegen is het ook een belangrijke 
ziektemarker bij patiënten met de chronisch inflammatoire aandoening, genaamd IgG4-
gerelateerde ziekte (IgG4-RD).
In onze eerste studie (Hoofdstuk 2) hebben we met behulp van flowcytometrie een 
nieuwe methode ontwikkeld waarmee IgE+ B-cellen in bloed kunnen worden aangetoond. 
We hebben laten zien dat deze cellen op basis van uiterlijke eigenschappen kunnen worden 
onderscheiden in twee verschillende IgE+ B-geheugencelpopulaties, die ofwel het typische 
geheugenoppervlaktemolecuul CD27 tot expressie brengen, ofwel de CD27-expressie 
missen. Door middel van het sorteren van beide IgE+ B-geheugencelpopulaties en de 
daaropvolgende analyse van hun moleculaire eigenschappen op DNA niveau, bleek dat 
CD27+IgE+ B- geheugencellen kenmerken vertonen van een T-celafhankelijke rijping, terwijl 
CD27-IgE+ B- geheugencellen zich lijken te ontwikkelen via een T-cel onafhankelijke route. 
Dit werd bevestigd bij patiënten met een CD40L-mutatie, waardoor deze patiënten geen 
T- en B-celinteractie kunnen ondergaan, maar waarbij toch CD27-IgE+ geheugen cellen 
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konden worden aangetoond. Ten slotte hadden volwassenen met atopische dermatitis 
een verhoogd aantal CD27-IgE+ geheugen B-cellen in hun bloed ten opzichte van gezonde 
personen terwijl het aantal CD27+IgE+ geheugen B-cellen vergelijkbaar was tussen deze 
groepen. Dit resulteerde in de conclusie dat de T-cel onafhankelijke, mogelijk lokale, 
ontwikkeling van IgE is verhoogd bij patiënten met een allergie.
Om de eigenschappen van IgE+ B-cellen bij allergische aandoeningen verder te 
onderzoeken, hebben we een studie uitgevoerd bij patiënten met verschillende allergische 
aandoeningen (Hoofdstuk 3). Hiertoe hebben we bloed verzameld van kinderen met astma, 
voedselallergie en atopische dermatitis en hebben we gekeken naar aantallen van IgE+ 
B-cellen en andere cellen die een belangrijke rol spelen bij de allergische reactie, zoals 
T-helper 2 cellen (Th2) en eosinofielen. De resultaten van deze studie bevestigden onze 
eerdere resultaten dat de aantallen van CD27-IgE+ B-geheugencellen zijn toegenomen 
bij patiënten met allergische aandoeningen in vergelijking met niet-allergische personen. 
In tegenstelling tot eerdere resultaten bij volwassenen hadden allergische kinderen ook 
een verhoogd aantal CD27+IgE+ B-cellen. Bovendien konden de aantallen van CD27+IgE+ 
B-cellen direct worden gecorreleerd aan Th2-cel aantallen, wat de T-cel-afhankelijke 
differentiatie van deze cellen ondersteunt.
Om een mogelijk versterkte differentiatie van IgE+ B-cellen in lokaal weefsel verder te 
onderzoeken, onderzochten we in Hoofdstuk 4 het immuunsysteem van patiënten met 
het syndroom van Netherton, een zeldzame ziekte die gekenmerkt wordt door mutaties 
in het SPINK5-gen. De aandoening gaat gepaard met huidafwijkingen en een verminderde 
barrièrefunctie van de huid. Hierdoor zijn patiënten vatbaarder voor infecties en hebben 
ze vaak een verhoogde allergeenblootstelling. In overeenstemming met volwassenen met 
atopische dermatitis hadden deze patiënten een verhoogd aantal CD27-IgE+ geheugen 
B-cellen in het bloed, maar normale aantallen CD27+IgE+ geheugen B-cellen ten opzichte 
van gezonde personen. Als gevolg hiervan hadden bijna alle patiënten verhoogde 
serumconcentraties van IgE en hadden alle patiënten klachten van allergieën. Een 
verhoogde blootstelling aan allergenen als gevolg van barrière-defecten in lokaal weefsel 
lijkt dus specifiek de differentiatie van CD27-IgE+ B-geheugencellen te versterken, wat leidt 
tot allergische sensibilisatie. Deze waarneming benadrukt het belang van intacte barrières.
Vervolgens hebben we gekeken naar het effect van behandeling op het immuunsysteem 
en hebben we specifiek het effect op IgE+ B-geheugencellen bestudeerd. Daarbij hebben 
we verschillende behandelingsstrategieën onderzocht. In de studie beschreven in 
Hoofdstuk 5 werden kinderen met matige tot ernstige atopische dermatitis gerandomiseerd 
voor ofwel een intensieve poliklinische behandeling in Nederland op zeeniveau, ofwel 
voor een intramurale behandeling in een alpine klimaatomgeving in Davos, Zwitserland. 
Beide strategieën bestonden uit een 6 weken durende multidisciplinaire behandeling met 
bloedafname vóór en direct na deze behandelingsperiode. De resultaten toonden een 
klinisch voordeel van beide behandelingen met verminderde ziekteactiviteit, geobjectiveerd 
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door allergische serummarkers zoals serum-TARC en eosinofielen. Klinische behandeling in 
een alpine klimaatomgeving resulteerde daarbij echter tot significant betere resultaten direct 
na de behandelingsperiode. Hoewel de aantallen van verschillende lymfocytenpopulaties 
veranderde na de behandeling, veranderden de IgE+ B-cel aantallen niet. Mogelijk geeft 
dit aan waarom het gunstige behandelingseffect niet standhield tot 6 maanden nadat de 
behandelingen waren beëindigd. Toch resulteerden beide behandelingsprotocollen in een 
vermindering van circulerende regulatoire T-cellen, transitionele B-cellen en plasmablasten 
(onrijpe plasmacellen).
Een andere benadering voor de behandeling van allergische aandoeningen is 
desensibilisatie door immunotherapie. Met deze behandeling wordt het immuunsysteem 
blootgesteld aan lage doseringen van het betrokken allergeen. In Hoofdstuk 6 hebben we 
het effect bestudeerd van desensibilisatie door middel van sublinguale immunotherapie 
(SLIT), oftewel dagelijks “een tabletje onder de tong”, en hebben we gekeken naar de 
aantallen van circulerende IgE+ B-cellen en andere B- en T-cel populaties. In onze studie 
werd het klinische voordeel van SLIT bevestigd. Bovendien toonden onze resultaten aan 
dat de IgE+ B-celaantallen niet werden beïnvloed, maar dat de IgG4+ B-celaantallen 
toenamen en dat hierdoor de IgG4+/IgE+ verhouding ook toenam. Dit behandeleffect 
kan verantwoordelijk zijn voor de gunstige klinische effecten die we hebben waargenomen, 
omdat wordt verondersteld dat IgG4 immuundempende eigenschappen heeft. Omdat deze 
IgG4+ B-cellen geheugencellen zijn, kunnen de gunstige behandelresultaten een langere 
periode aanhouden, wat ook in onze studie werd vastgesteld.
Zoals eerder genoemd, wordt over het algemeen aangenomen dat IgG4 
immuundempende effecten heeft. Verhoogde IgG4-serumniveaus en weefselinfiltratie 
van IgG4-producerende plasmacellen worden echter ook gezien bij de IgG4 gerelateerde 
ziekte (IgG4-RD), een ziekte die verder wordt gekenmerkt door fibrose (verlittekening) en 
verminderde functie van het aangetaste orgaan. In Hoofdstuk 7 hebben we deze fibro-
inflammatoire aandoening verder onderzocht en de bijdrage van IgG4+ B-cellen aan de 
ziekte pathogenese bestudeerd. Onze resultaten toonden verhoogde aantallen IgG4+ 
B- geheugencellen in het bloed van patiënten met IgG4-RD, met daarbij verminderde 
expressie van CD27 en CXCR5 en verhoogde tekenen van antistofrijping (verhoogd aantal 
mutaties in de genen die voor de B-cel receptor coderen). Bovendien hadden patiënten met 
IgG4-RD een verhoogd aantal circulerende plasmablasten en CD21low B-cellen, evenals een 
verhoogd aantal Th2 en regulerende T-cellen. Deze specifieke kenmerken namen wij waar 
in het bloed en kunnen mogelijk worden gebruikt voor het verder ondersteunen van de 
IgG4-RD diagnose, die nu nog afhankelijk is van invasieve weefselbiopten.
In aanvulling op de vorige studie, laten we in Hoofdstuk 8 zien dat patiënten met IgG4-
RD B-celfollikels hebben in aangetast weefsel en dat actieve reacties worden weerspiegeld 
door verhoogde folliculaire T-helper-2 cel aantallen in het bloed. Patiënten vertonen echter 
geen cellulaire of moleculaire kenmerken van versterkte B-celactivering in het bloed. 
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Integendeel, IgG4+ B- geheugencellen vertonen een meer anergisch (=niet reactief) 
fenotype. Bovendien vertonen transcripten van IgG4+ B-cellen geen aanwijzingen van 
antistofrijping. De exacte rol van IgG4+ B- geheugencellen in IgG4-RD zal dan ook nog 
verder moeten worden opgehelderd.
Concluderend tonen de resultaten van de verschillende studies in dit proefschrift aan 
dat IgE-producerende B-cellen in bloed kunnen worden geïdentificeerd en dat de aantallen 
IgE+ B-geheugencellen met een T-celonafhankelijke rijpingsroute zijn toegenomen in 
patiënten met een allergische aandoening. Bovendien beïnvloedt behandeling niet direct 
de IgE+ B geheugencel aantallen, maar immunotherapie leidt wel tot verhoogde aantallen 
IgG4+ B-cellen, wat resulteert in een gunstige IgE/IgG4-verhouding met daarbij een gunstig 
behandelresultaat. IgG4+ B-geheugencellen kunnen echter ook verhoogd zijn in de context 
van een chronische ontstekingsziekte. Of deze cellen daarbij ook rechtstreeks bijdragen aan 
de ziektepathogenese is nog niet helemaal duidelijk.
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DANKWOORD
Als laatste, maar wel als belangrijkste onderdeel van dit proefschrift, mijn dankwoord! Zeker 
ook in mijn geval, waar ik als arts niet specifiek opgeleid ben in laboratoriumonderzoek, 
heb ik veel mensen te bedanken die mij door de jaren heen hebben wegwijsgemaakt in 
dit vakgebied. In het begin wist ik niks en dankzij jullie nu in elk geval voldoende om min 
of meer zelfstandig onderzoek te doen. Ook vakinhoudelijk begon ik vrij onzeker aan een 
promotieonderzoek binnen de onderzoeksgroep moleculaire immunologie. Het is dat 
ik tijdens mijn keuzeonderzoek zo ontzettend goed ben opgevangen, maar anders had 
ik mijzelf wel afgevraagd wat ik hier te zoeken had. Dus bij dezen iedereen ontzettend 
bedankt die mij hierin hebben geholpen! Een aantal personen wil ik daarbij in het bijzonder 
bedanken.
Beste Menno (Dr. M.C. van Zelm), ik weet niet precies welke kwaliteiten jij in mij zag 
tijdens mijn keuzeonderzoek, misschien mijn enthousiasme of de potentie voor een leuk 
vervolg onderzoek, maar ik had nog veel te leren om onderzoeker te worden en hier heb 
jij mij geweldig in begeleid. Altijd was je bereid om dingen uit te leggen of toe te lichten, 
ook als het voor de derde keer was en ik was dan al blij als ik het voor de helft begreep. 
Soms denk ik dat ik jouw tolerantie voor mijn onwetendheid misschien nog deels te danken 
heb aan het feit dat ik geneeskunde heb gestudeerd, waardoor je wist wat je van mij kon 
verwachten en wat vooral niet. Je hebt hierbij in elk geval nooit negatieve zaken naar voren 
gehaald, maar altijd juist de positieve dingen benadrukt. Daarnaast was de tijd in Melbourne 
natuurlijk ook geweldig en ik ben heel erg blij dat ik daar weer onderdeel van je groep 
heb kunnen zijn. Hopelijk heb ik daar zelf ook wat kunnen bijdragen, maar de biertjes bij 
College Lawn waren in elk geval altijd een succes! Menno ik waardeer je wetenschappelijke 
en persoonlijke bijdrage aan dit proefschrift enorm en ik hoop dat we op beide vlakken 
nog vaak contact zullen hebben!
Beste Jacques (Prof.dr. J.J.M. van Dongen), als professor van de unit moleculaire 
immunologie met verschillende onderzoekslijnen en ook nog diagnostiek, was je altijd 
ongelooflijk druk en alles was voor jou belangrijk. Ik vind het daarom ook ontzettend 
knap dat je ondanks je schaarse tijd altijd op de juiste manier betrokken bent gebleven bij 
mijn onderzoek. Later was dat niet meer altijd inhoudelijk, maar wel om de voortgang te 
bewaken en ook dat is erg belangrijk. Daarnaast hebben we vanaf het eerste moment altijd 
een erg prettig contact gehad. Je hebt mij in elk geval altijd op een hele positieve manier 
gestimuleerd en daar ben ik ontzettend blij mee.
Beste Johan (Prof.dr. J.C. de Jongste), bij het begin van mijn promotie en bij het einde 
hiervan hebben wij het meeste contact gehad. Tussendoor heb je mij het vertrouwen 
gegeven dat mijn promotieonderzoek goed zou verlopen. Een rol die niet te onderschatten 
is. Daarnaast heb je waar nodig ondersteuning gegeven aan een omgeving waarin ik aan 
de slag kon met de verschillende studies. Al met al ben ik je hier ontzettend dankbaar voor!
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Beste Suzanne (Prof.dr. S.G.M.A. Pasmans), wat heb ik een plezier beleefd aan het feit 
dat jij betrokken bent bij zoveel van dit proefschrift. Vanaf moment één was jij ontzettend 
enthousiast en dat straalde elke keer weer af op het onderzoek. Overal zag jij mogelijkheden 
om mee aan de slag te gaan en dat is heel erg waardevol gebleken. Daarnaast waardeer ik 
ook je ontzettend fijne en energierijke persoonlijkheid. Hierdoor zag ik je niet alleen in het 
ziekenhuis, maar kwam ik je bijvoorbeeld ook weer tegen ergens halverwege de triatlon 
van Rotterdam. Wat leuk om met zo iemand samen te werken! Ik hoop dat we dit in de 
toekomst nog veel zullen doen.
Beste Prof. van Hagen, beste Martin, bedankt voor de bijdrage die je hebt geleverd 
aan de verschillende onderdelen van mijn promotie. Zowel bij de uiteenlopende studies, 
alsook voor het plaatsnemen in de commissie. Na mijn tijd als onderzoeker zit ik nu als AIOS 
in de kliniek, waarbij ik binnenkort ook op klinisch vakgebied hoop van je te kunnen leren 
ten aanzien van de immunologie.
Ook de andere leden van de commissie, Prof. van Bossuyt als onderdeel van de 
leescommissie en Prof. Gerth van Wijk, Prof. van Noesel en Prof. Aalberse, als onderdeel 
van de grote commissie, wil ik hartelijk bedanken voor de tijd en energie die ze hebben 
willen vrij maken door plaats te nemen in mijn commissie. Ik hoop dat jullie de verschillende 
wetenschappelijke studies kunnen waarderen. Ik kijk erg uit naar de discussie en ik hoop 
dat het voor jullie allen ook een leuke dag wordt.
Dan de mensen op het lab! Als eerste de mensen van de BCD groep; Magda B. thank 
you for teaching me the first practical skills considering lab research. I hope it hasn’t been 
to frustrating in the beginning, but I think in the end it was a succes! Diana, Magda R., 
Britt en Christina, jullie ook allemaal bedankt voor technische uitleg, hulp met antistoffen, 
samples opvangen en prepareren als ik er niet was, of mentale ondersteuning (met koffie) 
voor wat dan ook. Ik ben ontzettend blij dat er altijd een groot samenhorigheidsgevoel is 
geweest binnen de groep! Hanna, jij als kamergenoot hoort hier natuurlijk net zo goed 
bij! En Marieke ook jij schaarde je steeds meer bij de BCD groep. Daarna waren we deels 
tegelijkertijd in Melbourne, zijn we begonnen met de opleiding Interne geneeskunde en 
nu promoveren we ook nog op dezelfde dag! Gelukkig allemaal leuke dingen om te delen.
Daarnaast heb ik ook verschillende studenten gehad die hebben bijgedragen aan 
de onderzoeken in dit proefschrift, maar met name Liza bedankt voor al je inzet en vele 
harde werk op het lab! Wat goed om te zien dat je zelf ook al zo ver gevorderd bent met 
je onderzoek.
Fabian, was für ein Vergnügen habe ich daran erlebt, dass du der Abteilung 
beigetreten bist. Neben der gemeinsamen Zeit im Labor habe ich auch die gemeinsamen 
weiteren Aktivitäten, wie Burger und Bier auf der Witte de Withstraat genossen und das 
Triathlontraining auf dem Rad oder beim Schwimmen. Und wie toll dass du mir als Paranimf 
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bei der Verteidigung zur Seite stehst. Dann weiß ich zumindest, dass auf jeden Fall ein echter 
Wissenschaftler dem PhD-Komitee gegenübersteht.
Ook verder iedereen van de PID groep heel erg bedankt voor jullie ondersteuning. 
Mirjam bedankt voor je wetenschappelijke bijdrage, gebruik van jullie materiaal en je 
getoonde interesse in mijn onderzoeken en in de voortgang daarvan. Barbara, jouw 
aanstelling als mijn persoonlijke secretaresse is helaas nooit helemaal van de grond 
gekomen (met name omdat Jeroen B. je ook al had geclaimd), maar gelukkig heb je mij 
wel met heel veel kunnen helpen en was het altijd erg gezellig en daar ben ik ontzettend 
blij mee (blijft jammer dat je in Barendregt woont). Ook Ingrid en Sandra bedankt voor 
alle labondersteuning die jullie mij hebben gegeven.
Patricia en Maaike jullie zijn ook altijd zo ontzettend behulpzaam geweest bij alles wat 
ik niet snapte, of wel snapte, maar toch verkeerd deed. Wat een geduld en dan ook nog altijd 
met zo’n goed humeur, hierdoor durfde ik ook voor de tiende keer weer iets te vragen. Echt 
heel erg fijn dat jullie altijd voor mij klaarstonden!
Ten aanzien van de flowcytometrie hebben Jeroen, maar ook Romana, Claudia, 
Joyce en alle anderen van de LLD en MID mij altijd erg geholpen. Altijd kwam ik weer om 
antistoffen vragen, moesten er beads gemeten worden of zat er weer lucht in de Fortessa. 
Ik ben heel erg blij dat jullie mij hier altijd mee geholpen hebben. Daarnaast was het ook 
altijd gezellig om samen op het lab te pipetteren. Ook de (spaarzame) fietsritjes naast het 
werk vond ik erg gezellig Jeroen!
Dank ook aan de andere werkgroepleiders: Ton en Vincent alsook Wim en Marco voor 
jullie wetenschappelijke input tijdens de verschillende meetings en voor de bijdrage aan 
de labondersteuning vanuit jullie groepen.
Ook alle mede PhD’s van de afdeling bedankt voor jullie suggesties, hulp, ondersteuning 
of andere bijdrage. Jeroen, met name als ondersteuning bij het bier drinken in de Locus 
Publicus of in Den-Haag en om mij vervolgens weer veilig thuis te krijgen. Wouter, 
onmisbaar in de ondersteuning middels zijn Nespresso apparaat inclusief koekjes. Verder 
ook Willem Jan, Prisca, Martine, Marjolein, Anne, Malou, Chris, Jenna, Prayer en alle 
andere OIO’s bedankt voor de gezelligheid.
Dan zijn er nog zo veel anderen waar ik altijd terecht kon voor hulp of ondersteuning. 
Jane, Rianne, Wouter van Rijs, Monique, Nicole Nagtzaam, Marion, Conny en nog heel 
veel anderen. Bedankt voor jullie, altijd goed gehumeurde, behulpzaamheid! Ook de dames 
van het secretariaat, Bibi, Sacha, Danielle en Erna bedankt voor jullie ondersteuning. 
Gellof jij als eigenlijke afdelingshoofd hebt op de één of andere manier ook bijgedragen 
aan dit boekwerk, of in elk geval aan de leuke tijd tijdens de onderzoeken voor dit boekwerk. 
Bedankt hiervoor!
Daarnaast wil ik ook alle co-auteurs en mede onderzoekers bedanken die hebben 
bijgedragen aan dit proefschrift. Faiz, het IgG4 stuk heeft even geduurd, maar uiteindelijk 
heeft het mooie resultaten opgeleverd! Hopelijk wordt het vervolg onderzoek net zo 
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succesvol. Karin ook de data analyse voor de WKZ-Davos studie was nog best een uitdaging, 
maar heeft uiteindelijk goed uitgepakt. Kira, voor de Netherton studie moeten we vast 
nog wat doen, maar ook dit komt zeker goed. Ook de clinici van de afdeling Immunologie, 
Jan van Laar, Virgil Dalm en Paul van Daele (het Mastocytose onderzoek is ook nog aan 
de beurt!), bedankt voor jullie bijdrages en ondersteuning met de verschillende studies. 
Nicolette Arends heel erg bedankt voor je ondersteuning op de KinderHaven voor de 
Simba studie. Daarbij ook alle prikzusters voor de logistieke ondersteuning daar. Met name 
Yvonne, super dat je altijd zo behulpzaam was en energie wilde steken in mijn onderzoek!
Many thanks for a wonderful time also goes out to the Monash lab! All of you welcomed 
me so kindly and thanks to you I had a great time in Melbourne, including all the cappuccinos 
in Café 12, beers at College Lawn and burger picnics in Fawkner park. Jodie, Beatriz, Pei, 
Dan, Katherine, Maria, Sam, Eliza, Angela, Mahtab, Gavin, Neeru and all others thank 
you very much! Hope to see you soon!
Daarnaast is de mentale ondersteuning, of juist afleiding, naast het onderzoek doen net 
zo belangrijk voor het volbrengen van een succesvolle promotie. Daarvoor wil ik dan ook 
iedereen van mijn vrienden, collega’s en familie bedanken die hier aan hebben bijgedragen.
Wout, mooi dat je als paranimf mij tijdens de verdediging bijstaat. Allebei geneeskunde 
gestudeerd, allebei bij hetzelfde dispuut en we wonen in dezelfde straat, voor mij niet 
meer dan logisch dat je nu ook als paranimf naast mij staat. Maar daarnaast waardeer ik 
ook sowieso je mening en de discussies die we hebben. Gelukkig ook vaak genoeg met een 
biertje erbij, laten we daar vooral mee doorgaan!
Sas en Marjo, jullie als zussen zijn natuurlijk sowieso een voorbeeld voor mij. Allebei 
zo’n leuke familie, met geweldige neefjes en nichtje en daarnaast allebei succesvol. Ik vind 
het ontzettend knap en ik heb er heel veel bewondering voor. Voorlopig doe ik het jullie 
nog niet na, hopelijk in de toekomst wel. Ik ben in elk geval trots dat jullie mijn zussen zijn. 
Sas jij als mede-internist en ook gepromoveerd laat mij ook op professioneel vlak zien hoe 
het moet. Ik kijk er heel erg naar uit om elkaar in de toekomst te kunnen aanvullen als we 
samen een praktijk hebben!
Pap en Mam jullie zijn eigenlijk onmisbaar in vrijwel alles wat ik doe. Mam altijd 
stimuleer je mij om mijn volledige potentieel te benutten. Of als dat niet lukt, help je mij 
om te kijken waar dat aan ligt om dat vervolgens te herstellen. Pap jij bent de bron van mijn 
nieuwsgierigheid, zowel wetenschappelijk als metafysisch. Ik waardeer je enorme kennis 
en je vermogen om dit in relatie te stellen tot het geheel. Samen zorgen jullie ervoor dat ik 
kan bereiken wat ik wil en helpen jullie mij te ontdekken wat ik wil bereiken.
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Tropengeneeskunde gevolgd in Usangi, Tanzania. Na de studie Geneeskunde startte hij in 
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the study Economics at the Erasmus University in Rotterdam. In 2005 he switched to study 
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studies, he did an internship for 6 weeks at the UC Davis Medical Center in Sacramento, 
USA, and a 3 months rotation in Tropical Medicine at Usangi Hospital in Tanzania. After 
studying Medicine he started his PhD in January 2012 at the Department of Pediatrics and 
the Department of Immunology at Erasmus Medical Center, under supervision of Prof. dr. 
Johan C. de Jongste, Prof. dr. Jacques J.M. van Dongen and Dr. Menno C. van Zelm. During his 
PhD he worked for six months at the Immunology and Pathology department of the Monash 
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and now works at the Amphia Hospital in Breda (under supervision of Dr. J. van Esser). In 
addition to internal medicine, he has a great interest in Expedition Medicine and recently 
acquired his first experience in guiding a project in Uganda.
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